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Darragh O’LOughLin, President, iPu
MeSSAGe FROM the PReSIdent 
It has been another frustrating year for the Irish Pharmacy Union and for our members, 
as the pharmacy profession has endured an ongoing series of ad hoc direct and indirect 
cuts to our income, which, coupled with the difficulties caused by the adverse economic 
circumstances, have made it increasingly difficult to deliver the high quality service that 
our patients expect and deserve. However, the Union continues to fight on every front 
on behalf of its members and to advocate for greater recognition of the potential of the 
pharmacy profession to deliver cost effective, accessible and patient-friendly healthcare 
services to the public.
In a detailed submission, entitled “Time for a New Approach”, which we presented to the 
Minister during the last FEMPI review process and a copy of which was sent to all members, 
the Union highlighted that there was no scope for further unilateral or arbitrary cuts as 
pharmacists had already suffered far deeper cuts than any other sector. Nevertheless, 
we believe that additional efficiencies and savings can be achieved by adopting a new 
approach; one which involves substantial and direct engagement between the Union, the 
Department of Health and the HSE. This would offer an orderly and efficient way to bring 
about real and lasting change, offering tangible and substantial benefits for patients and 
the exchequer and providing a more secure basis for pharmacists to structure and plan 
their professional activities and their businesses.
I hope that by this time next year we will have seen some progress in advancing our 
hugely positive agenda for change with the new government with the consequent 
benefits for the profession, the State and our patients.
Your representatives on the Union’s committees have worked ceaselessly over the past 
year, demonstrating genuine dedication and unity of purpose. They have been ably 
assisted by all the staff in Butterfield House. It’s worth pointing out that the IPU didn’t 
increase employee numbers during the boom times and has continued to maintain a 
very lean staff complement, all of whom remain absolutely dedicated to supporting and 
advocating for the Union’s members. The organisation itself has no agenda other than to 
further the interests of its members and of the pharmacy profession.
The IPU has worked successfully to improve communications with members with a 
massively improved website, weekly email newsletters and, most recently, the launch of 
a members’ internet forum on which we can share tips on best practice and solutions for 
commonly encountered problems and also discuss the more esoteric and obscure issues 
which frequently raise their heads in a community pharmacy. I encourage you all to make 
the best use of the resources which the Union provides, to keep yourself informed and to 
participate in Union activities.
We should all take great pride in this year’s inaugural IPU National Pharmacy Conference. 
It is a superb event, a showcase for the best aspects of the community pharmacy 
profession in Ireland and just the sort of event the profession needs and deserves. This 
conference is the culmination of the extraordinary efforts of a small group of people who 
deserve our thanks and our congratulations for a job well done.
Finally, I would like to express my gratitude to Séamus Feely, Secretary General; Rory 
O’Donnell, Vice President; and Kathy Maher, Honorary Treasurer, for their loyalty, support 
and hard work over the course of the year and also to my family who have adjusted to my 
frequent and often unplanned absences with stoicism and good grace.
darragh O’Loughlin MPSI
Kathy Maher, hon. treasurer, iPu
rOry O’DOnneLL, Vice-President, iPu
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PReSIdent:  dARRAGh O’LOUGhLIn
VICe-PReSIdent:  RORy O’dOnneLL
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CO-OPtIOnS
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FInAnCIAL StAteMentS
Irish Pharmacy Union
Financial Reports and Accounts for Year Ended 31 December 2010
In accordance with the Constitution of the Union, the Executive Committee submits the audited accounts for consideration 
by members.
The full details of the Accounts have been circulated to members with the Summary of the 2011 Annual Report of the IPU 
Executive Committee.
If the Accounts are approved by the meeting after their presentation, members will be asked to formally adopt the Accounts 
for the year ended 31 December 2010 and agree the election of Auditors. In this context, the following motions will be put to 
the meeting: 
a.  “that the executive Committee report and audited Statement of accounts of the irish Pharmacy union for the year ended 
31 December 2010 as submitted to this meeting, be and are hereby adopted.”
b.  “that this meeting agrees to the election of Baker tilly ryan glennon for a further year as auditors for the iPu and iPu 
Services Ltd.”
Membership Subscriptions:
Subscriptions have been reduced by 38% over the past two years and no further change will be made until the completion of 
the work of the Group established by the Executive Committee to review the funding of the Union.
IPU Services Limited
Financial Reports and Accounts for Year Ended 31 December 2010
At this Annual General Meeting of IPU Services Ltd, members are asked to consider the Report of the Directors and the 
Auditors’ Report on the Accounts for Year Ended 31 December 2010.
The accounts and financial reports have been circulated to all members.
If the Accounts are approved, members will be asked to resolve: “that the Directors’ report and audited Statement of accounts 
for the year ended 31 December 2010 as submitted to this meeting, be and are hereby adopted.”
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Minutes of the 37th Annual General Meeting
of the Irish Pharmacy Union and IPU Services Ltd
Mullingar, Co Westmeath
 
24 April 2010
Present:   
The President, Ms Liz Hoctor, and 62 members.
In Attendance: 
Mr Seamus Feely, Ms Ciara Enright, Ms Kate Healy, Mr Darren Kelly, Ms Wendy McGlashan, 
Ms Roisin Molloy, Ms Aoibheann Ni Shúilleabháin and Ms Zuzanna Zwolan.
Apologies: 
Apologies were received from 38 members.
[A full report of the 2010 AGM is available from the IPU offices.]
1. The President welcomed the attendance to the 37th 
Annual General Meeting of the Irish Pharmacy Union.
2. On the proposal of the President all present stood in 
silence in memory of deceased members including 
Mr John Burke, Trustee of the Union, and all those 
who had died since the 2009 AGM. 
3. Financial Reports and Accounts 2009
a. Dermot Twomey (Honorary Treasurer) presented the 
Union’s Financial Report. The Honorary Treasurer 
drew members’ attention to the Pension figure for 
2009 on Page 28 of the Annual Report. The correct 
figure is €147,788 resulting in an over statement of 
the Profit by €26,459. The actual Profit for this period 
should read €545,579. 
 Following the presentation, the following motion 
approving the accounts was proposed by John 
Gleeson, seconded by Mark Beddis and carried. 
 “that the executive Committee report and audited 
Statement of accounts for the irish Pharmacy union 
for the year ended 31 December 2009 as submitted to 
this meeting be and are hereby adopted.”
b. The following motion was proposed by Marie Hogan, 
seconded by Jack Shanahan and carried.
 “that this meeting agrees to the election of Baker 
tilly ryan glennon for a further two-year period as 
auditors for the iPu and iPu Services Ltd.”
c. It was announced that the Executive Committee 
had agreed not to change to the annual subscription 
payable, pending the completion of the work of the 
Group established to review the funding of the Union.
4. IPU Services Ltd AGM
 The minutes of the 2009 AGM were taken as read.
 On the proposal of Joe Britton, seconded by Ross 
McEntegart, it was resolved:
 “that the Directors’ report and audited Statement 
of accounts for the year ended 31 December 2009 as 
submitted to this meeting, be and are hereby adopted.”
 This motion was carried.
5. Report of 36th AGM
 The report of the 36th Annual General Meeting was 
approved as a true and accurate record. The report had 
been circulated to all members prior to the meeting.
6. Report on Motions from 2009 AGM
 The report on motions from the 36th Annual General 
Meeting was taken as read and agreed.  
7. President’s Address
 Ms L Hoctor, President addressed the meeting and 
thanked members and the staff of the Union for their 
support during the year. 
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8. Union Secretariat Report
 The Union Secretariat Report was circulated to 
all members, prior to the meeting, as part of the 
Executive Committee report. The Secretary General, 
Mr Seamus Feely, introduced the Secretariat report.
9. Group Reports
a. Pharmacy Contractors’ Committee (PCC) Report 
This report was introduced by Mr Ger Browne, 
South Regional Representative of the PCC.
 A summary of the report was circulated in advance 
of the meeting and the full report published on the 
members’ section of www.ipu.ie.
 b. Community Pharmacy Committee (CPC) 
Report This report was delivered by Mr Keith 
O’Hourihane, Chairman of the Community 
Pharmacy Committee.
c. Community Pharmacy Committee (CPC) Report  
This report was delivered by Mr Bernard Duggan, 
Chairman of the Community Employee Committee. 
 A summary of the report was circulated in advance 
of the meeting and the full report published on the 
members’ section of www.ipu.ie. 
d. Public Relations Report  
This report was circulated in the Annual Report 
and was taken as read. 
e. International Pharmacy Matters  
This report was circulated in the Annual Report 
and was taken as read. 
10. Update on Strategy Review
 This issue had been addressed by the Secretary General 
in his address to the meeting and was taken as read.
11. 2010 AGM Motions
 The 2010 Motions and action taken on them are on 
Pages 8 – 12 of this report.
12. A.O.B
 The President, Ms Liz Hoctor, announced the new 
Standing Committee. Mr Darragh O’Loughlin was 
elected as President of the Union; Mr Rory O’Donnell 
as Vice-President; and Ms Kathy Maher as the 
Honorary Treasurer. Ms Liz Hoctor officially passed 
the chain of office to the new President of the Union.
 The Past President thanked all those who attended 
for their participation and also thanked the Vice-
President, Darragh O’Loughlin and Honorary 
Treasurer, Dermot Twomey for the work they had 
undertaken over the last year. The Past President also 
thanked the Secretary General and staff of the IPU 
for their hard work. 
 The incoming President addressed the meeting and 
thanked the outgoing President for all her leadership 
and efforts during a very difficult two year period. He 
said that he was committed to providing leadership 
for the next two years and would do everything 
possible to maintain and promote the interests of all 
members. 
2010 AGM MOtIOnS And RePORt On 
ACtIOn tAKen
 The following motions, proposed in accordance with 
Article 29 of the Constitution, were brought before 
the 2010 AGM for consideration:
1. Proposed: Liz Hoctor 
Seconded: Darragh O’Loughlin
 “that this agM calls on the hSe and the Department 
of health and Children not to introduce the 
Prescription Levy for patients on the Medical Card 
and Long-term illness Schemes but instead to work 
with pharmacists to ensure more cost-effective use of 
medicines through structured medicine use reviews for 
patients, where appropriate. “
 This motion was carried unanimously. 
 Action: In 2010 the Government announced the 
introduction of a prescription levy from 1 April 2010. 
However after repeated requests by the Union 
and other organisations, the introduction of the 
levy was delayed until later in the year. In August 
and September, the Union met with and wrote to 
officials from the Department a number of times 
to discuss the prescription levy, highlighting many 
concerns around its introduction, the impact it would 
have on patients and calling on the Government to 
refrain from introducing the levy. The Union also put 
forward other ways in which structured medicine use 
reviews could be implemented.
 On 1 October the prescription levy was introduced. 
The Union issued members with posters and leaflets 
to alert patients to the levy being imposed on them. 
Since the introduction of the levy, the Union has 
been liaising with the HSE to answer any questions 
which have arisen since the introduction of the 
levy and a number of updates have been issued to 
members over the past few months. The Union also 
met with representatives of Nursing Homes Ireland 
in an effort to resolve the issue over non-payment of 
the levy by nursing homes. 
 The Union lobbied Opposition Spokespersons on the 
matter and called on them to announce that they 
would repeal the legislation if in power. In advance 
of the General Election in March 2011, all Opposition 
Spokespersons confirmed to the Union that they 
would scrap the levy if in power.
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 Within the last few weeks the new Minister for 
Health, Dr James Reilly has given a commitment to 
abolish the levy on medical card patients. The Union 
welcomes this development.
 The Union participates in the HSE Pharmacy in Primary 
Care Group which has just completed a pilot Medicines 
Use Review (MUR) programme through GPs and 
community pharmacists. The results of the pilot are 
currently being analysed by TCD and it is hoped that an 
MUR service will be rolled out nationally. 
2. Proposed: Rory O’Donnell  
Seconded: Paul Fahey
 “that this agM calls on both the Minister for 
enterprise, trade and innovation and the Minister of 
health and Children to ensure that any exemption 
that may be granted in the new Competition act to 
the irish Medical Organisation should also apply to all 
representative bodies for healthcare professionals.”
 This motion was carried unanimously
 The Union wrote to the previous Minister for 
Enterprise, Trade and Innovation a number of times 
on this matter and raised it in meetings with the 
previous Minister for Health and Children. The Union 
lobbied Opposition Spokespersons on the matter and 
called on them to announce that they would ensure 
that any exemption that may be granted in the new 
Competition Act to the Irish Medical Organisation 
should also apply to all representative bodies for 
healthcare professionals if in power. Before the 
election, the now Minister for Health, Dr James Reilly, 
confirmed to the Union that he believes in the right 
of trade unions to represent and negotiate on behalf 
of their members and would have no reservations 
regarding the Department of Health or the HSE 
engaging with the unions or representative bodies  
of professions. 
3. Proposed: Noel Stenson   
Seconded: Morgan Power
 “that this agM calls on the Minister for health and 
Children to exercise caution if she decides to introduce 
reference Pricing and to ensure that the supply of vital 
medicines to patients is maintained and the viability 
of community pharmacy is not further undermined.”
 This motion was carried unanimously 
 Action: In 2010 the Union made two submissions 
and an oral presentation to the Department 
of Health and Children’s Reference Pricing and 
Generic Substitution Group chaired by Mark Moran. 
The Union advocated for a pharmacy led generic 
substitution and felt that this was important if any 
new system were to succeed. The Union also warned 
about a race to the lowest price and used European 
examples where there have been ongoing medicine 
shortages due to reference pricing systems. 
 The Department published their report in June 
2010. The report set out a proposed model for the 
operation of a system of interchangeable medicines 
and reference pricing. The report also stated that 
generic substitution should be pharmacy led as 
recommended by the Union. The Union welcomed 
the move by the Minister to allow pharmacists 
to offer patients the choice of a cheaper generic 
medicine but cautioned the Minister to be careful in 
taking steps towards the introduction of reference 
pricing as pharmacists had already suffered a major 
blow due to cuts imposed in 2009.
 The Heads of Bill for Reference Pricing are currently 
being prepared by the Department and are at an 
advanced stage. The PCC has requested a meeting 
with the Department.
 The Union has written to the new Minister for 
Health, Dr James Reilly asking to meet with him 
to discuss a number of issues related to pharmacy 
including reference pricing.
4. Proposed: Stephen Nolan 
Seconded: Rory O’Donnell
 “that this union calls upon the Minister for health 
and Children and the hSe to implement the 
recommendations of the Joint Committee for health 
and Children, published in their report on Primary 
Medical Care in the Community, that the role of the 
pharmacist be expanded to provide additional health 
services to patients.”
 The motion was carried unanimously.
 Action: The Union raised this issue in a meeting and 
follow up letter with the previous Minister for Health 
and Children. The Union also met with Dr Barry White, 
National Director Quality and Clinical Care, in relation to 
the extended pharmacist’s role within the HSE’s Clinical 
Care programme. Meetings also took place with Dr 
James Reilly and Jan O’Sullivan at which the extended 
role of the pharmacist was discussed.
 Before the election, the now Minister for Health, 
Dr James Reilly, confirmed that the introduction of 
Medicine Use Reviews was a good idea, particularly 
in improving compliance and ensuring better 
outcomes for patients; that a minor ailments scheme 
would make absolute sense as it would allow more 
timely access to medicines for medical card patients 
and would reduce congestion in GP surgeries; that 
pharmacists are ideally positioned to communicate 
health promotion messages to the public; that Fine 
Gael would see a role for pharmacists in health 
screening; and that he sees no reason vaccination 
programmes delivered by pharmacists cannot be 
done here. 
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 The Union participates in the HSE Pharmacy in 
Primary Care Group which is looking at a number 
of extended roles for community pharmacists such 
as Medicine Use Reviews, Compliance and Wastage 
schemes, vaccination, etc. 
5. Proposed: Bernard Duggan  
Seconded: Catriona O’Riordan
 “that the employee Pharmacists’ Committee of the 
iPu calls on the Minister for health and Children 
to ensure that funding is provided for the one 
year practical intern training completed under the 
supervision of a practising tutor pharmacist in line 
with similar practical training funding already 
provided to other Primary healthcare Professionals 
such as gPs and nurses.” 
 The motion was carried by the majority vote. There 
was one abstention.
 Action: The Union raised the issue of funding for 
pharmacists who act as tutors to pharmacy interns in 
meetings with the previous Minister for Health and 
Children and the Pharmaceutical Society of Ireland. 
6. Proposed: Fearghal O’Nia  
Seconded: Catriona O’Riordan
 “that the employee Pharmacists’ Committee of the 
iPu calls on the Minister for health and Children 
to ensure that funding is provided for the one 
year practical intern training completed under the 
supervision of a practising tutor pharmacist in line 
with similar practical training funding already 
provided to other Primary healthcare Professionals 
such as gPs and nurses.” 
 The motion was carried unanimously.
 Action: The Union raised the issue of the removal 
of bankruptcy from the PSI registration rules at 
meetings with the previous Minister for Health and 
Children and the Pharmaceutical Society of Ireland. 
The Union also wrote to the Law Reform Commission 
on the matter. 
7. Proposed: Joe Carroll  
Seconded: Brian Walsh
 “that this union calls upon the Minister for health 
and Children to proactively engage with the 
Pharmaceutical industry and the irish Medicines 
Board to encourage the deregulation of appropriate 
medicinal products from prescription only to 
pharmacist supervised sale” 
 The motion was carried unanimously.
 Action: The Union participated in a Switch on to 
Self-Care Working Group over the past 18 months. 
The Group was composed of representatives from 
key stakeholder organisations including the IPU, 
the School of Pharmacy TCD, the Department of 
General practice UCC, and representatives from 
the pharmaceutical industry. The Group has now 
finalised a Self-Care Framework for Ireland which 
recommends that the range of medicines made 
available to patients should be expanded through 
switching. The Union has also raised this matter in 
meetings with the IMB. The Union also advocates 
for centralised switching by the European Medicines 
Agency under the PGEU umbrella. Following the 
deregulation of Norlevo in February this year, it 
is understood that the IMB has now formed a 
committee to look at this issue further. 
8. Proposed: Joe Carroll  
Seconded: Ultan Molloy
 “that this union calls upon the Minister for health 
and Children to ensure that Medical Card holders, who 
are experiencing huge delays in having their cards 
renewed because of hSe structural reorganisation, 
are not placed in position of financial hardship by 
having to pay for their medicines while their cards are 
expired.” 
 The motion was carried unanimously.
 Action: Due to structural reorganisation, the 
HSE announced the centralising of Medical Card 
Applications. Unfortunately this has led to patients 
experiencing significant lengths of time for their 
medical cards. The Union has highlighted these 
delays in correspondence with the HSE and also 
raised the matter at the Joint Consultative Group 
Meetings which took place throughout the year.
 A knock on effect to the delay in issuing valid medical 
cards was pharmacies experiencing rejected claims 
throughout 2010. The Union received a large volume 
of calls from pharmacists in relation to the rejection 
of claims by the PCRS and some of the reasons given 
by the PCRS were invalid/out of date medical card 
number. 
 The Union worked with the HSE last year to 
implement an Incomplete Claims Protocol which 
addresses this problem. This was finalised in October 
2010. As well as addressing the issue of payment 
for members, this protocol also alerts patients to 
problems with their cards and gives them the time 
to contact the HSE and resolve the matter before it 
gets to the point whereby the HSE refuses to pay for 
the patient’s medicine. The HSE stopped rejecting 
GMS claims in October claims. The Union continues 
to monitor this situation in order to make sure 
that pharmacists are paid for medicines supplied 
to patients and patients, in turn, are not put in a 
position whereby they must pay for their medicines.
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 The Union participates in the HSE Pharmacy in 
Primary Care Group which is looking at a number 
of extended roles for community pharmacists such 
as Medicine Use Reviews, Compliance and Wastage 
schemes, vaccination, etc. 
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 “that the employee Pharmacists’ Committee of the 
iPu calls on the Minister for health and Children 
to ensure that funding is provided for the one 
year practical intern training completed under the 
supervision of a practising tutor pharmacist in line 
with similar practical training funding already 
provided to other Primary healthcare Professionals 
such as gPs and nurses.” 
 The motion was carried by the majority vote. There 
was one abstention.
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pharmacists who act as tutors to pharmacy interns in 
meetings with the previous Minister for Health and 
Children and the Pharmaceutical Society of Ireland. 
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 “that this union calls upon the Minister for health 
and Children to proactively engage with the 
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Board to encourage the deregulation of appropriate 
medicinal products from prescription only to 
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 The motion was carried unanimously.
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Self-Care Working Group over the past 18 months. 
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key stakeholder organisations including the IPU, 
the School of Pharmacy TCD, the Department of 
General practice UCC, and representatives from 
the pharmaceutical industry. The Group has now 
finalised a Self-Care Framework for Ireland which 
recommends that the range of medicines made 
available to patients should be expanded through 
switching. The Union has also raised this matter in 
meetings with the IMB. The Union also advocates 
for centralised switching by the European Medicines 
Agency under the PGEU umbrella. Following the 
deregulation of Norlevo in February this year, it 
is understood that the IMB has now formed a 
committee to look at this issue further. 
8. Proposed: Joe Carroll  
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 “that this union calls upon the Minister for health 
and Children to ensure that Medical Card holders, who 
are experiencing huge delays in having their cards 
renewed because of hSe structural reorganisation, 
are not placed in position of financial hardship by 
having to pay for their medicines while their cards are 
expired.” 
 The motion was carried unanimously.
 Action: Due to structural reorganisation, the 
HSE announced the centralising of Medical Card 
Applications. Unfortunately this has led to patients 
experiencing significant lengths of time for their 
medical cards. The Union has highlighted these 
delays in correspondence with the HSE and also 
raised the matter at the Joint Consultative Group 
Meetings which took place throughout the year.
 A knock on effect to the delay in issuing valid medical 
cards was pharmacies experiencing rejected claims 
throughout 2010. The Union received a large volume 
of calls from pharmacists in relation to the rejection of 
claims by the PCRS and some of the reasons given by 
the PCRS were invalid/out of date medical card number. 
 The Union worked with the HSE last year to 
implement an Incomplete Claims Protocol which 
addresses this problem. This was finalised in October 
2010. As well as addressing the issue of payment 
for members, this protocol also alerts patients to 
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gets to the point whereby the HSE refuses to pay for 
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that pharmacists are paid for medicines supplied 
to patients and patients, in turn, are not put in a 
position whereby they must pay for their medicines.
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9. Proposed: Richard Collis  
Seconded: Edward MacManus
 “that this agM endorses the iPu in its work to support 
iPOS purchasing pharmacists and calls on the union 
to continue its endeavours in working towards a fair, 
equitable and timely resolution of all outstanding 
issues between stakeholders ” 
 The motion was carried by the majority vote. There 
were three abstentions.
 Action: The Union set up an IPOS Purchasing 
Pharmacists’ Committee to oversee this issue. A 
number of meetings were held over the past year and 
the Committee has worked tirelessly with Uniphar to 
achieve an outcome which one hopes is acceptable 
to the majority of Purchasing Pharmacists. Uniphar 
announced the outcome of these negotiations at a 
meeting on 7 April 2011. 
 
10. Proposed: Ultan Molloy  
Seconded: Padraig Loughrey
 “that this agM urges the irish Pharmacy union 
to consider exploring new avenues of working in 
partnership with the three third level institutions 
offering degree courses in Pharmacy in ireland.” 
 The motion was carried by the majority vote. There 
was one abstention.
 Action: The issue of the IPU supplying a teacher 
practitioner in the Schools of Pharmacy was 
discussed at length by the Community Pharmacy 
Committee. The Committee was of the view that 
there were other ways of working in partnership with 
the Schools of Pharmacy. In the meantime, the Union 
has given a number of talks to students at the three 
Schools of Pharmacy, awarded a prize for the best 
intern project and had students write articles for the 
IPU Review. 
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Union Secretariat Report
 1. IntROdUCtIOn
 Over the past year the activities of the Union have been overshadowed by the ongoing problems with our rising 
national debt and efforts to bridge the gap between expenditure and revenue. All parts of society and the economy are 
adjusting to this harsh new reality. Pharmacy has played its part by continuing to deliver professional services at greatly 
reduced levels of payments in what is an economically depressed time for patients.
 The Union has also had to adjust to this new environment and we continue to deliver services and support to you, our 
members, to assist you in your professional and business activities. The Union did not expand or increase staff numbers 
during the boom years but used its resources wisely to provide more and more services with the same level of resources. 
The commitment of the staff of the Union to meeting the demands of and supporting our members is second to none. I 
would like to thank all my colleagues, the Officers of the Union and members for their continuing support. It is through 
this support and unity that we can all maintain our focus in ensuring the continuing viability of our businesses and 
profession. This is the only agenda and focus of this Organisation and we will not be deflected from this task.
2. detAILS OF IPU MeMBeRShIP And PhARMACy OWneRShIP (AS At 27 APRIL 2011)
(b) nUMBeR OF COMMUnIty PhARMACIeS
 Pharmacist Owned:
 Single shops 753
 Chains 591 1344
 non-Pharmacist Owned:
 Single shops 69  
 Chains 166 235 (1579)
(c) tOtAL nUMBeR OF ChAInS (2 And OVeR)
   Pharmacist non-Pharmacist
 Two pharmacies 113 4 235
 Three 31  93
 Four  13  52
 Five 7  35
 Six 4 1 30
 Seven  1 7
 Eight 3  24
 Nine 1  9
 Ten  1 10
 Thirteen 1 1 23
 Fourteen 1  14
 Fifteen 1  15
 Sixteen 1  16
 Twenty 1  20
 Twenty-Four 1  24
 Twenty -Six 1  26
 Fifty  1 50
 Seven-two  1  72
  (591) (166) (757
(a) MeMBeRShIP OF the IPU
 Community Proprietors  878
 Industry & Wholesale  7 
 Community Employees  851
 Hospital  9
 Army, Academic & Admin  4
 Associate Members   8 (1757)
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3. PROdUCt FILe UnIt
 The IPU Product File is managed by Fiona Hannigan 
and her team: Ger Gahan, Eilish Barrett and Aoife 
Garrigan. As well as supplying price updates and 
product information for members, they provide the 
following services and advice: 
n Product sourcing
n General queries on the IPU Product File
n GMS pricing issues
n Short Supply & Discontinued Lists
 The IPU also provides a Drug Interaction File and 
information files on drug use in Pregnancy and 
Breastfeeding, produced by the School of Pharmacy in 
Trinity College Dublin, linked to the IPU Product File. 
These are based on the ATC classification system and 
are designed to warn pharmacists of the possibility of 
an interaction. A PwC survey found the IPU file to be 
highly regarded and valued by users.
 the following areas are a priority in the Product File 
area during 2011
n Enhancements to the IPU Product File to facilitate 
reference pricing and generic substitution.
n PA/PPA/DPA/EMEA numbers, verification of 
products, etc.
n Direct links to the IMB website to facilitate access to 
SPCs and PILs. 
n A toolkit to assist system vendors in incorporating 
the IPU Drug Interactions File into their dispensary 
systems.
n Roll out of IPU Live Download of the IPU Product File.
n Development of a protocol to allow for broadband 
transmission of electronic orders.
4. AdMInIStRAtIOn UnIt
 The Administration Unit has four staff members: 
Patrice O’Connor, who works part-time, looks after 
reception and assists in the day-to-day running of 
the office; Ciara Enright, who works part-time as 
the Union’s accountant, is Secretary to the Finance 
Committee. She maintains books of account 
and advises members on a range of taxation 
and accountancy problems. Wendy McGlashan 
is responsible for IPU publications, including the 
production of the IPU Review and co-production 
of the IPU Yearbook, event organisation, general 
administration and personnel matters. Roisín Molloy 
is responsible for all aspects of membership and the 
management of the Secretary General’s office. 
5. COntRACtUAL And OtheR ReLAted ISSUeS 
 Jill Lyons, and Caroline Mulligan deal with a wide 
range of contractual issues. Jill Lyons is Secretary to 
the Pharmacy Contractor’s Committee (PCC). Jill and 
Caroline have played a key role in developing many 
of the key PCC initiatives throughout the year and in 
the resolution of some problems with the Health 
Service Executive, Primary Care Reimbursement 
Service and the Department of Health & Children. 
Throughout 2010 Jill Lyons was involved in preparing 
two submissions and two oral presentations to 
the FEMPI Reviews [June 2010 & December 2010], 
preparing for the implementation of the prescription 
levy, preparing for the implementation of a Needle 
Exchange Programme, and preparing the submission 
and oral presentation to the DoHC’s Working Group 
on Reference Pricing. Jill also represents the Union 
at the PGEU Economic Working Group. Jill and 
Caroline have spent much of the year participating 
in the Joint Consultative Group with the HSE and the 
implementation of the Incomplete Claims Protocol as 
well as addressing all other contractual queries that 
arise. Caroline also deals with remuneration queries, 
compiling information on the raids on pharmacies 
and collecting information on stolen and forged 
prescriptions. 
6. POLICy And PUBLIC AFFAIRS 
 Gerard Howlin was appointed on 15 November 2010 
as Head of Policy and Public Affairs. Following the 
departure of Paul Fahey there was a reorganisation of 
responsibilities at Butterfield House and Gerard has 
taken responsibility for communications, publications, 
events, business, policy research and public affairs. 
Subsequent to the announcement of the FEMPI 
review in December 2010 Gerard worked with Jill 
Lyons to organise a survey of members and to deliver 
time for a new approach, the IPU’s submission to 
the Department in January. Gerard is working with 
the Secretary General on an ongoing basis to liaise 
with stakeholders in Government and across the 
political parties. Gerard initiated a successful lobbying 
campaign to ensure that community pharmacy was 
included in the party manifestos. He is leading for 
the secretariat on the Clinical Platform Project and 
working with colleagues to ensure that plans in all his 
relevant areas are rolled out effectively
7. MedIA And COMMUnICAtIOnS
 Kate Healy, who ceased employment with the IPU 
in April was responsible for the promotion and 
coordination of all national and regional media 
coverage for the Union. She was secretary to the 
Executive Committee and assisted the Secretary 
General in the development and coordination of all 
regulatory, policy and political activities. She was 
responsible for the editorial content of the IPU Review 
and managed IPU advertising campaigns. Aoibheann 
Ní Shúilleabháin works on the co-ordination of all 
communications activities, organises events, manages 
the IPU website and the advertising for the IPU Review. 
She is Secretary to the Organising Committee for the 
IPU National Pharmacy Conference. Gerard Howlin has 
assumed overall responsibility for this area.
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 Communications
n Market Research: The Union undertook market 
research amongst the general public, which 
assessed how people had actually reacted to the 
dispute and how it had affected their view of the 
profession. The research showed that pharmacists 
continue to be held in high esteem by patients.
n Advertising and Public Relations: The Union ran 
radio advertising campaigns in October, November 
and December. The ads aimed to promote the role 
of the pharmacist and to encourage people to visit 
their pharmacy as a place to shop in the run up to 
Christmas. Public relations activities also raised the 
profile of pharmacists in the media, including a 
number of interviews on RTÉ One’s “Four Live”.
n Communications with Members: A lot of work 
has been done in terms of getting members’ 
feedback on our communications and, as a result, 
we have made great progress but we are working 
to develop better two-way communications and 
the greater use of e-communications. We have the 
IPU website, a dedicated IPU YouTube channel, the 
email service @ipumail.ie which provides members 
with easier and instant access to all IPU services and 
information and the weekly e-newsletter, which 
was launched during the year.
n Publications The IPU Review, Yearbook and a weekly 
e-newsletter are now all produced in-house rather 
than through external contractors for efficiency 
reasons.
8. PhARMACy SeRVICeS
 The Director of Pharmacy Services, Pamela Logan, 
co-ordinates all Professional, Business and Training 
matters within the Union. Pamela acts as Secretary to 
CPC and details of issues covered by this Committee 
can be found in the CPC report. She works with 
relevant departments and agencies, both nationally 
and internationally, to promote the role of the 
pharmacist. Pamela also represents the Union at ICCPE, 
PGEU, FIP and Europharm Forum.
9. tRAInInG dePARtMent 
 Susan McManus, Training and HR Manager, organises 
and co-ordinates a range of training courses for 
pharmacy staff. Janice Burke assists Susan in this 
department. The Pharmacy Technicians’ Course saw 112 
students graduating in March 2011. There are currently 
150 students participating in Year 1 and 146 students 
in Year 2 of the course. In addition, 132 students 
completed the MCA Course in 2010 in Claremorris, 
Cork, Dublin, Galway, Kilkenny and Tralee. 76 students 
completed the Interact course and 33 completed 
the Interact Plus course. The FÁS Pharmacy Sales 
Traineeship course was administered in Baldoyle and 
Loughlinstown, Dublin; Douglas, Cork; and Mervue, 
Galway. Susan also acts as Secretary to the Employee 
Pharmacists’ Committee, co-produces the IPU Yearbook 
and Diary and advises members on HR issues.
10. BUSIneSS SeRVICeS
 The Business Development Manager, Darren Kelly, 
is  responsible for business services to members. 
In 2010 “Strategies for growth” business training was 
held around the country to help members understand 
their business and maximise their profits. A number of 
affinity schemes have been negotiated for members 
on a range of products and services and details can 
be found on the IPU website. Members are kept up 
to date with current legislation through notices in 
the IPU Review, Yearbook, E-Newsletter and General 
Memoranda. Darren also produces the Business 
Newsletters on specific relevant topics which are sent 
out to members throughout the year. In addition, 
individual advice on retail and business issues is 
given to members on request. Members who paid 
their subscriptions for 2010 would have received their 
IPU membership card, “What the iPu does for you” 
information booklet and a discount booklet outlining 
the discounts available to IPU members. Darren also 
oversees the general maintenance and upkeep of 
Butterfield House.
11. exteRnAL COnSULtAntS
 Gordon MRM (PR Consultants); Coolamber (IT 
Consultants); John Behan (Industrial Relations Advisor) 
and Sean McHugh (Industrial Relations Advisor); 
provide advice and support to the Union as requested 
on an ongoing basis. Leaf Environmental has been 
retained as consultants to the Union on matters 
regarding environmental and waste management 
issues.
12.  MAILInGS tO MeMBeRS
 The number of mailings to members over recent years 
were: 2003, 25; 2004 19; 2005, 20; 2006, 24; 2007, 47; 
2008, 59; 2009, 53; 2010, 38.
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13. MAIn COMMIttee MeetInGS
 The number of committee meetings was:
  ‘10 ‘09 ‘08 
 Executive Committee 6 9 10
 Community Pharmacy Committee 5 6 5
 Pharmacy Contractors’ Committee  8 8 6
 Finance Sub Committee  7 7 7
 All Committee Meetings 0  3 3
 Employee Pharmacists’ Committee 4 3 4
14. UnIOn PUBLICAtIOnS
 The following are sent to members, on a regular basis:
n IPU Review
n IPU Weekly Newsletter – sent to members by email
n General Memoranda
n Price Index List Updates
n IPU Product File on Disk and CD
n Yearbook & Diary
n Wall Planner 
n Training Course Updates
n Employee Pharmacists’ Committee Newsletter
n Reap the Rewards of IPU Membership
15. PenSIOnS And InSURAnCe 
 AIC (Corporate) Ltd, Pharmacy Insurance Ireland and 
Liberty Asset Management provide insurance and 
pension services for members.
16. enqUIRIeS
 Union Staff handle enquiries on a wide range of topics 
and deal with questions raised by members regarding 
their difficulties with companies, Government and 
other agencies as well as a wide variety of professional, 
business and personnel issues including:
n Advertising
n Banks
n Computerisation
n Contracts of Employment
n Credit Cards
n Customs & Excise
n Data Protection
n Dismissals; unfair, etc.
n Dispensing, extemporaneous price list
n Drug Donations
n Education & Training / Training Grants
n Employer/employee disputes
n Employee Status
n General Medical Services; Fees, etc
n Health Centres
n Health & Safety
n Health Promotions
n Health Screening
n Health Services and Schemes
n HSE
n HSE PCRS queries
n Industrial Relations law; general
n Insurance
n Internet pharmacy
n IPHA
n Leave; Annual, Maternity, Compassionate, Public 
Holidays, Holiday Pay, etc.
n Legal issues
n Locum Lists / Situations Vacant
n Maternity Legislation
n Medical Translations
n Membership
n Methadone Treatment Scheme
n Monitored Dosage Systems
n Openings; pharmacy
n Pay; National Minimum Wage, etc.
n Part-time workers
n Pharmacy Contract
n Pharmacy Legislation
n Photographic issues
n Prescriptions, Emergency Hospital
n Prices; including negotiations
n Products; agents, availability, confined, 
discontinued, etc
n Professional Indemnity Insurance
n PRSI
n Prescriptions; Stolen, Forged, etc.
n Psychiatric Scheme
n Publishing Scams
n Record Keeping
n Redundancy
n REPAK charges
n Returns; for credit, etc
n Salaries
n Security; Pharmacy Raids, etc.
n Sickness
n Signage
n Standard Operating Procedures
n Suppliers
n Taxation
n Trading Terms
17
AnnUAL RePORt 2011
n Union Posters requested on a regular basis include:
• Medicines & Pregnancy
• DPS Threshold 
• Paracetamol
• EHC 
• Prescription Validity 
• Refunds on Medicines 
• Privacy
• Tax Relief 
n Unit Pricing
n Unlicensed Medicines
n VAT; IPU Scheme, etc
n Waste Management
n Withholding Tax
n Wholesalers
17. SUBMISSIOnS
 The following submissions were made during the year. 
Extracts of these are published in the appendices to 
this report and all are available on the IPU website:
n Review of Methadone Treatment Protocol – HSE – 
June 2010 
n Review under the FEMPI Act – DoHC – June 2010
n Retail Planning Guidelines – DEHLG – July 2010
n Oral Presentation on Methadone Treatment 
Protocol Review – HSE – Sep 2010 
n Draft Guidelines on Sourcing, Storage and Disposal 
of Medicines – PSI – Sep 2010 
n Draft National Standards for Safer Better Healthcare 
– HIQA – Nov 2010
n Mental Health Vision for Change – DoHC 
Independent Monitoring Group – Nov 2010
n IPU VAT Scheme –Revenue Commissioner – January 
2011
n Review under The FEMPI Act 2009 – Time for a New 
Approach - January 2011
18. IPU ReVIeW
 The IPU Review is produced in-house by Gerard Howlin, 
Wendy McGlashan and Aoibheann Ní Shúilleabháin. 
19. COnCLUSIOn
 Finally, I would like to thank all the staff of the Union 
for their support to me and their hard work on behalf 
of members throughout the past year. 
 Seamus Feely, 
Secretary general.
18
AnnUAL RePORt 2011 	
Pharmacy Contractors’ Committee  
(PCC) Report 2011
 The current Pharmacy Contractors’ Committee, under 
the Chairmanship of Liam Butler, took office following 
the 2010 Annual General Meeting (AGM) in April. 
Morgan Power was elected Vice-Chairman. The PCC 
met seven times since the AGM 2010.
 This year the PCC’s energies have been focussed 
on preparing for two reviews under the Financial 
Emergency Measures in the Public Interest Act 2009 
(FEMPI) along with many other urgent issues which 
have arisen during the year. 
the MAIn IteMS On the COMMIttee’S AGendA SInCe 
the LASt AGM:
 FeMPI Act 2009: 
n Preparing the Submission and Oral Presentation 
to the FEMPI Act Consultations in June 2010;
n Preparing the Submission and Oral Presentation 
to the FEMPI Act Consultations in January 2011;
n Communicating with members in advance of 
both FEMPI Act reviews; and
n Communicating with members in the aftermath 
of the FEMPI Act reviews.
 hSe Matters:
n Participating in the Joint Consultative Group 
with the HSE; 
n Resolving any issues on the re-issuing of 
Contracts to Members
n Negotiating a streamlined system for unlicensed 
medicines under the Hardship Scheme and 
Drugs Payment Scheme;
n Advocating for an agreed list of medicines for 
the LTI Scheme;
n Negotiating an agreed Protocol with the HSE 
around Incomplete Claims and ensuring all 
outstanding claims were paid;
n Monitoring of the Psychiatric Scheme and 
dealing with changes which took place in the 
Scheme in 2010;
n Advising Members on matters related to the 
Drugs Payment Scheme;
n Ongoing preparation and discussions for the 
introduction of a Needle Exchange Programme 
with the HSE and Elton John Foundation; 
n Liaising with the HSE and DoHC to resolve issues 
around the Community Pharmacy Contract;
n Monitoring all pharmacy payments; and
n Ongoing HSE PCRS Administration issues.
 department of health and Children Matters:
n Preparing for the implementation of the 
Prescription Levy;
n Preparing the Submission and Oral Presentation 
to the DOHC’s Working Group on Reference 
Pricing; and
n Meeting with the Minister for Health and 
Children.
 Monitoring the Cost of Medicines:
n Monitoring the reduction in the cost of medicines 
from APMI in September 2010; and
n Monitoring the reduction in the cost of medicines 
from IPHA in January 2011.
 FeMPI Act 2009:
 Submission and Oral Presentation in June 2010 
Last year’s Review under the FEMPI Act 2009 began 
in May. The PCC, along with economist Jim Power, 
worked on the submission to the Minister. The Union 
also engaged PwC to conduct a survey of members 
on the impact of the previous FEMPI cuts in relation 
to pharmacy income, services and viability. Members 
of PCC also made a presentation to officials in the 
Department of Health and Children and the HSE. 
 In the submission and at the oral presentation the PCC 
highlighted:
n The reduction of 30% in pharmacy income due to 
the cuts in 2009;
n The inconsistencies in the figures provided to the 
Union; and
n The impact of the cuts on individual pharmacies, 
which is of the order of €100,000 per pharmacy.
 In July, after further representations by the PCC, the 
Minister wrote to the Union informing it that she had 
completed her review of the operation, effectiveness 
and impact of the amounts and rates fixed by the 
regulations and would not be making any further cuts 
at this time. The PCC welcomed this decision from the 
Minister.
 Submission and Oral Presentation in January 2011 
On 8 December the Minister for Health and Children 
launched a third review of pharmacy payments under 
the FEMPI Act 2009. A further survey from PwC was 
conducted which built on the survey earlier in the year. 
The PCC also sought data from the PCRS which was 
helpful in formulating the submission. 
19
AnnUAL RePORt 2011
 The submission was sent to the Minister for Health 
and Children on 5 January 2011. A delegation from the 
PCC made an oral presentation to the Department of 
Health and Children on 7 January.
 In both the submission and oral presentation, the PCC 
stressed that:
n pharmacists had taken more than their share of 
cuts over the past two years; direct and indirect 
cuts of 32% or €153m which is more than that 
suffered by any other sector;
n additional efficiencies and savings could be 
achieved but only by adopting a new approach 
which would involve substantial and direct 
engagement with the Union to review all 
existing administrative, contractual and 
payment arrangements;
n if arbitrary cuts continue to be inflicted on 
the pharmacy profession; it would have a 
detrimental impact on pharmacists and  
patient care. 
 Follow up letters were sent the week after the 
presentation to the Department and the Minister. 
In March, a new Minister for Health was appointed, 
Dr James Reilly. The PCC wrote to him requesting a 
meeting immediately and asked him to consider the 
issues raised in the submission made in January. The 
PCC again strongly argued against any cuts being 
made to pharmacy payments, particularly against any 
reductions in dispensing fees and margins.
 On 31 March, the Minister for Health announced 
further cuts to pharmacy payments. 
 On initial examination, it is estimated that the cuts will 
reduce pharmacy payments by €24m from May to end 
December 2011 and over €36m in a full year. This amounts 
to an 8% decrease across the sector and an estimated loss 
of €15,000 to the average pharmacy business. 
 The PCC wrote to the Minister on 1 April requesting 
that any changes be delayed for a minimum period of 
six weeks to allow for the appropriate IT amendments 
to software systems to take place. The Committee 
stated that they hoped that this would be the end of 
the recent ad hoc and arbitrary cuts. The PCC believed 
that discussion on a wider agenda would offer an 
orderly and efficient way to work together in bringing 
about real and lasting change in the future and 
offered to meet with the Minister on this matter.
 hSe Matters:
 Participation in meetings of the Joint Consultative Group
 The Joint Consultative Group met three times since 
the AGM. As part of this Group, the Union and the HSE 
agreed to cooperate in the areas of modernisation, 
efficiency and flexibility. The Group is also a forum for 
discussion on matters of concern for members. 
 
 Return of Contracts
 Since August 2009 the PCC had been in constant 
contact with the HSE and the Department of Health 
and Children to resolve this matter. A slightly amended 
contract was negotiated between the PCC and the HSE 
in early 2010 and this was issued to all the members 
involved in May. The PCC encouraged members to 
return the contracts and welcomed the resolution  
of this issue which had caused members  
considerable strain. 
 Changes to dispensing ULMs
 Over the past few years the PCC had been raising 
issues and concerns around the dispensing of 
Unlicensed Medicines (ULMs) to patients under 
the Drugs Payment Scheme (DPS), the Long Term 
Illness (LTI) Scheme and Hardship Arrangements 
in correspondence and at meetings of the Joint 
Consultative Group.
 In May 2010 the HSE issued a circular which outlined 
changes to the dispensing of unlicensed medicines 
and also a list of reimbursable unlicensed medicines. 
The list included details of the supplier, the cost of 
the medicine and a reimbursement code. The PCC 
will continue to monitor the dispensing on medicines 
under this list and will work with the HSE to make the 
system even more user-friendly.
 Clarification of Medicines allowed on the LTI Scheme
 After ongoing requests from the PCC for clarity and  
transparency around the LTI Scheme, the HSE issued 
an LTI Circular in July 2010. The HSE included a list of 
automatically approved items for LTI patients with 
Diabetes Mellitus and Epilepsy. The circular is intended 
to increase transparency and reduce administrative 
burden for pharmacists. There are still ongoing issues 
around LTI which the PCC will continue to monitor.
 Introduction of an Incomplete Claims Protocol
 The PCC has been monitoring this matter since it first 
arose in 2010. The PCC’s primary concern was securing 
payment of all outstanding claims and safeguarding 
payments going forward. The Union received a large 
volume of calls from pharmacists in relation to the 
rejection of claims by the PCRS. 
 The PCC pursued the matter vigorously and met with 
the HSE numerous times to work towards a resolution 
and payment of all outstanding claims. An Incomplete 
Claims Protocol was finalised in October which 
addressed the matter and ensured that problems 
such as this would not occur in the future. The HSE 
stopped rejecting GMS claims and paid all outstanding 
amounts to members with their October claims. 
However, pharmacies who claim manually continue to 
have problems with their claims and these are being 
followed up by the PCC on an ongoing basis.
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 The PCC believed that this was a reasonable outcome 
as it addressed the first priority of the Union which 
was to ensure that pharmacists got paid for the 
services that they provided with the minimum of 
delay. The PCC asked all members to comply with the 
terms of the Protocol. The PCC and the HSE will be 
monitoring the implementation of the protocol at the 
JCG meeting throughout the year.
 Psychiatric Scheme
 In September 2010 Psychiatric Clinics in the Old 
Northern Area Board (north of the Liffey) took the 
decision to refer all GMS Psychiatric Patients back to 
their GP to have their medicines written on a GMS 
prescription form. The changes took place in Areas 6, 7 
and 8. Patients attending these clinics were told that 
from 1 October they need to go to their GP to get a 
GMS prescription to take to the pharmacy. The change 
was introduced without any discussion with the PCC 
and apparently with no thought given to the impact 
of the changes on this vulnerable cohort of patients. 
The PCC complained to the HSE about the manner in 
which this change was implemented and argued that 
the new arrangements had placed a barrier in the 
pathway to accessing medicines for these patients and 
would compromise patient safety. The HSE intended to 
introduce this change to all areas in 2010; however, the 
roll out was halted after the PCC complaint. The PCC 
continue to monitor this issue.
 Advice on the Drugs Payment Threshold
 Throughout the year, the PCC dealt with a large 
number of queries in relation to the Drugs Payment 
Threshold. The advice to members was that it is 
entirely a matter for each individual pharmacist to 
decide for themselves what price they charge to 
private patients, including sub threshold patients. The 
legislation only applies to the amount that the State 
reimburses to healthcare professionals and the level 
of refunds that are made to patients under the various 
State Schemes. The matter now appears to form part 
of the IMO agreement with Government and this is a 
very worrying development. The PCC will continue to 
pursue this matter with the HSE and Department of 
Health and other relevant Departments.
 Roll out of a Needle Exchange Programme
 Throughout 2010 there were on-going discussions 
about the introduction of a Needle Exchange 
Programme between the PCC, the HSE and the Elton 
John Foundation. Subject to further discussions with 
HSE officials, the PCC has committed to participate in 
this worthwhile service for the Community.
 department of health and Children Matters:
 Meeting with the Minister
 Officials from the Union met the Minister for Health 
and  Children on 29 April 2010. The Union raised 
a number of issues at the meeting including the 
prescription levy, reference pricing, and the FEMPI 
review. The officials from the Union also left a copy 
of the 2010 AGM motions with the Minister for 
consideration by her and her officers. 
 Prescription Levy
 The prescription levy was originally due to be 
introduced in April 2010. Throughout the summer 
there was constant contact between the PCC and 
the HSE/DoHC. Members of the Union met with and 
wrote to officials from the Department a number of 
times to discuss the prescription levy, highlighting 
many concerns around its introduction and the impact 
it would have on patients. 
 On 1 October the prescription levy was finally introduced. 
The Union issued members with posters and leaflets 
to alert patients to the levy being imposed on them. 
The PCC has been liaising with the HSE to answer any 
questions which have arisen since the introduction of 
the levy and a number of updates have been issued to 
members over the past few months. The Union met with 
Nursing Homes Ireland in an effort to resolve the issue 
over the collection of the levy from patients in nursing 
homes. The PCC continues to seek the abolition of this 
levy or, at the very least, further exemptions for nursing 
home patients and other vulnerable patient cohorts. 
The incoming Government has indicated its intention to 
abolish the levy. The PCC will keep the issue under review.
 Reference Pricing and Generic Substitution
 The PCC Sub Group on Reference Pricing made 
two submissions and an oral presentation to the 
Department of Health and Children’s Reference Pricing 
and Generic Substitution Group chaired by Mark 
Moran. The PCC advocated for a pharmacy led generic 
substitution and felt that this was important if any 
new system were to succeed. The PCC also warned 
about a race to the lowest price and used European 
examples where there have been ongoing medicine 
shortages due to reference pricing systems, which put 
patient welfare at risk. 
 The Department published their report in June 2010. 
The report set out a proposed model for the operation 
of a system of interchangeable medicines and 
reference pricing. The report also stated that generic 
substitution should be pharmacy led as recommended 
by the PCC. The PCC welcomed the move by the 
Minister to allow pharmacists to offer patients the 
choice of a cheaper generic medicine but also asked 
the Minister to be careful in taking steps towards the 
introduction of reference pricing as pharmacists had 
already suffered a major blow due to cuts imposed  
in 2009.
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 The Heads of Bill for Reference Pricing are currently 
being prepared by the Department and are at an 
advanced stage. The PCC has requested a meeting 
with the Department.
 Monitoring the Costs of Medicines
 Reduction in the Cost of APMI Medicines
 The new APMI Agreement came into effect on 1 
October. In advance of the implementation date the 
PCC wrote to the Department of Health and Children 
stressing that the implementation of any price 
reductions should allow sufficient time to update 
pharmacists’ IT systems and to allow them to try to 
dispense stock reimbursed at the higher price. The 
PCC also requested a deferral of the implementation 
date; however, the Department would not consider 
any deferral of the Agreement. As soon as the price 
changes were received from the HSE, the IPU  
Product File for October was emailed and posted  
out to members. 
 Reduction in the Cost of IPHA Medicines
 As part of the Budget 2011 in December, the 
Department announced that they would make savings 
of €140m through reductions in the cost of medicines 
from 1 January 2011. 
 The PCC:
n advised members to manage their stock: 
n wrote to the Department, the Minister, the Chief 
Executive of the HSE and the wholesalers on the 
matter; and
n was also in constant contact with officials from 
the Department, the HSE and IPHA. 
 The Department only informed the Union of the 
changes that were taking place on 23 December. The 
Union was informed on 5 January that ‘all associated 
Parallel imported products will be reduced pro rata’. The 
manner and the speed in which these price reductions 
were implemented were totally unacceptable and 
there was considerable annoyance among members 
about this. The PCC met with and wrote to the DoHC 
complaining about the manner in which these 
reductions were implemented and requesting that 
they put in place safeguards to prevent the high level 
of loss experienced by pharmacists in January in any 
future reduction in the price of medicines. The DoHC 
have confirmed to the PCC that they will strive to give 
as much notice as possible in the event of further price 
reductions. The PCC will continue to monitor this matter 
having regard to the current economic situation.
 
 Conclusion
 The above provides a summary of some of the major 
issues dealt with throughout the year. However, 
officials of the Union intervened in many other 
instances to resolve individual issues for members. 
 The PCC is actively working with the HSE on members’ 
behalf. Progress can be slow and discussions take time. 
There are often difficult issues to resolve, but at all 
times, the PCC continue to pursue issues on behalf of 
members until a resolution is found.
 Liam Butler,
	 Chairman	PCC.
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Community Pharmacy Committee  
(CPC) Report 2010-11 
The Community Pharmacy Committee (CPC) is chaired by 
Stephen Nolan with Bernard Duggan as Vice-Chairman. 
CPC’s mission statement is CPC – working to serve and 
support community pharmacists in their practices and 
to promote and expand their role as pharmacists by 
continually developing professional, ethical, business and 
technological ideals and standards.
The CPC is split into three sub-groups as follows:
Professional development Steering Group
Bernard Duggan, Oonagh Harnett, Niamh Murphy, Ultan 
Molloy (Ciara Cronin resigned in September 2010). 
Business and Policy Steering Group
Roy Hogan, Michael Tierney, Daragh Connolly, Elizabeth 
Lang, Aidan Walsh (replacing Peter Fox in January 2011). 
It Steering Group
Louise Begley, Ross Mc Entegart, Jack Shanahan, Rory 
O’Donnell. Sean Reilly (Exec), Brian Walsh (PCC) and John 
Barry have also been co-opted onto ITSG.
CPC has met five times since the April 2010 AGM (May, 
August and October 2010 and January and March 2011). 
The Committee has dealt with a wide variety of issues 
over these meetings. The following is a summary of the 
key issues dealt with during this time. 
PROFeSSIOnAL ISSUeS 
PSI Consultations and Inspections
Championships in Athy in September instead of the Over 
50s Show.
SOPs / Guidelines
CPC has made a number of submissions to the PSI over 
the year: Consultation Areas; Codeine Guidance; and 
Sourcing, Storing and Disposal of Medicines. All of these 
submissions are available on the IPU website. 
In July 2010, the PSI produced guidance on the sale of 
medicines containing codeine. To assist members in 
complying with the new guidance, CPC produced a 
Codeine Sales Protocol and posters and leaflets were sent 
to pharmacies to assist them in communicating with 
patients. 
The PSI Guidelines on Patient Consultation Areas in Retail 
Pharmacy Businesses came into effect on 1 November 
2010. To assist members in the implementation of the 
guidelines, CPC put guidance on issues to consider 
when designing and equipping a Consultation Area and 
guidance on the layout of the area on the IPU website. A 
Privacy Poster was sent to all pharmacies in July.
 
The IPU Inspections checklist was updated to reflect new 
PSI guidance and also to include issues around CDs that 
have been reported by members following inspections. 
Much positive feedback has been received from members 
who have used the Inspections checklist and CPC 
recommends that all pharmacies utilise it to prepare for 
inspections. The checklist can be downloaded from the 
IPU website.
The final PSI Guidelines on Sourcing, Storing and Disposal 
of Medicines have yet to be published but in anticipation 
of the final draft, CPC has produced a set of SOP templates 
to assist members in complying with the guidelines. These 
can be downloaded from the IPU website. 
The PSI Service Plan for 2011 proposes the production of 
guidelines on: Supply and Counselling of NPMs; Premises 
and Equipment; Supply of POMs; Record Keeping; 
Management and Supervision; and; Supply of Medicines 
to Nursing Homes. CPC will produce SOP templates to 
cover these guidelines when drafted.
extended Pharmacy Services
Health Screening Pilot
43 pharmacies participated in the Union’s Health  
Screening pilot from July 2009 until February 2010. The 
results are now being analysed by TCD to provide evidence 
to support the expansion of the professional role of the 
pharmacist. Aisling Reast, who coordinated the pilot on 
behalf of the Union, presented preliminary findings at 
FIP in Lisbon in September 2010 and at the All Ireland 
Pharmacy Conference in February 2011. 
Medicine Use Review Pilot
The Union is participating in the HSE Pharmacy in  
Primary Care Group which is considering a number of 
extended roles for community pharmacists. A Medicines 
Use Review (MUR) pilot took place over the past six 
months and the results are now being analysed by TCD. It 
is hoped that MURs will soon be rolled out nationally. 
Asthma Management Demonstration Project
The Asthma Management Demonstration Project ran 
from October 2009 until July 2010. The aim of the 
project was to identify facilitators and barriers to the 
implementation of evidence-based asthma management 
guidelines. 25 GP practices and 70 community pharmacies 
participated in the project. All patients recruited received a 
written Asthma Plan and subsequent GP visits were based 
on the patient’s clinical status. At the same time, the 
Union has been participating in the HSE’s Asthma Health 
Policy Project Team which is looking at best practice care 
pathways for the treatment of asthma. It is hoped that 
the asthma project will soon be rolled  
out nationally. 
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  Needle Exchange Scheme
The HSE has received funding for a pharmacy-based 
needle exchange scheme from the Elton John Aids 
Foundation. The scheme will initially commence in 65 
pharmacies around the country with further expansion 
of the scheme over the next three years. As part of the 
scheme, a National Pharmacy Coordinator for methadone 
will be appointed by the HSE. The scheme should 
commence shortly. 
Methadone Treatment Protocol
The Union made a written submission and oral 
presentation to the HSE on the Review of the Methadone 
Treatment Protocol. The Union’s presentation highlighted 
the issues facing community pharmacists involved in 
the Methadone Treatment Scheme and we made a 
number of recommendations to improve the Scheme: 
the appointment of a National Pharmacy Coordinator; 
a system for filtering unstable methadone patients; a 
support system for community pharmacists; correct 
payment for take-away doses of methadone; a review 
of patients in Garda custody and the prison system; and 
pharmacists being able to correct errors on methadone 
prescriptions. 
The Review acknowledged that pharmacy involvement 
is a critical component in the overall delivery of the 
Methadone Treatment Protocol, allowing for a large 
number of opiate dependent persons to be treated in their 
own local area. The Review Group recommended that 
the methadone regulations be redrafted to incorporate 
buprenorphine and buprenorphine/naloxone treatment. 
Consequently, the title of the protocol was changed to The 
Opioid Treatment Protocol. 
Patient Safety
The Union continues to participate in the Department 
of Health’s Medication Safety Forum which currently is 
focusing on: the development of a national prescription 
form; development of SOPs for pharmacies; guidelines 
for codeine medicines; the roll-out of the Asthma 
Management Programme; the re-launch of PIP; and the 
management of patient discharge.
Palliative Care
The IPU has participated in a number of initiatives 
under the End of Life Forum umbrella over the past year. 
The Forum seeks to extend access to palliative care to 
people with illnesses other than cancer such as COPD, 
heart failure and dementia. The IPU’s submissions and 
presentations focused on the role of the community 
pharmacist in palliative care, highlighting provision 
of timely access to essential palliative medication for 
patients cared for at home, the information resource 
of the community pharmacist and the liaison with 
other healthcare professionals on issues related to 
pharmaceutical care. The Forum’s Report and Action Plan, 
published in June 2010, acknowledged the importance of 
the role of the community pharmacist in these areas.
The Union is also participating in a project run by Our Lady 
of Lourdes Hospice, focusing on the primary care role of 
community pharmacists in the treatment of palliative  
care patients. 
Deregulation of Medicines
The Union participated in a Switch on to Self-Care 
Working Group over the past 18 months. The Group 
was composed of representatives from key stakeholder 
organisations including the IPU, the School of Pharmacy 
TCD, the Department of General Practice UCC, and 
representatives from the pharmaceutical industry. The 
Group has now finalised a Self-Care Framework for 
Ireland which recommends that the range of medicines 
made available to patients should be expanded through 
switching. The Union also advocates for centralised 
switching by the European Medicines Agency under the 
PGEU umbrella. Following the deregulation of Norlevo in 
February this year, the IMB has formed a committee to 
look at this issue further.
health Promotion
In May 2010, the IPU ran a health promotion around 
European Obesity Day. Posters and leaflets were displayed 
in pharmacies, advising people to ask their pharmacist 
about obesity and healthy eating.
In June, the Union collaborated with Western Alzheimers 
in a mini health promotion to raise awareness of 
Alzheimers in Counties Galway, Mayo and Roscommon. 
Leaflets were displayed in pharmacies and the Western 
Alzheimers ran a  
radio appeal. 
In September, the IPU had a stand at the National 
Ploughing Championships in Athy which was attended by 
over 200,000 people. Pharmacists promoted the role of 
the pharmacist in veterinary medicines and gave lifestyle 
advice to people following basic health-checks.
In March 2011, the Union provided pharmacies with 
promotional materials to assist in the supply of Norlevo to 
patients. 
SOPs / Guidelines
A range of Standard Operating Procedures, Guidelines 
and Protocols are available in the members’ only section 
of the IPU website under Professional Assistance > 
Guidelines and Protocols. These simple guidelines have 
been produced for members so that they can easily draw 
up protocols saving them money and time in doing. Topics 
covered include:
n Dispensing Process (including a guide to SOPs); 
n Prescription Collection and Delivery;
n Dispensing Errors Log;
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n Dispensing EEA Prescriptions;
n Parallel Imports;
n Health Screening including Lifestyle Advice;
n Medicines Sales Protocol;
n Codeine Sales Protocol;
n alli Sales Protocol;  
n Levonorgestrel Sales Protocol
n Methadone Guidelines;
n Needle Exchange;
n Sharps Disposal;
n Asthma Inhaler Technique;
n Consultation Areas;
n Nursing Home Guidelines;
n Sourcing, Storage and Disposal of Medicines. 
Medicines Shortages
The Union wrote to the Department of Health, the Irish 
Medicines Board and the Health Service Executive in 
March 2011 expressing concern at the significant number 
of medicines shortages that we had experienced in 
Ireland in previous months. We noted that other European 
countries had introduced a public service obligation 
which requires wholesalers to guarantee permanently 
the provision and timely delivery of medicinal products 
to meet the needs of patients. Obviously, wholesalers 
can only fulfil this type of obligation if they receive the 
medicines in the first place. We felt that it was time 
that the Department, IMB and HSE introduced a similar 
provision in Irish legislation.
training
The Union produced its first IPU Open Learning 
Programme for Pharmacists in March 2011 on emergency 
contraception as part of our ongoing service to members, 
another benefit of IPU membership. The programme was 
free of charge to all IPU members; this was supported by 
HRA Pharma as a service to pharmacy. We would hope 
to produce more continuing education resources for 
members in the coming year to assist them in their CPD.
Susan McManus, Training and HR Manager, organises 
and co-ordinates a range of training courses for pharmacy 
staff. Janice Burke assists Susan in this department. 
The Pharmacy Technicians’ Course saw 112 students 
graduating in March 2011. There are currently 150 students 
participating in Year 1 and 146 students in Year 2 of the 
course. In addition, 132 students completed the MCA 
Course in 2010 in Claremorris, Cork, Dublin, Galway, 
Kilkenny and Tralee. 76 students completed the Interact 
course and 33 completed the Interact Plus course. The FÁS 
Pharmacy Sales Traineeship course was administered in 
Baldoyle and Loughlinstown, Dublin, Douglas, Cork and 
Mervue, Galway.
IPOS
The Union set up the IPOS Purchasing Pharmacists’ 
Committee to assist IPOS Purchasing Pharmacists 
(PPs) following the liquidation of the IPOS funds. The 
Committee has met six times since April 2010 and had 
a number of meetings with Uniphar to resolve issues. 
Uniphar announced the outcome and a possible resolution 
to the issues at a meeting on 7 April 2011 and this will now 
be discussed with individual purchasing pharmacists.
Business Issues
The Business Steering Group has met three times since 
the April 2010 AGM to discuss a range of issues that would 
assist members in running their businesses.
Business training
The Union, in conjunction with Cara Healthcare, 
developed the Strategies for Growth business training 
sessions for members. The training took place in Dublin 
(3 sessions), Cork, Galway, Limerick, Dundalk and Sligo. 
Over 100 pharmacists, owners, and pharmacy managers 
attended. CPC has agreed that the Union should work 
with Cara Healthcare again  
for 2011.
Business newsletters
Business Newsletters with information on: Health & 
Safety; an Index of Business Services; and Business 
Regulations were sent out to members in 2010. Further 
Newsletters in 2011 will cover issues such as Maintaining 
Profits and Cash Flow; and Dealing with the PCRS.
Buying Group Pilot 
30 pharmacies participated in a buying group pilot 
scheme for front-of-pharmacy products. Order volumes 
were disappointing and following discussions with the 
wholesaler the CPC agreed that the Union should not 
continue with this initiative.
Benchmarking for Pharmacies
The Union is looking to collate business information 
from members in order to help them to benchmark their 
business. We hope to be able to build up data on the 
pharmacy sector that will assist members in running their 
businesses more efficiently. 
Business Checklists 
The Business Steering Group has developed a Business 
Review Checklist and a Data Protection Checklist as guides 
to help members review their business and ensure that 
key areas of the business are addressed. The checklists  
are available on the  
IPU website.
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Key Performance Indicators (KPI) template
The Business Steering Group has developed a KPI 
Template to help members monitor and benchmark 
the different categories and departments within their 
pharmacy. The KPI Template is available to download from 
the IPU website.
Affinity Schemes
The Union has set up a number of affinity schemes for 
members for a range of products and services including 
Business Management and Coaching, Insurance (Business, 
Professional Indemnity and Travel) and Pharmacy 
Consumables. Further details of these and existing affinity 
schemes can be found in the members’ section of the IPU 
website. 
It Issues 
The CPC IT Steering Group has met six times since the  
April 2010 AGM (April, August, October, November, 
December 2010 and March 2011) to discuss a range of  
IT issues. 
IPU Product File
The Union’s Product File Department is in the process 
of implementing a number of developments to the IPU 
Product File so that it continues to meet the needs of 
members and other users. Live downloads of the IPU 
Product File are being facilitated. System vendors adapted 
their systems to incorporate the FEMPI regulations and 
prescription levy. The Union is working on a toolkit to 
assist system vendors in incorporating the IPU Drug 
Interactions File, produced for the Union by TCD, into their 
dispensary systems. The IPU Product File will soon have 
direct links to the IMB website to facilitate access to SPCs 
and PILs. The Union is working with frontline wholesalers 
and system vendors to allow for broadband transmission 
of electronic orders. The IT Steering Group will continue 
to monitor user requirements for pharmacy systems and 
communicate these to system vendors. Work will soon 
commence on facilitating reference pricing and generic 
substitution with the IPU Product File and dispensary 
systems. 
PCRS and ItSG Meeting
The IT Steering Group met with officials from the HSE 
PCRS in March 2011 to discuss a number of IT issues 
that had been referred by the Joint Consultative Group: 
Pharmacy Security Certificates; Electronic Reports; 
Multiple File Submissions; Nursing Home Issues; High 
Tech Interface; First Generation Wind Down; Manual 
Claiming; Owings; DPS Records; Electronic Prescribing; and 
Reference Pricing. These discussions will continue through 
the Joint Consultative Group. 
It Communications
The Union has received very positive feedback from 
members on the new IPU website, the ipumail service, 
e-Newsletter and text alert service. These media allow 
members to have easier and instant access to all IPU 
services and information. 
i would like to take this opportunity to thank all of the  
Committee members and union staff for their dedication, 
support and enthusiasm over the past year. 
Stephen nolan
Chairman CPC
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Employee Pharmacists’ Committee  
(EPC) Report 2011
The Employee Pharmacists’ Committee (EPC) represents the 
interests of community pharmacy employee members of the 
Irish Pharmacy Union. The committee is chaired by Louise Begley 
with Caitriona O’Riordan as Vice-Chairperson. The mission 
statement of the EPC is: “to promote the professional and 
economic interests of employee pharmacists and constructively 
engage with other Committees of the union and other 
stakeholders through the employee Pharmacists’ Committee.” At 
present there are 851 community employee members of the IPU 
members which constitute 48.5% of the entire membership. 
Work Programme
The EPC has met four times since the 2010 AGM (May, 
August, November 2010 and February 2011). The EPC also 
continues to have active representation on other IPU 
committees, with an allocation of three employee 
representatives on the Executive Committee and four 
representatives on the Community Pharmacy Committee. 
This ensures that the views of employee pharmacists are 
expressed and heard on the other committees of the Union, 
thus enabling employee input into decisions and in the 
development and implementation of the policies of the IPU. 
The EPC has continued to communicate through regular 
articles in the IPU Review magazine which have covered 
topics such as Entitlement to Sick Leave, Locum 
Pharmacists- employed or Self employed, Pharmacy Jobs 
Crisis, Mediation Service and the ePC Survey results-reveals 
Pay Cuts. The EPC has also issued their fourth newsletter, in 
two parts, to community employee members. Both 
newsletters provided information on tax issues, credits and 
allowances. It aims to assist employee members to 
navigate their way through the complicated tax system 
and ensure they are in receipt of all their entitlements 
under this system. 
Mediation Service
The EPC feel that the current climate in the community 
pharmacy sector presents the opportunity to introduce a 
structured mediation service for the resolution of disputes. 
Although driven by the EPC, this service is available to all 
members of the IPU. It could be beneficial to all parties by 
helping to achieve an early resolution of a dispute at a local 
level and, at the same time, avoid unnecessary legal costs, 
save time and maintain a good working relationship. The 
Mediation Service was launched in July 2010 and was this 
was highlighted in the IPU Review.
After the success of the first IPU Pharmacy Employee 
Seminar that was held in February 2010, the second 
Employee Seminar will be held during the National 
Pharmacy Conference in May. This Seminar will be 
designed specifically for Employee Members and will deal 
with Employment Law and HR issues as they present to the 
employee. These will include Performance Management 
for Staff, Recruiting Safely and Effectively, Managing a 
Dismissal and Negotiating Terms and Conditions.
Locum Pharmacists
In December 2010 Revenue clarified, in their letter to the IPU 
17 December 2010, its position on the issue of locum 
pharmacists remains unchanged. Revenue considers that all 
locum pharmacists should be treated as employees and that 
any remuneration is subject to deductions under the PAYE 
system, PRSI and Universal charges. This was communicated 
to all members of the IPU in February 2011 and the Revenue 
letter may be viewed on www.ipu.ie/locum-issues. 
Interns
In September 2010 the IPU organised an information 
evening for Pharmacy Interns. The evening consisted of a 
presentation to the interns which covered background 
information on the inception of the IPU, the role of the IPU, 
the key strategic objectives, public affairs activates and 
current situation within the community pharmacy sector. 
The benefits of IPU membership were also highlighted.
Benefits of IPU Membership
In March 2011 the EPC produced a leaflet on the benefits of 
IPU membership. The objective of this leaflet is to remind 
current members of the array of benefits that is available, 
while also informing employee pharmacists who are currently 
not members of the benefits that IPU membership provides. 
This leaflet was also circulated to 1571 pharmacies.
next Steps
n The EPC is half-way through its second term of office at 
the AGM. The current committee will continue to 
pursue its objectives with intent and to actively 
represent the interest of employee members. It will 
also ensure that the IPU continues to provide services 
and support to employee members within the 
community pharmacy sector. The future years will be 
challenging for all in community pharmacy. It is 
important now, more than ever, that employee 
pharmacists have a representative body which 
supports on their behalf. The EPC will continue to be 
this body and it encourages the involvement of more 
employees at both a regional and national level within 
the IPU so as to strengthen the resolve of employee 
pharmacists both in the IPU and the profession.
n The EPC encourages employee members to utilise their 
membership to the fullest and keep themselves 
informed on professional and business issues by 
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reading the General Memoranda, IPU Review magazine 
and other information provided by the Union. In June 
2010 all IPU Members were designated with an @
ipumail.ie email account, the EPC would urge employee 
members who have not activated their account to do 
so immediately. The EPC would also recommend that 
employee members check the members’ only section of 
www.ipu.ie, in particular the employee pharmacist’s 
area of the website on a regular basis.
I would like to thank all the members of the EPC for all 
their work over the last year and the staff of the IPU, in 
particular Seamus, Pamela and Darren for their support 
and advice on all matters. I would especially like to thank 
the Secretary to the EPC, Susan McManus, for her hard 
work and commitment to the EPC and the President, 
Darragh O’Loughlin, for all his advice and assistance 
throughout the year.
Louise Begley, 
Chairperson.
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Public Relations Report 
Public Relations Strategy played a key role in communicating 
the key messages of the Irish Pharmacy Union and its 
members over the past year. Once again, it has been an 
extremely busy time for the Communications team.
Political engagement
The build up to the General Election was a very active 
period in generating opportunities for the IPU to engage 
in a meaningful way with political parties and to build 
new relationships within the political arena generally. This 
resulted in a successful lobbying campaign of the main 
parties to get them to include community pharmacy in 
their individual manifestos. A significant step in this 
regard was the IPU’s breakthrough in securing the 
inclusion of pharmacy in the Fine Gael’s Manifesto. 
Pharmacy had not been included in their original health 
document ‘Fair Care’. 
The President of the Union led a delegation of IPU 
members at the ‘health hustings’ initiative last February 
where the health spokespeople of each of the main five 
political parties, including the now Minister for Health Dr 
James Reilly, outlined their policies on a range of key 
services for patients and customers for the future. In 
addressing the IPU concerns, Darragh O’Loughlin 
highlighted the vital role pharmacists have to play as 
healthcare professionals in developing and delivering an 
efficient and cost-effective health service. Among the 
Union’s key messages at this forum were the fact that 
there is no further scope for cuts to pharmacies and a call 
to expand the role of the pharmacist in primary care to 
include public health programmes such as Health 
Screening and the participation in national immunisation 
programmes. 
FeMPI
The draconian FEMPI Cuts was also high on the PR agenda 
again this year. As a key priority for the Union and its 
members we responded strongly to the initial review of 
the FEMPI cuts last June pointing out that 1,600 jobs have 
been lost in the wake of the cuts and that patient services 
have been curtailed. In our submission of January 2011 to 
the Department of Health ‘time for a new approach’, we 
highlighted how pharmacists suffered large and 
disproportionate cuts in payments since July 2009 at the 
hands of the former Minister for Health and Children. 
Most recently in March we came out again in a strongly 
worded statement to the media reiterating the 
unsustainable impact of the cuts on our members. 
Advertising Campaign – ‘Ask Your Pharmacist First’
Following on from the success of previous marketing 
campaigns, we also invested in a major awareness 
campaign on radio to promote the ‘ask your Pharmacist 
First’ message. The campaign ran during November and 
December 2010 and received very positive feedback from 
members and key stakeholders alike. The IPU message 
was heard by 1.8 million listeners.
Media Relations
Other key issues that contributed to the media relations 
agenda this year included:
n Emergency Hormonal Contraception – A call for the 
medication to be provided through pharmacies and a 
response to the development of Boots introducing this 
medication under the Patient Group Directives. Finally, 
a welcome to the landmark decision that this choice of 
medication was to be made available through all 
pharmacies across the country.
n Prescription Levy – The introduction of the Prescription 
Levy in October led to a high profile hard hitting media 
relations campaign by the IPU highlighting the impact 
on patients and members. The reversal of this decision 
in March of this year by Minister for Health, Dr James 
Reilly gave the IPU an opportunity to speak to key 
audiences welcoming this decision in the interest of 
our most vulnerable patients.
n Consultation Areas - The mandatory introduction of 
private consultation areas gave the IPU the 
opportunity to talk about the professional role of the 
pharmacist as medicines and health care professionals. 
We linked the successful advertising campaign on 
radio with the consultation areas to highlight ‘ask 
your Pharmacist First’. 
n Generics – We continue to beat the drum of generic 
substitution and issued a press release on behalf of 
members welcoming the decision to introduce generic 
substitution.
tV Opportunity
To promote the role of the pharmacist, we secured a very 
high-profile TV slot on RTE’s Four Live show, which has a 
viewership of 107,000. The ‘On the Couch’ pharmacist 
series covered a number of topics including advice on 
quitting smoking, children’s health and generic medicines, 
which helped to reinforce pharmacists as healthcare 
experts who can provide advice to patients.
Lose Weight Campaign
Our main Health Awareness Campaign last year was the 
Obesity Health Campaign which we ran in association 
with the Diabetes Federation of Ireland and GlaxoSmithKline 
to coincide with European Obesity Day. Promotional material 
was made available to members for the campaign including 
an information leaflet and a poster.
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Ploughing Championships
The Union had a stand at the National Ploughing 
Championships in September 2010, providing a valuable 
opportunity to engage with the public on health issues. 
Pharmacists were on hand to give free advice to patients 
and to provide free blood pressure and BMI testing. 
Media Coverage
All of the above generated extensive media coverage to keep 
the Union and its members in the news and on the airwaves 
during what has been overall a saturated media agenda with 
regards to the economy and the banking crisis. 
Communications to Members
Following the revamp of the IPU website in February 2010, 
extra features have been added to improve 
communications with members. Over the past year, a 
template for mobile phones has been developed and the 
recently-launched IPU Members’ Forum. IPU News, the 
weekly e-news update for IPU members, was launched in 
May 2010 and is designed to keep members up-to-date on 
all issues relating to pharmacy on a weekly basis. The SMS 
service was launched in November 2010 so that members 
can be alerted of urgent news or deadlines for pharmacy.
Finally, this year the communications team of Kate Healy 
and Aoibheann Ní Shúilleabháin, along with our external 
advisers saw the strengthening of the team with the 
arrival in November of Gerard Howlin as Head of Policy 
and Public Affairs, which has already had an impact on our 
engagement with key political stakeholders.
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International Pharmacy Matters
n Recognition of Professional Qualifications – a 
revised system of recognition of the professional 
qualifications of pharmacists from other Member 
States;
n Late Payments – the creation of a legal obligation 
for health authorities to pay contractors on time; 
and
n Consumer Rights – the harmonisation of 
consumer rights in all EU countries.
Pharmacovigilance
The Pharmacovigilance Directive was published in 
the official journal on 31 December 2010 and national 
governments now have 18 months in which to 
introduce legislation to implement it. PGEU succeeded 
in getting many of its amendments included in the 
final text, including the recognition of the role of the 
pharmacist in pharmacovigilance and pharmacists’ 
role in reporting ADRs, including medication errors. 
Pharmacists will report to the national regulatory 
agency (IMB) who will then forward collated reports 
to the European Medicines Agency (EMA). The text 
of the Directive has suggested that these reports 
should be confidential, i.e. contain no personal data; 
however, it will be up to individual Member States to 
clarify the scope of the confidentiality.
Information to Patients
This Directive which proposes relaxing restrictions 
on industry providing information to patients has 
proved most controversial. The European Parliament 
has voted on this Directive and made it less centred 
on the industry agenda and more patient-centred. 
Information from industry must be approved by the 
relevant competent authority (IMB). The Council of 
Ministers is concerned that the current proposals may 
give industry an opportunity to promote medicines 
directly to patients. The Commission has now decided 
to produce a new version of the Directive and has 
indicated that it will be given priority during the 
Hungarian Presidency. It accepts that material must 
first be approved by the competent authority. In 
addition, there will be no suggestion that pharmacists 
would be obliged to distribute this material. 
Falsified Medicines
This Directive was adopted by the European 
Parliament in February 2011. It is the most significant 
legislation that has happened to pharmacy in Europe 
for years. The Directive requires that a safety feature 
be placed on medicines open to counterfeiting and 
that pharmacists and wholesalers will authenticate. 
1. PGeU RePORt 
 The Pharmaceutical Group of the European Union 
(PGEU) is the European association representing 
community pharmacists in 32 European countries 
including EU Member States, EEA countries and 
EU applicant countries. Overall, PGEU represents 
over 400,000 community pharmacists in Europe 
through their professional bodies and pharmacists’ 
associations. 
 The IPU is represented at PGEU by Liz Hoctor, Past 
President, Pamela Logan, Director of Pharmacy 
Services and Jill Lyons, PCRS Contract Manager. The 
Union has been very active within PGEU over the 
past year, ensuring that community pharmacy is 
considered in a wide variety of EU Directives. 70% of 
legislation in Ireland comes from EU Directives so it 
is vital that lobbying is done at this level rather than 
waiting for transposition into Irish legislation. 
Overview of 2010
 2010 was a year of extraordinary activity in European 
pharmacy. PGEU was involved to an unprecedented 
extent in the shaping of European legislation. We saw 
the adoption of the Directive on Pharmacovigilance, 
which for the first time recognises the crucial 
contribution pharmacists make to ensure the risks 
of medicines are fully understood and adverse drug 
reactions properly recorded. Other Directives such 
as the Patient’s Rights Directive, the Directive on 
Falsified Medicines and the Directive on Information 
to Patients were hotly debated. 2010 also saw 
pharmacy in the European Court of Justice once again 
with important rulings relating to the establishment 
of pharmacies and pharmacy opening hours. 
directives
PGEU actively worked on seven Directives throughout 
2010:
n Pharmacovigilance – the creation of a new 
system of managing the risks of marketed 
medicines;
n Information to Patients – a proposal to allow the 
pharmaceutical industry to provide information 
on medicines directly to patients;
n Falsified Medicines – the creation of a system 
of authentication of medicines at pharmacy 
level and the regulation of the sale of medicines 
through the internet;
n Patient’s Rights – the legal obligation to 
recognise prescriptions from another  
Member State;
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The Directive also refers to the internet, proposing 
an awareness of the dangers of medicines purchased 
on the internet; a requirement for a community logo 
and register for internet pharmacies; and the right of 
Member States to prohibit the sale of prescription-
only medicines (POMs) on the internet. 
One significant effect this Directive will have on 
pharmacy is with regard to the selling of non-
prescription medicines (NPMs) on the internet. PGEU 
had wished to ensure that the country of destination 
rules applied. Although this wording is not specified 
in the Directive, it does say that Member States can 
place restrictions on the sale of NPMs by internet as 
long as they are justified in terms of public health. 
The Directive also makes it clear that licensing of 
medicines is a matter for the national competent 
authority (IMB) therefore POMs may not be sold on 
the internet in Ireland. 
While this Directive to put in place a medicines 
verification system was adopted in February 2011, 
the European Commission is using its powers, i.e. 
‘Delegated acts’, gained in the Lisbon Treaty, to design 
the technical aspects of the Directive. This means 
that two key aspects have not yet been decided – 
the systems of verification and authentication in 
pharmacy. There is a reference to the need to respect 
the ownership of data to the pharmacist and the 
Directive also says that manufacturers must pay for 
the database to host the authentication system as 
well as the safety feature. There is an obligation for 
wholesalers to verify packs. 
the following assumptions can be made:
n Safety Feature – most likely a serial code in a 2D 
bar code presentation along with an anti-tamper 
seal;
n Risk Assessment – will be carried out as to 
whether the safety feature is required on both 
POMs and NPMs. All POMs will carry a safety 
feature unless shown not to be at risk, i.e. on 
black list, and NPMs will not carry a safety feature 
unless shown to be at risk, i.e. on white list.
PGEU’s position is that all medicines should carry a 
safety feature.
The Directive permits the use of the safety 
feature to be extended to include reimbursement, 
pharmacoepidemiology and pharmacovigilance. If 
Member States wish to use the safety feature for 
these purposes, generic medicines would need to be 
included. 
There is no strict obligation on Member States to 
adopt medicines authentication, only to apply the 
safety feature. However, it is hard to argue not 
adopting authentication when all of the systems are 
in place to facilitate it. 
PGEU has produced a “ten Principles Paper” which will 
form the basis of discussions with the Commission 
during the Delegated Acts process. The position paper 
is supported by EFPIA (industry), GIRP (wholesalers). 
1. Combining tamper evident packaging with a 
unique serial number.
2. Guaranteeing continuity of protection 
throughout the entire supply chain.
3. Ensuring a single coding and identification 
system on each pack across the EU.
4. Ensuring product verification database systems 
can work together across the EU.
5. Verifying every serialised pack at pharmacy level.
6. Maximising all the potential benefits of mass 
serialisation.
7. Focusing on securing patient safety and 
protecting patient privacy.
8. Using safety features that are simple, robust and 
cost effective.
9. Working together in the interests of patient 
safety.
10. Involving other stakeholders.
Patient’s Rights
The purpose of this Directive, adopted in March 
2011, is to establish a clear community framework to 
facilitate cross border health care. The Commission 
will need to develop a system to recognise 
prescriptions and PGEU will monitor and attempt 
to influence the development of this system of 
recognition. The PGEU Statement on the Recognition 
of Prescriptions will ensure that national dispensing 
practices are not undermined by the new legislation 
and that pharmacists’ roles in dispensing cross 
border prescriptions are well understood. In relation 
to internet pharmacy, PGEU proposed that Member 
States’ rules on internet pharmacy should be 
respected and this was adopted. 
Recognition of Professional Qualifications
The original Directive was adopted in 2005 and is 
now being reviewed by the Commission with the 
aim of publishing a Green Paper in early 2011 and a 
new Directive in 2012. The proposal advocates for a 
minimum level of education for pharmacists and a 
minimum duration of the undergraduate degree/
Masters. 
The revised Directive will include new skills with 
regard to the expanded role of the pharmacist, e.g. 
pharmaceutical care and CPD. It is also likely that the 
3 year derogation, which is enshrined in the current 
Directive, will be abolished.
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Late Payments Directive
The aim of this Directive is to combat late payment 
in commercial transactions. Public and private 
hospitals and health services will be allowed 60 
days to pay their bills. Those who fail to pay in time 
will pay penal interest rates of “at least 9%” higher 
than the statutory rate as well as a fixed fee of €40 
compensation for recovery costs. The Directive has 
been published in the Official Journal and will be 
transposed into national legislation by March 2013.
Consumer Rights Directive
This Directive has been on-going since October 
2008 and is reaching conclusion. There have been 
a lot of disagreements in relation to the degree of 
harmonisation. PGEU has been successful in having 
pharmaceuticals removed from the 14-day time 
frame for returning goods when withdrawing from 
distance-sales contracts. The Council has also agreed 
to exclude health service contracts from the scope of 
this proposal as these require special regulations.
eCJ Rulings
The European Court of Justice (ECJ) delivered its ruling 
in June 2010 in the case regarding the demographic 
and geographical rules limiting the establishment 
of pharmacies. The ECJ decided that such rules are 
justified in the interests of public health and are 
therefore compatible with European Union law. 
Specifically, they contribute to an even distribution of 
pharmacies across the territory and therefore ensure 
a reliable and high quality pharmaceutical service for 
citizens. 
In July, the ECJ ruled on a case regarding national 
legislation governing opening times and closing days 
of pharmacies. The Court judged that European law 
was irrelevant for opening hours’ restrictions. 
Professional Issues Working Group (PIWG) 
The mandate for PIWG is to explore and develop 
pharmacy practice in Europe. PIWG considered a 
number of topics during 2010 that were of particular 
relevance to pharmacy practice, including eHealth, 
patient information, patient safety, pharmacy 
education and the pharmacists’ role in non-
prescription medicines. 
2. RePORt On FIP COnGReSS, LISBOn, PORtUGAL FROM 
28 AUGUSt - 2 SePteMBeR 2010
Introduction
The International Pharmaceutical Federation 
(FIP) together with the Associação Nacional das 
Farmácias (ANF) opened the 70th World Congress 
of Pharmacy and Pharmaceutical Sciences on 28 
August 2010 in Lisbon, Portugal. Through its 120 
member organisations and 4000 individual members, 
FIP represents and serves almost two million 
practitioners and scientists around the world. FIP 
President, Dr Kamal Midha, greeted the audience of 
almost 3000 pharmacists, pharmaceutical scientists, 
academics, researchers, students and guests who had 
come together for a week of pre-satellite symposia, 
workshops, lectures and meetings focused on this 
year’s Congress theme – From Molecule to Medicine 
to Maximising Outcomes: Pharmacy’s Exploratory 
Journey.
FIP’s mission is “to improve global health by 
advancing pharmacy practice and science to enable 
better discovery, development, access and safe 
use of appropriate cost-effective quality medicines 
worldwide.” The focus of FIP over the past year and 
over the next few years is pharmacy education, 
present and future workforce needs, collaborative 
pharmacy practice and counterfeit medicines. 
new FIP President 
The FIP Council elected Dr Michel Buchmann 
(Switzerland) as the new FIP President. Dr Buchmann 
will serve a four year term (to 2014) following the 
Presidency of Dr Kamal Midha, who will carry on 
as FIP Immediate Past President. Dr Buchmann is 
assuming the role of FIP President after extensive 
experience within FIP Boards, community pharmacy 
practice and Swiss politics. In his remarks following 
the release of the election results, Dr Buchmann 
reiterated his commitment to advancing FIP’s 
Strategic Plan to advance pharmacy practice, the 
pharmaceutical sciences and pharmacy education on 
a global level.
FIP and Pfizer Joint Survey
A new international survey, launched at the Congress, 
showed that over 90% of pharmacists believe they 
are key to improving patients’ health, and while 
most pharmacists surveyed see their responsibilities 
increasing, they voiced concerns on training and pay. 
The survey showed that almost 3 in 4 pharmacists 
(73%) now provide patients with health promotion 
and management services. Nearly all (9 in 10) 
pharmacists agree that more information and advice 
- including on specific medications and treatments 
- are expected from pharmacists than ever before. 
However, most pharmacists (78%) say that they are 
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asked to provide additional services, such as advice, 
without fair and proper compensation.
“Pharmacists’ roles are changing, and we find 
ourselves increasingly working with patients and 
other healthcare professionals to prevent and treat 
disease. this survey shows that pharmacists welcome 
this expanded role, as it highlights what they like 
doing most - helping deliver better patient outcomes 
- while increasing visibility of pharmacists’ expertise. 
however, we also see an education and income gap 
that will need to be closed to ensure the pressure 
on current pharmacists isn’t too great, and so that 
we can continue to attract the best and brightest to 
the profession in the future,” said Ton Hoek, Chief 
Executive Officer of FIP. 
Pfizer, in collaboration with FIP, commissioned the 
international survey to better understand the needs, 
concerns and attitudes of pharmacists. Interviews 
were held with over 2,000 community, retail and 
hospital pharmacists in 8 countries (Australia, France, 
Germany, Italy, Portugal, Turkey, the UK and the U.S.) 
between April and June 2010. The full survey results 
can be found on www.fip.org 
does pharmacists’ changing role offer value for 
money for the health system?
Suzete Costa from Portugal posed this question and 
discussed how pharmacy has been practising a trade-
off between monopoly, prestige and reward - benefits 
sought since the foundation of the profession – 
and patient safety and expertise – responsibilities 
demanded by the public. Even though pharmacists’ 
role and pharmacy itself has greatly evolved in 
the past 20 years, this social contract in the public 
interest between pharmacy and the public preserves 
its main elements today. The added value generated 
by pharmacist-led initiatives for health systems in 
various parts of the world was highlighted, with 
an emphasis on the economic value and potential 
benefits that pharmacists could bring as the scope 
of practice is expanded in response to consumer 
expectations and behaviour changes. For every US$1 
invested in pharmacist clinical services, US$4.81 was 
achieved in reduced costs or other economic benefits.
emerging Pharmacy Business Models
Charlie Benrimoj from Australia discussed how 
community pharmacy has developed an excellent 
logistic and business capacity to dispense and sell 
medicinal and other products. The infrastructure, 
including personal management, information 
technology, physical structure, marketing and 
positioning, have been directed to optimise a 
business model that increases the efficiency and 
volume of products. Essentially the viability of the 
business models has been dependant on products. 
In recent years, the profession has attempted to 
incorporate cognitive pharmaceutical services into the 
professional practice of pharmacists. Even with direct 
payment of services, implementation has become a 
challenging task. Recent research has demonstrated 
that a key issue in the implementation of services 
is the strategic decision by the pharmacy proprietor 
to position his business in the healthcare market by 
offering a service/product mix. With the availability 
of payment for services, some parts of the community 
pharmacy industry have commenced to differentiate 
away from purely using price/product and to using 
health care services as the differentiator. These 
emergent models can be classified into classic, health 
solution, retail destination and network business 
models. The evidence suggests that professional 
development needs to be linked to the business 
development of the pharmacy. Unless this integration 
of business and professional occurs, service provision 
may not occur or be sustainable. Some of the current 
business models will need to focus on evolving 
to become service /product models with ensuing 
changes in infrastructure.
negotiating for new Pharmacy Services
Warwick Plunkett from Australia explained 
how, as health care expenditure rises, there has 
been a greater scrutiny on costs associated with 
pharmaceuticals. The area of pharmaceuticals 
has been seen by governments as a soft target. 
Maintaining current levels of remuneration for 
dispensing pharmaceutical products is very much 
under threat, leaving pharmacy to evolve its business 
model from the past product supply to one of 
product and service. The challenges for community 
pharmacy have included: the task of convincing 
community pharmacists of the need to change and 
commence delivering services along with the sale 
and supply of products; the identification of suitable 
health and medication management services for 
pharmacy to deliver cost effectively; finding resources 
to provide support for community pharmacies to 
implement new services; and developing the right 
strategy to negotiate payment from governments, 
health insurers and patients. Successive five year 
agreements between the government and the 
Pharmacy Guild of Australia for the payment of 
dispensing fees and additional professional services 
have worked successfully over the past 20 years. 
Australian examples of aligning research results, 
health policy priority, support for practice change and 
the key ingredients for successful negotiating were 
presented. Developing and maintaining a strong and 
effective lobbying presence is one of the essential 
foundations for government negotiations but it 
must be followed with a clear understanding of how 
services provided by community pharmacy can deliver 
cost effective solutions that fit the needs of existing 
health policy.
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Pharmacy in Canada
Jeff Poston from the Canadian Pharmacists’ 
Association described the legislation and regulations 
that have been introduced in Canada over the past 
3 years to enable an expanded scope of practice for 
community pharmacists, including some form of 
prescriptive authority. Pharmacist prescribing includes 
a wide range of activities: prescribing over-the-
counter and prescription medicines to treat minor, 
self-diagnosed or self-limiting conditions; providing 
emergency supplies of prescribed medication to 
a patient; monitoring and authorising the refill of 
existing prescriptions to ensure appropriate and 
effective care; modifying a prescription written by 
another prescriber to alter dosage, formulation, 
regimen or duration of the prescribed drug; 
independent prescribing in collaboration with the GP. 
OtC Market 2020
Per Troein from IMS described how the OTC market 
is now worth €69bn and continues the recent trend 
of outgrowing prescription-only medicines. While 
Pharma growth experiences a number of constraints, 
e.g. generics, demand constrained by payers, etc. OTC 
benefits from a range of growth drivers, e.g. emerging 
markets like Russia and China, increased access through 
new channels, switching from POM to P. In European 
countries where medicines are largely state funded, 
many countries are looking at drastic measures to 
curb growth and reduce costs of medicines: price cuts; 
margin adjustments; generic strategies; reduction of 
new innovations; etc. Patients are willing to spend 
money on medicines that give immediate reward, 
e.g. headache relief, but in general prefer reimbursed 
prescriptions as opposed to self-paid OTC. 
Community Pharmacy Services at the Primary-
Secondary Care Interface
Bernard Duggan, community pharmacist from 
Dublin and Vice-Chairman of the IPU Community 
Pharmacy Committee, explained how the primary-
secondary care interface provides significant 
opportunities for medication errors. The views of 
a nationwide stratified sample of community and 
hospital pharmacists were sought in anonymous, 
self-administered postal questionnaires. A record 
of community pharmacy-hospital communications 
was kept for 365 days and a 6 month review of 
new discharge and post-discharge prescriptions 
for medication errors was performed. Results of 
the survey showed that there is currently little 
communication across the interface at discharge. 
11% of community pharmacists reported no hospital 
contact at this time and a further 80% only 
occasional contact. Hospital pharmacists reported 
on-going difficulty obtaining medication histories 
on admission. Both parties agreed that standard 
protocols and designated seamless care pharmacists 
would improve safety. Discharge/post-discharge 
prescription analysis showed a 27% error rate.
health Screening in Pharmacies in Ireland
Aisling Reast, community pharmacist from Dublin, 
presented a poster on the IPU’s Health Screening 
Pilot. Pharmacies selected patients either for 
monitoring or for screening for clinical signs and each 
performed all or some tests of total blood cholesterol, 
blood pressure, blood glucose, body mass index (BMI), 
waist circumference and carbon monoxide. Standard 
Operating Procedures and guidelines were provided 
by the IPU while patient data recording forms and 
physician notification letters were developed and 
tested for face and content validity by Trinity College 
Dublin. 164 patients (97 women) were screened at 15 
sites and 161 total blood cholesterol, 152 blood glucose, 
145 blood pressure, and 101 BMI measurements were 
made and recorded and a decision whether to refer 
was recorded in 107 cases. 
Problems with Prescriptions and their Significance 
in Primary Care
Martin Henman from TCD, Dublin, presented a poster 
on prescription and medicine-related problems and 
their potential impact on pharmacists and patients. 
A study was carried out in a convenience sample of 
community pharmacists in a region near Dublin over 
one week. Nine pharmacies returned information 
on 905 prescriptions and 1,340 problems. Almost 
80% of problems occurred with the first dispensing 
and problems with the prescription form accounted 
for 54% while problems with prescribed items 
comprised 44%. The most frequent categories of 
prescribed item problems were dosing and regimen 
issues (43%) while possible adverse drug reactions 
(5.6%) and interactions and allergies (3.5%) were the 
least frequent. In almost 14% of cases, pharmacists 
were unable to provide a medicine without further 
clarifying details and in around 10% of cases a change, 
an omission or a reintroduction of a prescribed item 
occurred without a reason being apparent to the 
pharmacist. Omission of a child’s age was the most 
common problem with drugs for infections whereas 
dosing and regimen problems were common for 
cardiovascular drugs. Pharmacists reported that 
9.2% of problems were potentially serious and they 
considered that 12.2% were potentially serious from 
the patient’s perspective. Multiple methods were 
used to resolve most problems, with patients (61%), 
computerised medication records (57%) and prescriber 
contacts (39%) the three most frequent. Over 800 of 
prescriptions with problems were completely resolved 
while 58 were partially resolved and 13 remained 
unresolved. Pharmacists deal with a wide range of 
problems, particularly at first dispensing and most 
problems if unresolved would have a clinical impact 
on the patient.
The 71st World Congress of Pharmacy and 
Pharmaceutical Sciences 2011 will take place in 
Hyderabad, India from 2-8 September 2011. The theme 
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of the conference will be “Compromising Safety and 
Quality, a risky Path”. The FIP Centennial World 
Congress 2012, celebrating 100 years of Advancing 
Pharmacy Worldwide, will take place in Amsterdam, 
The Netherlands from 3-8 October 2012. The FIP 
Congress will be held in Dublin, Ireland in 2013.
Pharmacists are encouraged to attend FIP to meet 
and share experiences with pharmacy colleagues 
from all over the world. 
3. 19th GeneRAL ASSeMBLy OF eUROPhARM FORUM 
And PROFeSSIOnAL COnFeRenCe
The 19th General Assembly of the Europharm Forum 
was held in Copenhagen on 2 October 2010, preceded 
by a Professional Conference on 30 September – 1 
October. Over 50 people attended the meeting 
representing 20 countries and a range of observer 
organisations. The IPU was represented by the 
President and the Director of Pharmacy Services.
europharm Forum Priorities
Europharm Forum is a joint network of national 
pharmacy associations and the World Health 
Organisation (WHO) Regional Office for Europe. The 
mission of Europharm Forum is to improve health 
in Europe according to priorities set by WHO and to 
strengthen the position of pharmacists by showing 
their value to people involved in health issues. 
the Forum’s Vision to Practice 2020 is based on six key 
principles:
n Practice adapted to new public expectation;
n Practice close to patients;
n Provide up-to-date and evidence-based therapies 
and services;
n Ensure quality based on Good Pharmacy Practice;
n Secure a competent workforce (education, 
training);
n Provide integrated care in a collaborative practice.
To achieve this vision, Europharm Forum translates 
WHO and FIP strategies into the European context 
and supports PGEU activities in order to inspire 
national associations and practicing pharmacists to 
implement good practice. 
Professional Conference
The main theme for the Professional Conference was 
Pharmaceutical Care. There was much discussion 
about the definition of Pharmaceutical Care and there 
was general consensus with the FIP 2003 definition:
n	 Pharmaceutical Care is the responsible provision 
of pharmacotherapy for the purpose of achieving 
definite outcomes that improve or maintain a 
patient’s quality of life;
n It is a collaborative process that aims to prevent 
or identify and solve medicinal product and 
health-related problems;
n There is a continuous quality improvement 
process for the use of medicinal products.
The outcome indicators of Pharmaceutical Care 
should be based on ECHO: - Economical, Clinical, 
Humanistic Outcomes.
economic indicators, to measure outcomes, include: 
n Cost-effectiveness or cost benefit for society or 
healthcare;
n Cost-effectiveness or cost benefit for payers;
n Drug expenditure;
n Patient costs; and
n Pharmacy business viability.
Clinical and humanistic outcomes include:
n Mortality;
n Morbidity;
n Health status;
n Quality of life; and
n Patient satisfaction.
However, it is recognised that preventable, drug-
related morbidity is so preventable and costly that 
improved quality may be possible without additional 
total cost to the healthcare system. 
Choosing which indicators to use to measure 
Pharmaceutical Care is a question of choosing 
purposes and audiences, for example:
n Health authorities;
n Healthcare professionals;
n Pharmacists, pharmacy management, pharmacy 
staff;
n Politicians;
n Patients, public, press.
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General Assembly
The General Assembly opened with addresses from 
Kees De Jancheere from WHO Regional Office for 
Europe; Thony Bjork, Vice President of FIP; Cecilia 
Bernsten, Vice President of the European Society for 
Clinical Pharmacists; and Dick Tromp, President of 
Europharm Forum. 
Over the last two years, Germany, Austria, 
Latvia, Italy, France, Switzerland and Spain have 
notified Europharm Forum of termination of their 
membership of the Forum. At the GA, further 
withdrawals were notified from the Czech Republic, 
Belgium, Iceland and the Irish Pharmacy Union. 
FIP described Europharm Forum as the ‘arms and 
legs’ of FIP in Europe and sees the Forum’s role as 
implementing FIP strategy in Europe. FIP cannot fulfil 
the needs of all FIP regions as local differences are 
considerable; therefore it needs organisations such as 
Europharm Forum. FIP has broadened its scope with 
other organisations such as United Nations, World 
Bank, WHO Geneva and other global donors. FIP is 
willing to support Europharm Forum in having access 
to these organisations. 
WHO (Europe) acknowledged the importance of 
Europharm Forum in assisting WHO to improve 
health in Europe and offered to assist the Forum in 
communications with WHO Geneva (Global). Both 
WHO and FIP expressed their concerns about the 
number of withdrawals by national associations from 
the Forum. 
The Treasurer of Europharm Forum reported that the 
Forum had operated within its reduced means during 
2010 and was therefore in a position to continue 
operating in 2011, despite its reduced membership, as 
it still had reserves left.
It was agreed that the Forum would continue to 
participate in meetings where pharmacy practice and 
the role of the pharmacist were on the agenda. The 
Forum will focus on one or two projects on developing 
pharmacy practice, continue to develop and expand 
the Observatory and run an annual professional 
conference. 
executive Committee
the executive Committee is composed of:
n Th(Dick) Tromp (The Netherlands), President;
n  Balázs Hankó (Hungary), Vice-President;
n  Lidija Petrusevska-Tozi (FYR Macedonia);
n Frans van de Vaart, (The Netherlands);
n Gerald Alexander (UK);
n Kaidi Sarv (Estonia);
n Carin Svensson (Sweden).
The 20th Annual Meeting of the Europharm Forum 
will take place on 14-15 October 2011 in Ohrid, Republic 
of Macedonia.
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2011 AGM Motions
The following motions, proposed in accordance with 
Article 29 of the Constitution, are brought before the 
meeting for consideration:
1. Proposed: Liam Butler
 Seconded: Grainne O’Leary
 “that this agM calls on the Minister to recognise that 
there is no scope for any further unilateral and 
arbitrary cuts to pharmacy payments and to engage 
substantially with the iPu, under a process similar to 
that set out and agreed with the health Service 
executive and the Department in april 2008, to review 
all existing administrative, contractual and payment 
arrangements.”
2. Proposed: Louise Begley
 Seconded: Bernard Duggan
 “that the iPu welcomes the recent irish Medicines 
Board decision to reclassify the emergency hormonal 
contraception product norlevo from prescription to 
non-prescription status and calls on the iMB to 
reclassify other appropriate medicines in order to 
improve the public’s access to medicines.”
3. Proposed: Caitriona O’Riordan
 Seconded: Fearghal O’Nia
 “that the iPu calls on the irish Medicines Board, hSe 
and Department of health to take all necessary steps, 
including the adoption in ireland, as in other european 
countries, of a public service obligation, to ensure the 
uninterrupted supply of prescription medicines to 
patients.”
4. Proposed: Rory O’Donnell
 Seconded: Noel Stenson
 “that this agM calls on the Minister to act on his 
proposition to enable pharmacists to provide a 
vaccination service; including for swine flu, seasonal 
flu, travel vaccines.”
5. Proposed: Kathy Maher
 Seconded: Morgan Power
 “that the iPu calls on the Minister for health to 
engage positively with the iPu to agree a time-lined 
series of specific steps to deliver a better and more 
cost-effective primary care system for patients, which 
must necessarily include an enhanced role for 
community pharmacists as the single most accessible 
part of ireland’s primary care network.”
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Appendix I
extRACt OF SUBMISSIOn By the IPU tO the ReVIeW UndeR the FeMPI ACt 2009 SeCtOR 
exeCUtIVe SUMMARy
1. Last June the Minister for Health and Children 
announced reductions in payments to pharmacists 
under the Financial Emergency Measures in the Public 
Interest (FEMPI) Act (2009) in order to reduce the cost 
to taxpayers of drugs and medicines dispensed under 
the GMS (medical card) Scheme, the Drugs Payment 
Scheme, the Long Term Illness Scheme and other 
community medicine schemes. The Minister estimated 
at that stage that the income received by pharmacists 
under these schemes would decline by €55m in 2009 
and €133m in a full year. The Union disputed these 
figures at the time and have now concluded that its 
original reservations were well founded.
2. The annualised savings accruing to the Exchequer will 
amount to a minimum of €144m, even taking into 
account the lower than anticipated level of consumption. 
However, the figure could be as high as €166m and 
further information and clarification is required from the 
Department to provide an accurate figure of the true level 
of savings from the pharmacy sector. 
3.  The Exchequer also benefited by virtue of the lower 
than predicted level of activity while, in contrast, 
pharmacists had to spread their fixed costs over a 
reduced income base. The cuts imposed last year are 
having a significant impact on services rendered by 
pharmacists, which we illustrate elsewhere in this 
submission. 
4. In January 2010, a survey of Irish Pharmacy Union 
members conducted by PricewaterhouseCoopers 
(PwC) estimated that the average pharmacy has seen a 
reduction of 30% in public medicine scheme earnings. 
This decline occurred despite no associated reduction 
in the nature or complexity of dispensary activity. The 
estimated decline of 30% has to be considered in the 
context of the many other difficulties and challenges 
that the pharmacy sector is already facing as a result of 
the very difficult economic environment. At the same 
time, the level and general nature of expenses and 
commitments of pharmacists have not substantially 
changed over that period. 
5. The Union recognises that the Department of Health and 
Children (Department) and the Health Service Executive 
(HSE) are also being challenged to deliver cost effective 
healthcare in these difficult economic times.
6. The Minister for Health and Children has a number 
of issues and initiatives to be implemented. The HSE 
also has an agenda for change. The Union, for its part, 
has issues that it wishes to have addressed. Therefore, 
the time is right to embark on a new relationship with 
the Minister, the Department and the HSE to chart a 
strategic approach to the challenges that now confront 
all of us.
7. For this reason, the Union is calling on the Minister 
to facilitate a dialogue and discussion through a 
structured process on an agenda for change, which we 
have outlined in this submission. The Union is prepared 
to engage in a constructive manner and real progress 
can be achieved through partnership and agreement.
8. The level of savings being achieved of between €144m 
and €166m is significantly in excess of the target set by 
the Minister last year. It is also considerably in excess of 
that achieved from other parts of the medicine supply 
chain and from other healthcare professionals. Having 
regard to the impact and extent of last year’s cuts, the 
Union does not consider the level of cuts imposed in 
2009 to be either fair or appropriate.
9. The analysis conducted by PwC on behalf of the Union 
clearly shows that the savings of €133m sought by 
the Minister have been exceeded. According to our 
analysis, even with the reduced volume of dispensing, 
the annualised savings will not be less than €144m and 
could be as high as €166m. The final figure can only 
be determined when clarification is provided by the 
Department on a number of outstanding issues 
10. In the circumstances, the Union is calling on the 
Minister to: 
n Reinstate the Over Seventies Fee; 
n To eliminate the €3.50 fee band, which is 
unsustainable (the minimum fee should not fall 
below €4.50); and 
n Establish a process to address the many challenges 
being faced by all stakeholders.
 This is the Executive Summary from the IPU’s 
Submission to the FEMPI Review 2010. The full 
submission was sent to all members in June 2010 and 
is available on www.ipu.ie.
40
AnnUAL RePORt 2011
Appendix II
extRACt OF SUBMISSIOn By the IPU tO the hSe On ReVIeW OF MethAdOne tReAtMent PROtOCOL 
24 June 2010
1. IntROdUCtIOn
The Union applauds Action 35 in the National Drugs 
Strategy (interim) 2009-2016 that requires that a 
review of the Methadone Treatment Protocol take place 
to maximise the provision of treatment, to facilitate 
appropriate progression pathways and to encourage 
engagement with services. The Union welcomes the 
opportunity to make a submission to the Health 
Service Executive (HSE) on this review. 
2. MethAdOne tReAtMent SCheMe
The Methadone Treatment Scheme was set up in 
the old Eastern Regional Health Board Area (ERHA) 
to enable patients to receive methadone treatment 
in their local community pharmacy, as opposed to 
visiting one of the methadone clinics which were set 
up by the ERHA in the 1980s. There was major public 
opposition to the building of methadone clinics in 
local communities at that time and the network of 
community pharmacies provided the solution for the 
delivery of methadone treatment.
Patients currently receive methadone treatment 
through the 470 community pharmacies who 
participate in the scheme. Pharmacies are not obliged 
to participate in the Methadone Treatment Scheme 
under their contract with the HSE; they do so, on a 
voluntary basis. The scheme has been very successful 
to date, enabling those addicted to heroin to regain 
control of their lives, allowing them to re-enter 
employment or education, provide for their families 
and be positive contributors to society in general. 
Needless to say, methadone is only part of the solution; 
an ideal situation would be where patients would 
be free of addiction completely. For this to happen, 
patients need other support services, such as addiction 
counselling.
There is an urgent need to reach out to heroin addicts 
who are not currently receiving treatment. There are 
14,000 opiate addicts and only 8,000 in treatment 
according to the Mid-Term Review of the National 
Drugs Strategy. Patients are faced with a waiting list for 
accessing treatment. There is also considerable scope 
to expand the numbers of pharmacies participating 
in the Methadone Treatment Scheme, with a network 
of 1,540 pharmacies across the country. Pharmacists 
are interested in developing their role in this scheme, 
provided there is adequate support given to them. 
Delivering methadone treatment through community 
pharmacies is not only beneficial for the patient, but it is 
also less conspicuous and more convenient for them to 
receive treatment from the local pharmacist than to travel 
to one of the methadone clinics. It has also been proven to 
be more cost-effective for the State. It is worth noting that 
the National Advisory Committee on Drugs, in its report 
on the use of Buprenorphine as an intervention in the 
treatment of Opiate Dependence Syndrome in March 2002, 
confirmed that it is up to twelve times more cost-effective 
to treat opiate addiction in the community setting than in 
a specialist clinic. 
Pharmacists have been keen to get involved in the 
scheme in order to help people who have made the 
brave decision to tackle heroin addiction. Pharmacists 
get great personal satisfaction from providing this vital 
service in their local community. However, the people 
involved in providing this service need support and 
there is a critical lack of support for pharmacists, both 
financially and in terms of general support, involved in 
the Methadone Treatment Scheme. 
Community pharmacists have experienced a number 
of problems in recent years relating to the scheme, 
which is likely to lead to the numbers of pharmacists 
participating in the scheme to decrease over time. This 
will have a knock-on effect on the HSE’s resources, as 
well as increasing the cost to the HSE of providing the 
service to patients.
The Methadone Treatment Scheme was originally 
intended to cater for patients who had already been 
stabilised in the methadone clinics; however, the 
scheme has been expanded outside of the ERHA area, 
where there are few clinics. Many patients are currently 
referred to community pharmacies for treatment 
before they have been stabilised in a clinic. In some 
areas, there are no clinics and unstable patients will 
take their first dose of Methadone in a community 
pharmacy. Outside of the ERHA area, the only person 
with regular contact with the patient is the community 
pharmacist. Pharmacists experience severe difficulties 
in managing such unstable patients. 
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3. IPU ReCOMMendAtIOnS
The Union suggests a number of recommendations 
which, it believes, would improve the Methadone 
Treatment Scheme delivered through community 
pharmacies.
a. The appointment of a National Pharmacy 
Coordinator
b. A system for filtering unstable methadone 
patients
c. A support system for pharmacists dispensing 
methadone
d. Correct payment for takeaway doses of 
methadone 
e. Review of patients in the prison system 
4. COnCLUSIOn
These issues have been on the agenda with the 
Department of Health and Children and the HSE 
since 2005. Whilst there has been a little progress 
in some areas, it has been slow. In conclusion, the 
Union would ask the HSE, as a matter of urgency, to 
appoint a National Pharmacy Coordinator who would 
be able to liaise with pharmacists, local Pharmacy 
Liaison Officers and the Union to address any issues of 
concern that arise. This will ensure the continued long-
term participation of community pharmacists in the 
Methadone Treatment Scheme and will help to attract 
new community pharmacists to join the scheme. This 
is essential to maximise the provision of treatment, 
to facilitate appropriate progression pathways and to 
encourage engagement with services.
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Appendix III
extRACt OF IPU SUBMISSIOn tO dePARtMent OF enVIROnMent heRItAGe And LOCAL GOVeRnMent On A ReVIeW OF 
RETAIL PLANNING GUIDELINES (2005)
June 2010
This submission was prepared by BMA Planning on behalf 
of the IPU in response to an invitation by the Minister for 
the Environment, Heritage and Local Government seeking 
submissions by stakeholders in the retail industry in 
relation to the Review of the Retail Planning Guidelines for 
Planning Authorities, 2005 (RPGs).
The IPU position was that pharmacies are an essential 
component of and make a very positive contribution to 
the vitality and viability of town, neighbourhood and 
local centres and that this should be maintained and 
strengthened in the forthcoming RPGs.
the submission focussed on:
1. The planning implications and threat to community 
pharmacies posed by the development of large 
superstores with on-site pharmacies, 
2. The planning implications and associated threat to 
community pharmacies posed by the location of 
pharmacies in large out-of-town health centres. In this 
regard, the IPU consider it imperative that pharmacies 
should not be considered as an “ancillary use” within a 
health/ medical centre but rather as an independent 
unit or “shop” and assessed accordingly in accordance 
with the “sequential approach”. 
A number of recommendations were presented to address 
these issues in the context of the RPGs Review.
the outcome sought was that the revised rPgs should:
a. Outline policy which recognises the important health, 
economic and social function of pharmacies in the 
context of town centres and local centres and in 
meeting the needs of patients in the community e.g. 
the elderly, people with special needs, families with 
children, and those without access to a car.
b. Specifically identify that all pharmacies should be 
subject to the sequential test in the same way as other 
local shops and that pharmacies should be discouraged 
within out-of-centre Superstores and Health Centres 
where they would have an adverse impact on the 
vitality and viability of existing town centres or local/ 
neighbourhood centres
this is a short extract from the IPU’s Submission to 
the department of environment heritage and Local 
Government on a Review of Retail Planning Guidelines 
(2005). the full submission is available on www.ipu.ie.
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Appendix IV
IPU SUBMISSIOn tO the PSI On dRAFt GUIdeLIneS On SOURCInG, StORAGe And dISPOSAL OF MedICInAL PROdUCtS 
WIthIn A RetAIL PhARMACy BUSIneSS
17 SEPTEMbER 2010
1. IntROdUCtIOn
 The Union welcomes the opportunity to make a 
submission to the Pharmaceutical Society of Ireland 
(PSI) on its draft guidelines on Sourcing, Storage 
and Disposal of Medicinal Products within a Retail 
Pharmacy Business. 
2. tIMInG/FORMAt OF the GUIdeLIneS
The Union welcomes the decision by the PSI to extend 
the deadline for submissions to 17 September 2010 
as August is a key month for staff holidays. In this 
context, the PSI may wish to consider not issuing any 
future draft guidelines for consultation during the 
summer months or over the Christmas period. These 
recent draft guidelines are the third published for 
consultation by the PSI this year. It would be helpful to 
the Union and its members if the PSI could provide a 
work plan for the next 12 months on what further draft 
guidelines it hopes to publish for consultation, so that 
the views of members can be sought, fully considered 
and collated for submission. It would also be useful if 
future guidelines were circulated in ‘Word’ format to 
facilitate people making highlighted comments in  
the text. 
 3. OVeRVIeW 
Pharmacists are fully committed to providing a 
professional service to their patients but a balance 
must be struck between meeting the needs of patients 
and maintaining paper trails and written procedures. 
Pharmacists are getting increasingly concerned 
about the ongoing imposition of bureaucracy and 
paper trails in pharmacy practice. These guidelines 
alone require in excess of 20 different types of 
procedures and processes to be developed. It is vital 
that pharmacy does not become dominated by having 
written procedures rather than the more fundamental 
requirement in pharmacy to have skilled, well trained 
and alert staff at the interface with patients which 
is the ultimate guarantee of patient safety. It is fully 
accepted that there is a need for Standard Operating 
Procedures (SOPs) that cover some fundamental 
operations of a pharmacy but the documenting of 
every procedure has the added risk that the important 
gets lost in the ever growing paper pile. 
The Union would ask the Society, therefore, to review 
their current approach in this area and recognise 
that there is a need for balance and reasonableness 
in all of these changes and, above all, to recognise 
that pharmacists’ first priority is to provide timely, 
professional and cost effective services to their 
patients. While the Union is fully committed to 
supporting high pharmacy standards, it is vital that the 
important does not get lost in a paper melee. We make 
some specific points on the draft guidelines in the 
remainder of this submission. 
4. StORAGe OF MedICInAL PROdUCtS
The Union would like to make the following comments 
on specific issues dealt with under Draft guidelines 
on the Storage of Medicinal Products within a retail 
Pharmacy Business. 
humidity Monitoring
The draft guidelines require that, where particular 
humidity storage requirements are prescribed, 
humidity monitoring should be incorporated as part 
of the monitoring of the storage area. When PSI 
inspectors have visited Retail Pharmacy Businesses, 
inspectors have requested that the pharmacy monitors 
humidity on a daily basis. The PSI should issue 
pharmacies with standards for measuring humidity, 
e.g. how is humidity measured, what is the range to 
monitor, etc., and guidance on what type of humidity 
monitor to use and also consider the associated costs. 
Controlled drugs Cabinet 
The Regulation of Retail Pharmacy Businesses 
Regulations 2008 (S.I. No. 488 of 2008), Paragraph 4(4), 
require that the CD cabinet meets the requirements 
of Regulation 5 of the Misuse of Drugs (Safe Custody) 
Regulations 1982 (S.I. No 321 of 1982) (as amended by 
Regulations 26(2) of the Misuse of Drugs Regulations 
1988 (S.I. No. 328 of 1988)). In order to comply with 
these regulations, the cabinet must meet the 
specifications set out in the standard specification 
for Burglar-Resistant Cabinets for the Storage of 
Controlled Drugs 1985 (I.S. 267:1985). The cabinet 
must either be marked permanently with (i) the 
manufacturer’s name and address, (ii) the capacity of 
the cabinet in cubic metres, (iii) the type approval test 
reference number and (iv) the inscription “I.S.267: 1985” 
or a member of An Garda Síochána (not below the rank 
of Superintendent) may issue a certificate which will 
last for 2 years.
It has been brought to our attention that I.S. 267:1985 is 
not available in Ireland. Consequently, it is not possible 
for safe manufacturers to inscribe the cabinet with 
this standard. This leaves the pharmacist with only 
one option – to get a member of An Garda Síochána 
(not below the rank of Superintendent) to issue a 
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certificate. Members have reported that when they 
have contacted the Gardaí to obtain a certificate, 
many Gardaí are not aware of this requirement and 
are reluctant to sign a certificate. We would suggest 
that the PSI produce an updated standard which can 
be given to both manufacturers of CD cabinets, so 
that they can inscribe the cabinet appropriately, and 
also brief the Gardaí so that they are aware of the 
requirements and advise them on the matter. 
Veterinary Medicines
The draft guidelines propose that veterinary medicinal 
products requiring 2-8oC storage should be kept in a 
separate animal medicines refrigerator reserved solely 
for this purpose. Whilst this may be a reasonable 
requirement for a pharmacy which has a significant 
veterinary business, it is neither practical nor efficient 
for a pharmacy which deals in a small amount of 
veterinary medicines to have a separate fridge for 
veterinary medicines. We would ask that the PSI 
guidelines reflect some practicality in this matter. 
high tech/exempt Medicines
We do not feel that it is practical to require that 
documentation for High Tech medicinal products 
or Exempt medicinal products be kept with the 
medicinal products. Pharmacies have a comprehensive, 
logical, filing system for suppliers’ invoices, copies 
of prescriptions, etc., and it does not make sense 
for paperwork for these products to be stored in a 
different manner. Likewise, it is not practical to store 
such paperwork in the fridge with the product. 
5. dISPOSAL OF MedICInAL PROdUCtS
The Union would like to make the following comments 
on specific issues dealt with under Draft guidelines 
on the Disposal of Medicinal Products within a retail 
Pharmacy Business. 
Storage of Waste Medicines
The draft guidelines require that waste medicinal 
products should not be stored in the dispensing/
working area of the pharmacy. The Union would 
argue that, as long as these medicinal products were 
segregated from normal stock and clearly labelled 
‘Medicines for Destruction’, there would be no issue 
with them being stored in an area of the dispensary 
where they would be under the control of the 
pharmacist. Equally, as explained further in the next 
paragraph, the PSI should ensure that the HSE has a 
nationwide system in place for the disposal of such 
waste. 
Patient Counselling
The draft guidelines suggest that patients should be 
encouraged to return unwanted or expired medicinal 
products to the pharmacy for disposal. Whilst 
many pharmacies provide this service as a gesture 
of goodwill to their patients, it is unfair to expect 
pharmacies to cover the considerable cost of such 
disposal. Some HSE areas provide a DUMP scheme 
through pharmacies in their area but many more 
do not. The Union has, for many years, called for a 
national DUMP scheme to be put in place. Indeed, this 
was a recommendation of the Joint Committee on 
Health and Children in their report on the Adverse Side 
Effects of Pharmaceuticals. The PSI should be cognisant 
of the costs involved in expecting pharmacies to 
provide such a service and should liaise with the 
Department of Health & Children and the HSE to 
ensure that a DUMP scheme, funded by the HSE, is put 
in place nationally before imposing such a requirement 
on community pharmacies. 
6. StAndARd OPeRAtInG PROCedUReS
The draft guidelines impose requirements for a 
significant number of SOPs to be put in place as 
part of the implementation of these guidelines; the 
Union has noted 22 separate SOPs! Whilst the Union 
acknowledges the appropriateness of setting standards 
in community pharmacies, the PSI should consider 
practicalities, costs and the workload involved for a 
single pharmacist pharmacy to produce such a suite of 
SOPs. We would hope that the PSI would acknowledge 
the professionalism of community pharmacists and 
that practicality and common sense would prevail in 
the methods used to apply such standards. We would 
be concerned that the onerous requirements involved 
in producing so many SOPs would result in many 
pharmacies spending their time writing and reviewing 
SOPs instead of advising and counselling patients. 
This has the added risk of critical SOPs not getting 
the attention they deserve and pharmacists, and their 
staff, drowning in paper and procedures. We would 
also expect that the implementation date of these and 
any further guidelines should reflect the time it will 
take most pharmacies to produce even just a selection 
of these SOPs. 
7. COnCLUSIOn
In conclusion, whilst the Union accepts that all 
pharmacies should meet the appropriate standards in 
sourcing, storing and disposal of medicinal products, 
the Union would expect that the PSI be cognisant 
of the practicalities from a pharmacist’s perspective 
in relation to the large number of SOPs required to 
implement these guidelines. There is now a serious 
risk of SOP overload and critical patient care issues 
losing out to the maintenance of written procedures 
and practices. The PSI should seriously review the level 
of bureaucracy now being imposed on pharmacists 
and prioritise what they view as the critical SOPs. 
The Union looks forward to working with the PSI on 
the production of a more practical version of these 
guidelines which will incorporate the issues addressed 
in this submission. 
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Appendix V
SUBMISSIOn By the IPU tO hIqA On dRAFt nAtIOnAL StAndARdS FOR SAFeR BetteR heALthCARe
4 November 2010
 1.  the ROLe OF the PhARMACISt In SAFeR BetteR 
heALthCARe
Patient care is becoming increasingly complex 
with: an ever increasing range of disease-specific 
medicines, both prescription and non-prescription; 
the impact of pharmacogenomics; the demands 
of pharmacoeconomics; the plethora of drug and 
disease evidence and other interventions available 
to the healthcare team. Superior clinical practice 
founded on collaboration among healthcare 
professionals is a key solution to this complexity. 
Collaborative pharmacy practice is defined as the 
clinical practice where pharmacists collaborate with 
other healthcare professionals in order to care for 
patients, carers and public. Integrating pharmacists 
into a collaborative healthcare team improves 
patient outcomes. There is strong evidence that 
pharmacists’ interventions on prescriptions are 
clinically appropriate and have a high acceptance 
rate. There is also strong evidence of the value of 
medication review services where pharmacists review 
a patient’s medication regime and make appropriate 
clinical recommendations. There is growing evidence 
of enhanced clinical benefit and good patient 
acceptability when pharmacists’ practice is advanced 
collaborative practice. The number of preventable 
medicines-related problems makes a compelling 
argument for a collaborative approach to medicines 
use and healthcare generally. The greater complexity 
of healthcare, the complex diseases afflicting 
patients, the growing sophistication of medication 
therapies all support the need for, and the value of, 
community based pharmacists, who are medication 
experts, to be fully engaged in collaborative pharmacy 
practice with the one aim to ensure safer and better 
health outcomes for patients. 
2. StAndARdS And CRIteRIA
In this section, we make general comments on the 
Standards and Criteria under each of the themes laid 
out in the HIQA document. However, before we do, 
we would like to point out that, while the Standards 
Advisory Group had representation from ICGP, 
Nursing and Midwifery, Surgeons, Health and Social 
Care Professionals, Anaesthetists and Paediatricians, 
disappointingly there was no representation from the 
pharmacy sector. This is surprising given the key role 
that pharmacists play in healthcare delivery and that 
pharmacists are invariably the first port of call for 
most patients. 
theme 1: Person-Centred Care
The IPU agrees with the Standards and Criteria 
identified to cover Person-Centred Care. The Union 
regularly undertakes consumer research through 
Behaviours & Attitudes to ascertain what new 
services patients would like to see in community 
pharmacy and to review what patients feel about the 
services offered. The Union has always highlighted 
community pharmacy as being the most accessible 
part of the health service. Other jurisdictions, 
having recognised this, have moved to provide an 
increasing number of primary care services through 
community pharmacies, for example, vaccination, 
health screening, medicine use reviews and health 
promotion.
theme 2: Leadership, Governance and Management
Most of the Standards and Criteria identified in this 
section are addressed for community pharmacy 
through pharmacy regulations and guidelines 
produced by the PSI under the Pharmacy Act 2007. 
Pharmacies have Standard Operating Procedures in 
place to ensure the required standards for pharmacy 
activities are met and maintained. Some of the 
criteria in this section would only be applicable in 
larger healthcare settings, e.g. hospitals, rather than 
in community pharmacies. A balance always needs 
to be struck between the maintenance of written 
procedures and the focus on patient safety so it is 
important to ensure that guidelines focus on the 
important rather than try to cover every single aspect 
of professional practice.
theme 3: effective Care
The PSI is responsible for registering community 
pharmacists and pharmacies and for monitoring 
and auditing the quality of pharmacy services. The 
Union welcomes the Standards and Criteria on 
integrated care as we have regularly highlighted 
concerns about the lack of integration across the 
primary and secondary care interface and indeed 
within primary care itself, e.g. recent changes to the 
Psychiatric Scheme which were introduced with little 
regard to their impact on patients. In this context, it 
is important that the Health Service Executive (HSE) 
consults with the relevant healthcare professionals 
before making changes to any scheme to improve 
operational efficiencies to ensure that patient safety 
is preserved. 
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theme 4: Safe Care
The Union will shortly become a signatory to the 
Department of Health and Children’s Patient Safety 
First initiative and we therefore support the ethos 
behind the Standards and Criteria identified in this 
section. New national legislation to support the new 
Pharmacovigilance Directive will also go some way to 
addressing these criteria. However, in a bid to learn 
from and prevent adverse events, it is vital that a ‘no 
blame’ culture be adopted to encourage reporting of 
adverse events by healthcare professionals. 
theme 5: Workforce
PSI regulations under the Pharmacy Act 2007 
incorporate a requirement for pharmacy owners to 
ensure that their staff has the necessary training 
and competencies to deliver services to patients. 
In addition, the PSI has recently announced the 
introduction of a mandatory CPD system for 
pharmacists. 
theme 6: Use of Resources
The Union has always advocated for community 
pharmacists to have an increased role in the delivery 
of primary care as evidence has shown pharmacy to 
provide value for money, an important consideration 
in these economically challenging times. Examples 
of such services are medicine use reviews, disposal of 
unused medicines, health screening, etc. 
theme 7: Use of Information
Community pharmacies are all registered with the 
Office of the Data Protection Commissioner and are well 
used to treating all patient information with the utmost 
confidentiality. The Union hopes to work with the 
Department of Health and Children and the HSE in the 
introduction of electronic health records and electronic 
prescribing, both of which will improve delivery of 
healthcare services to patients and patient safety. 
theme 8: Promoting Better health
Community pharmacy is the ideal place for health 
promotion and the Union has run a number of health 
promotion campaigns nationally over the years. 
3. COnCLUSIOn
In conclusion, whilst the Union welcomes the new 
HIQA standards to promote safer better healthcare, it 
is important that clarity on the role of HIQA and the 
PSI is given to avoid overlap and confusion. 
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Appendix VI
extRACt FROM SUBMISSIOn By the IPU tO the IndePendent MOnItORInG GROUP FOR A VISION FOR CHANGE
19 November 2010
1. the ROLe OF the PhARMACISt In MentAL heALth
Community pharmacists are in a unique position to 
contribute to the care of people with mental health 
difficulties, especially those with mental illness, 
and to alleviate the workload of other healthcare 
professionals in tackling often complex health 
problems. Pharmacy is the most accessible and visited 
part of the health service for patients with mental 
illness. 
2. PROBLeMS FOLLOWInG ChAnGeS tO the 
PSyChIAtRIC SCheMe
Recent changes to the arrangements in place for the 
dispensing of prescriptions within the Psychiatric 
Scheme have caused much disruption to the lives of 
patients with mental illness. The Psychiatric Scheme 
has operated in the greater Dublin area since 1998. 
It has enabled patients with full eligibility (GMS 
patients) to present a prescription issued by one 
of the clinics operated by the Community Mental 
Health Services at a community pharmacy and 
subsequently obtain their medication free-of-charge. 
Since 1 October 2010, GMS patients must obtain 
a medical card prescription from their GP in order 
to obtain medication prescribed for them by the 
Community Mental Health Services. The patient is 
now given a prescription or a list of their medication 
by the clinic which then has to be transcribed by their 
GP onto a medical card prescription. 
The Report of the Commission on Patient Safety and 
Quality Assurance 2008 stated that “when patients 
move from one care setting to another…a significant 
level of discrepancy between actual medication 
treatment and what was intended can arise.” Recent 
national research found that, when prescriptions 
issued by acute general hospitals were transcribed by 
GPs, 30% of medicines were transcribed incorrectly. 
This error rate was found to be consistent for all 
transcribed prescription items over a six month period. 
Patients attending the Community Mental Health 
Services represent a particularly vulnerable group 
within society. The Psychiatric Scheme has enabled 
these patients to readily access essential medicines and 
professional advice from their community pharmacist 
in a timely fashion. The new arrangements have placed 
a barrier in the pathway to accessing medicines for 
these patients and will compromise patient safety. The 
IPU believes that these new arrangements should be 
reconsidered in light of their detrimental impact on 
this vulnerable patient group. 
3. PhARMACy SeRVICeS
Patients need better services and health outcomes 
and Government continues to seek better value for 
money, particularly in these difficult economic times. 
In this context, the IPU has been advocating for the 
introduction of a number of initiatives, for example, 
Medicines Use Reviews, Monitored Dosage Systems 
and Structured Health Promotions, which would be 
relevant to patients with mental health problems. The 
Joint Committee on Health and Children in its report 
Primary Medical Care in the Community recommended 
that the HSE should consider how pharmacists could 
provide these services.
Minister Harney is supportive of an expanded role 
for pharmacists in the delivery of services at primary 
care level as “part of a structured framework of 
patient care”, which demonstrates “direct benefits to 
patients.” The Minister recently referred in the Dáil to 
“a number of developments taking place in community 
pharmacy practice; namely, reviews of medicine use, the 
introduction of private consultation areas in pharmacies 
and the involvement of pharmacists, both community 
and hospital based, in ongoing work to implement the 
recommendations of the report of the Commission on 
Patient Safety and Quality assurance.” 
4. COnCLUSIOn
The existence of a relationship between patients 
with mental illness and their community pharmacist 
provides the ideal framework to deliver primary care 
services, which would result in positive outcomes being 
achieved in a cost effective manner. The IPU believes 
that recent changes in arrangement to the dispensing 
of medicines to patients under the Psychiatric Scheme 
have led to problems for patients with mental illness 
and these changes should be reconsidered. People with 
mental illness need timely and uncomplicated access 
to medications and advice on how to take them. This is 
important from a reassurance perspective. 
AnnUAL RePORt 2011
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Appendix VII
exeCUtIVe SUMMARy OF RePORt PRePARed By the IPU “ReVIeW UndeR the FeMPI ACt 2009  
– tIMe FOR A neW APPROACh”
5 January 2011
COMMUnIty PhARMACy ROLe 
n  the pharmacy profession plays a critically important 
role in the Irish healthcare system, being the most 
accessible and efficient element of the national 
primary healthcare network; 
n  the cost-effective nature of the service, and the 
significant potential offered for the generation 
of additional system-wide cost savings, has been 
highlighted by a series of independent bodies, 
most recently the ESRI (October 2009) and the Joint 
Oireachtas Committee on Health & Children (February 
2010); 
n  health authorities in other jurisdictions are now 
effectively leveraging this potential to the significant 
benefit of taxpayers, healthcare providers and  
patients alike;
n  the Irish Pharmacy Union (IPU) and its membership 
wishes to engage in a meaningful dialogue with 
the Department of Health & Children (DoHC) and 
the Health Service Executive (HSE) on how such 
experiences can be replicated in the Irish context – at 
a time when the need for cost-effective healthcare 
services has never been greater;
COMMUnIty PhARMACy ReIMBURSeMent 
n  the community pharmacy sector suffered large and 
disproportionate cuts in payments as a result of the 
introduction of FEMPI provisions in July 2009; 
n  using HSE data, community pharmacists have 
contributed €123m in savings directly to the Exchequer 
from the FEMPI Cuts; 
n  the FEMPI impacts, are compounded by a number 
of other policy initiatives which have or will serve to 
further reduce earnings, including: 
n  a series of reductions in the price of off-patent 
medicines in 2010;
n  introduction of a prescription levy for GMS patients; 
• planned introduction of generic reference pricing; 
• new costs of regulation; and
• implementation of the IPHA Agreement in 2011.
n  with regard to the IPHA Agreement, it is estimated that 
the community pharmacy sector will deliver €20m 
of the targeted €200m in savings in 2011 and will 
also have, and continues to, contributed €10m from 
the IPHA and APMI cuts that took place in 2010 on an 
ongoing basis; 
n  this means that pharmacy has yielded savings of 
€153m or about €95,000 per pharmacy as a direct 
consequence of changes since July 2009 – this is a 
direct hit on bottom line profit;
n  this equates to a reduction of more than 32% in the 
payments made directly to community pharmacy 
contractors in the year to end-June 2010; 
n  taking into account the sub-threshold or gross DPS, 
pharmacists have suffered a loss of revenue of €181m 
or over €112,000 per outlet;
n  using CSO Annual Services Inquiry data, this equates 
to more than 45% of average outlet operating profit in 
2007 – the final year of the economic boom;
n  operating profit is that sum of money available to 
cover the capital costs of the business (i.e. interest and 
depreciation), taxes, owner profits and reinvestment in 
the business;
n  moreover, pharmacists will incur losses as a result of 
the devaluation of stock holdings as a result in the 
recent IPHA cuts – estimated at more than an average 
of €10,000 per outlet; 
n  this means that, in addition to the €20m that 
pharmacists will contribute on an ongoing basis from 
the recent IPHA cuts, the cost of the first month’s 
savings totalling €12m will come directly from 
pharmacists (who purchased stock at the old price) and 
not from the pharmaceutical companies;
n  the collapse of the DPS yielded public scheme savings 
of more than €75m in excess of the targeted €133m, 
with more than €16m of these savings lost to 
community pharmacy outlets;
n in the computation of FEMPI impact, no account is 
taken of this development and this should also be 
taken into account in this review;
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COMMUnIty PhARMACy ReSPOnSe
n  in order to maintain viability, pharmacies have reduced 
costs by cutting staff numbers. Regrettably services 
and opening hours have also been cut; 
n  in human terms employment in the community 
pharmacy sector has been reduced by 10%, with 
pharmacist employment falling by 4%; 
n  despite severe retrenchment, it is clear from PwC 
survey research (December 2010) that a sizeable 
proportion of the community pharmacy network is 
now struggling for financial viability; 
n  in calendar year 2009, when FEMPI had been in 
operation for only six months, 14% of pharmacy 
contractors reported net losses after tax - combined, 
these contractors account for 20% of the national 
outlet network;
n  any further reduction in payments and any significant 
change in interest rates in the coming months may 
permanently compromise the viability of these outlets; 
n  the IPU recognises the importance of effective and 
transparent regulation, however that regulation comes 
at a significant cost that should be recognised;
n  there is a limit to which any profession or business can 
cut costs and sustain a high quality service. Community 
pharmacy has now reached this point; 
n  given the substantial savings that have already been 
achieved from community pharmacy and further 
savings planned for 2011, the IPU believes that no 
further cuts should be made at this time; 
n  current reimbursement rates are, quite simply, 
inadequate to support the development of the 
community pharmacy sector in line with best 
international practice and to the benefit of all 
stakeholders; 
n  a more strategic approach should be taken to achieve 
savings and efficiencies; 
tIMe FOR A neW APPROACh 
n  the IPU is calling on the DoHC and the HSE to engage 
substantially with the IPU and its membership 
within a defined time period to review all 
existing administrative, contractual and payment 
arrangements with a view to identifying the scope 
for the realisation of pharmacy-specific, system-wide 
efficiencies and savings; 
n  this could be carried out through a process similar to 
the one agreed with the HSE and DoHC in April 2008;
n  unilateral and arbitrary cuts with limited engagement 
result in short-term savings which generate long-
term costs and serve to alienate the most accessible, 
affordable and cost-effective element of the Irish 
healthcare system, particularly in the context of the 
current economic climate and the increasing demand 
for community based patient services; 
n the time for a new approach is now. 
This is the Executive Summary of the IPU’s Submission to 
the FEMPI Review 2011. The full submission was sent to all 
members in January 2011. The submission is also available 
on the IPU website.
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Appendix VIII
extRACtS FROM SPeeCh By MR dARRAGh O’LOUGhLIn MPSI, IPU PReSIdent’S dInneR, 10 nOVeMBeR 2010 
Minister, Deputies, Senators, Honoured guests, colleagues 
and friends
Tonight is an important occasion – it’s that time of the year 
when we in the Irish Pharmacy Union, and I as the elected 
President, say a sincere “thank you” to all who work with us. 
In this room tonight are members of our Union who give of 
their time to keep us the strong, professional and focused 
representative body that we continue to be. 
Present here too are representatives of the Department 
of Health and Children, the Health Service Executive, the 
Pharmaceutical Society of Ireland, the Irish Medicines Board, 
our colleagues from Europe, the Northern Ireland and the 
UK and the many other stakeholder and representative 
organisations we interact with on a daily basis, most of 
which have been mentioned already.
I especially want to welcome Minister Mary Harney and her 
husband Brian Geoghegan here this evening. Your presence 
here tonight Minister is an important signal to us of your 
commitment to community pharmacy (and I welcome your 
comments earlier). 
We here may come from different organisations and from 
different perspectives but we share a common goal. That 
common goal is a better, more efficient and more cost 
effective health service which delivers the best possible 
outcomes for patients. As health care professionals, 
delivering high quality care for our patients is our life’s work.
However, we need to reflect tonight that Ireland is not on 
a steady course. The best case scenario facing our country 
is one of extraordinary challenge and unprecedented 
difficulty. And that’s the best case scenario; it cannot be 
automatically assumed. A business-as-usual strategy will 
not suffice if we are to succeed in putting our country back 
on a path towards prosperity. And – to be blunt – policy-
makers, pharmacists and patients all share a vested interest 
in restoring national prosperity. 
Right now, there is a compelling case for doing things 
differently from how they have been done before and this 
equally applies to healthcare delivery. As a representative 
organisation, the Irish Pharmacy Union has a clear agenda 
for pharmacy. We aim to position community pharmacy not 
only as the most readily available and the most accessible 
interface for patients – which it already is – but also to 
build on that accessibility and convenience and on the care 
community pharmacists already provide by delivering more 
services and delivering them cost-effectively, achieving 
positive outcomes for patients. 
While the IPU is in the vanguard, advocating a bigger role 
for pharmacy in the delivery of health care for patients in 
the community, we are not alone in this: we are greatly 
encouraged by recent reports from both the ESRI and the 
Oireachtas Committee on Health and Children. Like us, 
these interested, expert and astute observers of health care 
believe that pharmacists could and should be doing more 
for the benefit of all.
As well as hard times, there have been many positive 
developments in pharmacy. The Pharmacy Act is an 
important and positive step forward. Adjusting to 
increasing regulation is costly and never easy. In the cultural 
shift away from the assumption of quality to the assurance 
of quality, a reasonable balance has to be found between 
increasing accountability requirements and the costs of 
meeting those requirements and also the need to ensure 
pharmacists are not detracted from their focus on patients, 
who are the reason we do what we do.
The roll-out of a new regime of Continuing Professional 
Development and Competency Assurance will undoubtedly 
pose an additional challenge for all of us, but we must see 
it as providing the solid concrete foundation on which our 
ambitions for the future of our profession will be built. It 
ensures that patients who trust and rely on the professional 
judgment and discretion of their pharmacists can continue 
to have full confidence in the professionals caring for them. 
We, as a profession, are now better placed than ever to 
deliver more for patients and to bring better value to health 
care delivery. 
Pharmacies have stepped up to the mark in a whole range 
of different ways. In difficult times, pharmacists have 
invested in making the changes needed. Last year, in the 
shadow of the flu pandemic, almost 1,000 pharmacists 
were trained, at their own expense, and were ready to 
participate in the national immunization effort if the need 
had arisen.
More recently, we have installed private consultation areas 
where patients can discuss their health in private with their 
pharmacist, thus enhancing their experience of using a 
pharmacy. Clearly these new consultation facilities make 
a whole range of patient services more feasible as well 
as more patient friendly. These are the ideal locations for 
providing diabetes and cardiovascular screening, cholesterol 
testing, for blood pressure testing, for helping patients 
manage their chronic illnesses and for delivering services 
locally – at times and in locations that meet the diverse 
needs of people in the community.
And we are not just talking about this; we’re doing it. 
Pharmacists are now engaged in a number of important 
patient and public health pilot programmes – including 
Health Screening, Medicine Use Reviews and Asthma 
Management. We are working with the HSE and with other 
stakeholders because we believe that these programmes 
have the potential to deliver real value to patients and to 
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deliver an efficient and economical model of preventative 
healthcare. These ongoing projects are gathering concrete 
evidence of the benefits of the services being provided.
Innovative approaches and solutions like these need to be 
found. The status quo is not an option. Neither do I accept that 
an ad-hoc series of reactive and uncoordinated spending cuts – 
ultimately self-defeating – leaving an already inadequate state 
of affairs further decimated, but putting nothing different or 
better in its place is the way to proceed.
I have a vision of a patient dropping into a pharmacy after 
she finishes work or at the weekend in a response to a 
targeted cardiovascular screening programme. She has 
her blood pressure, her cholesterol and her blood glucose 
measurements taken by her pharmacist. Where those 
measurements indicate that she is at risk of cardiovascular 
disease, because her blood pressure or other measurements 
are outside of the normal range, she is given the necessary 
lifestyle and dietary advice to make the changes necessary 
to improve her health prospects and she is also referred 
to her GP. At the GPs, her doctor would start her on an 
appropriate treatment plan which has been drawn up by 
clinical specialists in the area based on international best 
practice. She comes back to the pharmacy with her care 
plan and her prescription. And then, on an ongoing basis, 
the pharmacist can monitor her progress for example by 
measuring her blood pressure, and, if necessary, adjust the 
doses of her medication step by step in line with the care 
plan agreed with her doctor. This ensures that she gets 
the full benefit from her medication, that she has support 
in managing her condition and that she achieves the 
best outcome possible for herself, potentially avoiding an 
unnecessary hospital stay down the line.
Minister, you and the Government rightly call on all to play 
their part and to pay their share. Pharmacists have already 
paid more than their fair share – in the twelve months since 
we last enjoyed this dinner, employment in the pharmacy 
sector has declined by well over 10%; 1,600 of our members 
or their staff have lost their jobs. 
The future of pharmacy and of patient care generally 
depends greatly on all of us engaging together in a 
constructive manner for the common good. That common 
good is clear. We have together a shared responsibility to 
ensure our country pulls through this crisis, that patients 
continue to be cared for, and that we deliver a sustainable, 
convenient and cost effective model of healthcare that will 
serve Ireland well for the future. 
In conclusion:
n As a Union of professional pharmacists we are strong 
and we are united. 
n As Irish citizens we recognize and we understand the 
realities our country faces. These are hard times. There 
are no easy choices. 
n The choice we want to embrace is that of dramatic 
change and not of piecemeal retreat. We can glumly 
face a slow death by a thousand cuts or we can say NO! 
We can say instead that there is a different way. 
n It is a way that points to the bigger picture and to the 
longer term. 
n Its achievement requires a collaborative, team-based 
approach to the delivery of sustainable healthcare.
n It involves care in the community and pharmacy is 
central to this new model of healthcare. We are there 
in every community. We are accessible and we are 
passionately dedicated to our patients. 
n Minister, we are part of the solution and we are 
committed to playing our part.
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Appendix IX
SOMe Key LetteRS And ReSPOnSeS ReCeIVed thROUGhOUt the yeAR
topics
n Financial emergency Measures in the Public 
Interest Act 2009
n Fees for Pharmacists and Pharmacies
n Prescription Charges
n Rejected Claims
n needle exchange Programme
n hardship and Psychiatric
n dPS Reimbursement Letter
n Memorandum of Understanding 
n It Issues
n Generic Substitution and Reference Pricing
n new Services
n Methadone treatment
FInAnCIAL eMeRGenCy MeASUReS In the PUBLIC 
InteReSt ACt 2009 
Financial emergency Measures in the Public Interest Act 
2009 – Letter 1
From Secretary General to Assistant Secretary dohC  
[20 January 2010]
I wish to refer to your letter of 13 January and to thank you 
for the two enclosed reports. 
At our meeting in October 2009, the Minister indicated 
that she intended tracking, on a monthly basis, the level of 
savings being achieved under the FEMPI Regulations. The 
Minister also indicated at that meeting, and publicly, that 
the Department and the HSE would share this analysis with 
the Union in the interest of transparency and, if the Union 
required further clarification, this would also be provided. 
The Department based its analysis of savings on forecasts 
for 2009 which have not to date been made available to 
the Union. The Union sees a benefit therefore in having 
a meeting between the Departments advisers, FGS and 
the Union’s advisers, PwC to guarantee transparency and 
understanding on all data. 
In the meantime, I would ask that you provide the 
information originally requested on 14 December and 23 
December as soon as possible to enable the Union to make 
an informed submission to the Minister’s Review. 
The information requested is:
n Information showing the estimated amount 
being saved for each month by the HSE since the 
introductions of the cuts, including the calculations, 
methodology and underpinning computations; and
n Information on dispensing trends and payments over 
the past six months. (Jill Lyons sent two spreadsheets 
requesting both contract specific data and aggregate 
data by email on 23 December).
I look forward to hearing from you.
Financial emergency Measures in the Public Interest Act 
2009 – Letter 2
From Secretary General to Assistant Secretary dohC 
[11 February 2010]
I wish to refer to my previous letter of 20 January 2010 
and would appreciate if you could arrange to provide the 
information originally requested on 14 December and 23 
December as soon as possible. This information is vital to 
enable the Union to make an informed submission to the 
Minister’s Review. 
 The information requested is:
n Information showing the estimated amount 
being saved for each month by the HSE since the 
introductions of the cuts, including the calculations, 
methodology and underpinning computations; and
n Information on dispensing trends and payments 
over the past six months. (An email containing two 
spreadsheets requesting both contract specific data 
and aggregate data was sent on 23 December).
Following receipt of your last letter and enclosed report, 
PwC has now reviewed the data and has written to the 
Union to outline some concerns they have in relation to the 
methodology and underpinning computations used in your 
calculations (copy attached). 
I would appreciate if you could let me have the 
information previously requested and your views on 
the PwC analysis. It is important that both sides have 
a shared understanding of the data in advance of the 
Minister’s consultation getting underway.
I look forward to hearing from you.
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Financial emergency Measures in the Public Interest Act 
2009 – Letter 3
From Secretary General to Minister for health and Children 
[22 March 2010]
I wish to refer to our meetings in October 2009 and 
December 2009.
At both of the meetings, you indicated your intention 
to track, on a monthly basis, the level of savings being 
achieved under the FEMPI Regulations. You also indicated 
that the Department and the HSE would share this 
analysis with the Union in the interest of transparency 
and, if the Union required further clarification, this would 
also be provided. 
The Union has written and/or emailed your Department 
and the HSE on the following occasions for information 
relating to the FEMPI Regulations:
n 14 December 2009
n 23 December 2009
n 20 January 2010
n 11 February 2010
The information requested was:
n The two Farrell Grant Sparks (FGS) Reports;
n Information showing the estimated amount being 
saved for each month by the HSE since the introduction 
of the cuts, including the calculations, methodology 
and underpinning computations; and
n Information on dispensing trends and payments over 
the past six months.
The Union has only received the FGS reports to date. We 
are still awaiting the other two pieces of information 
requested. 
Arising from the FGS reports our advisers PwC have raised a 
number of issues around the forecasts for 2009 which the 
Department based its analysis of savings to be achieved 
from the cuts in payment. These issues were brought to the 
attention of the Department in a letter dated 11 February 
but to date no response has been received. 
I would ask you to intervene as a matter of urgency to 
ensure that this information is provided as soon as possible. 
This information is vital in the interests of transparency 
but also in ensuring that the Union can make an informed 
submission to the Review that you will be conducting under 
the FEMPI Legislation. 
Financial emergency Measures in the Public Interest Act 
2009 – Letter 4
From Secretary General to Assistant Secretary dohC 
[20 May 2010]
I wish to acknowledge your letter of 19 May in relation 
to the Minister’s Review under the Financial Emergency 
Measures in the Public Interest Act 2009. 
I wish to confirm that the Union will be making a 
submission to the Minister’s Review. We would also 
welcome an opportunity to make an oral submission to the 
Department.
I also wish to acknowledge receipt of the report by Farrell 
Grant Sparks. However this does not contain the detailed 
data we had previously requested in our letters of:
14 December 2009; 23 December 2009; 20 January 2010; 11 
February 2010; 23 March 2010
In summary, the information requested is:
n	  Information showing the estimated amount 
being saved for each month by the HSE since the 
introductions of the cuts, including the calculations, 
methodology and underpinning computations; 
n	  Information on dispensing trends and payments 
over the past six months. (An email containing two 
spreadsheets requesting both contract specific data 
and aggregate data was sent on 23 December); and
n	  Clarification on the ongoing basis of the calculations  
(which is referred to in our letter of 11 February).
This information is now requested as a matter of urgency to 
ensure that the Union can make an informed submission to 
the Review. 
Financial emergency Measures in the Public Interest Act 
2009 – Letter 5
From PCRS Contract Manager to Assistant Secretary dohC 
[21 december 2010]
I wish to refer to your letter of the 8 December 2010 
regarding the Minister for Health and Children’s review of 
payments to Pharmacy Contractors in respect of services 
they render to, or on behalf of, the Health Service Executive.
I wish to confirm that the Union will be making 
a submission and would also like to make an oral 
presentation. The Union would appreciate if we could be 
accommodated on the morning of Friday 7 January 2011 and 
would suggest 12 noon.
I look forward to hearing from you.   
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Financial emergency Measures in the Public Interest Act 
2009 – Letter 6
From IPU President to Minister for health and Children 
[11 January 2011]
I wish to write to you following a meeting with your 
officials last week regarding the FEMPI review. Our written 
submission (a copy of which is enclosed) together with our 
discussions last week are intended, as stated in the title 
of our document, to provide a basis for a new approach 
towards community pharmacy. This agenda would both 
save the Exchequer resources in the short term as well as 
better utilize the capacity of community pharmacy going 
forward.
Regarding the discussions at our recent meeting I wish to 
reiterate a few points that we made to your officials last 
week.
n	  According to the Department’s own figures, 
pharmacists will have contributed €123m per year 
arising directly from the cuts that were made in  
July 2009. 
n	  It is totally disingenuous to suggest, as happened 
at the meeting, that pharmacists are not taking a 
direct hit as a consequence of the reductions in the 
reimbursable price of medicines. 
n	  The Union estimated that pharmacists will contribute 
another €30m on a full year basis as a direct result of 
recent agreements on the price of medicines based on 
2008 data and taking into account the impact of the 
reduction on both the mark-up and the reimbursable 
price. 
n	  Pharmacists will also contribute a significant 
element of the first month’s €12m savings arising 
from the recent IPHA reductions as the failure to 
give pharmacists any reasonable notice of the price 
reductions left them holding significant stocks of 
medicines which will have devalued considerably.
n	  As pharmacists have seen a reduction of 32% in 
payments – or 45% of the CSO estimate of operating 
profit for 2007 – there is simply no scope for further 
arbitrary cuts. 
n	  This is not to say that additional savings and 
efficiencies cannot be achieved through direct 
engagement with the Union on a change agenda 
within a tight timeframe. 
n	  This can be done through a process similar to the one 
agreed with the Department and the HSE in April 2008. 
I would welcome an opportunity to meet you to expand on 
our views on the appropriate way forward at this juncture. I 
hope that you will respond favourably to this proposal as it 
provides a focused and strategic basis for the future.
Financial emergency Measures in the Public Interest Act 
2009 – Letter 7
From PCRS Contracts Manager to Assistant Principal 
Officer dohC 
[21 January 2011]
I wish to refer to your telephone discussion with Seamus 
Feely about certain figures included in the Union’s 
submission to the FEMPI Review.
At the outset, I want to reiterate that any reduction in the 
reimbursable price of medicines affects pharmacists directly 
and any savings that flow from these reductions comes 
directly from pharmacy. For example, in our submission and 
at the presentation with the Department of Health and 
Children on the 7 January, we stated that pharmacists will 
contribute nearly €20m on a full year basis from recent 
reduction to the price of medicines.
This figure comprises of the following:
n	  €14m from the decrease in the reimbursable price of 
medicines which directly affects the pharmacy; and
n	  €5.5m from the decrease in the mark up paid to 
pharmacists primarily on the DPS and LTI Schemes
I hope this clarifies matter and if you have any further 
questions, please do not hesitate to contact me.
Financial emergency Measures in the Public Interest Act 
2009 – Letter 8
From Secretary General to Minister for health 
[11 March 2011]
I wish to write to you regarding a review of payments to 
pharmacists that was commenced by former Minister 
Harney in December last year under the Financial 
Emergency Measures in the Public Interest Act 2009 
(FEMPI).
As part of that review, the Union made a detailed 
submission to the then Minister entitled “time for a new 
approach”. In the submission, the Union highlighted that 
there is no scope for further unilateral and arbitrary cuts. 
Pharmacists have already suffered direct and indirect 
cuts of 32% or €153m which is more than that suffered by 
any other sector. Nevertheless we believe that additional 
efficiencies and savings can be achieved by adopting a new 
approach. This approach would involve a substantial and 
direct engagement with the Union within a defined period 
of time to review all existing, administrative, contractual 
and payment arrangements with a view to the realisation 
of pharmacy specific, system wide efficiencies and savings 
as well as addressing other aspects of Government policy 
including reference pricing and generic substitution. 
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Such engagement could get underway immediately 
under a process similar to that set out and agreed with 
the Health Service Executive and the Department in April 
2008. This process envisages direct engagement on all 
matters including payment models under an independent 
chairperson.
The Union believes that this offers an orderly and efficient 
way to work together in bringing about real and lasting 
change and would welcome an opportunity to meet you to 
elaborate on our views.
Financial emergency Measures in the Public Interest Act 
2009 – Letter 9
From Assistant Secretary doh to Secretary General  
[31 March 2011]
I refer to the consultations under the above Act in regard to 
payments made to community pharmacy contractors under 
the General Medical Services and community  
drugs schemes. 
I wish to inform you that the Minister for Health and 
Children, Dr. James Reilly T.D., has decided to make the 
following changes in payments: 
A reduction to 8% in the wholesale mark-up on all drugs 
dispensed under the GMS and community drugs schemes 
A reduction to 20% in the retail mark-up payable under the 
Long Term Illness Scheme and Drugs Payment Scheme for 
those items which currently attract a retail mark-up of 50% 
A 50% reduction in the Patient Care Fee under the High-
Tech Medicines Scheme for months when an item is not 
dispensed (Fee reduced from €60.52 to €30.26). 
Regulations are required to give effect to these changes. 
The Minister has directed that these be drafted as soon as 
possible. I will let you know when the regulations have  
been signed. 
Financial emergency Measures in the Public Interest Act 
2009 – Letter 10
From PCRS Contracts Manager to Minister for health 
[1 April 2011]
Re: FEMPI Announcement 
I wish to refer to yesterday’s announcement on reductions 
to pharmacy payments under the FEMPI Act. 
The IPU is disappointed at the introduction of further 
reductions to payments. Only nine months ago it was 
accepted by the Department that pharmacists had taken a 
significant reduction in their payment and no further cuts 
should be implemented.
The IPU does not believe that any further reductions should 
be made. However, if the reductions are to be introduced 
the implementation date of the changes should allow 
sufficient time to update the IPU Product File and to 
allow IT vendors to amend pharmacy systems. Therefore 
we would request that any changes be delayed for a 
minimum period of six weeks to allow for the appropriate 
IT amendments to software systems to take place.
We sincerely hope that this is the last in a line of recent ad 
hoc and arbitrary cuts. The IPU welcomed your statement 
on Prime Time (28 March) where you outlined your 
intention to commence discussions on a new contract 
for pharmacists. The IPU continues to advocate for a new 
approach which would involve substantial and direct 
engagement with the Department of Health (‘Department’) 
and the Health Service Executive (‘HSE’). 
A review of all existing administrative, contractual and 
payment arrangements, as well as discussion on other 
aspects of Government policy including reference pricing 
and generic substitution, could take place within a defined 
period of time. Such engagement could get underway 
immediately under a process similar to that set out 
and agreed with the HSE and the Department in April 
2008. This process envisages direct engagement on all 
matters including payment models under an independent 
chairperson.
The IPU believes that this offers an orderly and efficient 
way to work together in bringing about real and lasting 
change, and would welcome an opportunity to meet you to 
elaborate on our views.
 I look forward to hearing from you on the two matters 
highlighted in this letter. 
Financial emergency Measures in the Public Interest Act 
2009 – Letter 11
From Minister for health to PCRS Contract Manager 
[4 April 2011]
The Minister for Health, Dr James Reilly, TD, has asked me to 
thank you for your letter concerning the FEMPI Announcement 
and to let you know that it is receiving attention.
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FeeS FOR PhARMACIStS And PhARMACIeS
Fees for Pharmacists and Pharmacies – Letter 1
From Secretary General to Registrar & Chief executive PSI 
[19 April 2010]
Re: IPU/PSI Meeting
I would like to thank you and your colleagues for taking the 
time to meet with the delegation from the Irish Pharmacy 
Union (IPU) on 30 March 2010 to discuss issues of mutual 
concern. I think we all found the meeting most productive 
and conducive to both our organisations working in 
collaboration in the future.
I thought it would be useful to highlight the points that 
were made during our discussion where further actions 
may be needed. 
1.  PSI Register 
The issue was raised at the meeting that, if a 
pharmacist fails to re-register with the PSI when their 
current annual registration expires and their name 
has been off the register for more than six months, 
the Pharmacy Act 2007 does not prescribe a means for 
them to re-register with the PSI. We would ask  
that you seek to redress this anomaly in any 
forthcoming amendments to the Pharmacy Act  
that may be contemplated.
2.  electronic Invoices 
We raised this issue in a previous letter prior to our 
meeting and we would ask that the PSI consider 
allowing electronic invoices to suffice for inspection 
purposes for the reasons we have outlined to you. 
3.  Charter for Inspections 
It was agreed that the PSI and IPU would liaise to draw 
up a Charter for Inspections. Perhaps you could let us 
know who the contact person in the PSI will be for this. 
Our contact person will be Pamela Logan, Director of 
Pharmacy Services.
4.  Proposed Prescription Charges 
At the meeting, we reiterated the concerns highlighted 
in a previous letter to you about the proposed 
prescription charges. The PSI confirmed that you 
also had concerns in relation to the pharmacist’s 
responsibility, under the Code of Conduct, of ensuring 
that patients get their medicines as required. We would 
ask that you continue to highlight these issues to the 
Minister.
5.  Bankruptcy 
We discussed the issue of pharmacists who have been 
declared as undischarged bankrupts being prohibited 
from registering with the PSI under Section 14(f) of 
the Pharmacy Act. In light of the current economic 
situation and the financial vulnerability of many 
independent pharmacy businesses following the 
drastic cuts in reimbursement in the last year, we 
would ask that you seek to amend this part of the 
legislation in any forthcoming amendments to the 
Pharmacy Act. 
Again, I would like to thank you and your colleagues for the 
meeting and look forward to continuing our dialogue with 
you on matters of mutual concern.
Fees for Pharmacists and Pharmacies – Letter 2
From Secretary General to national director Integrated 
Services - Performance and Financial Management, hSe 
[25 June 2010]
Many thanks for your recent correspondence regarding the 
payments that are currently being withheld by the PCRS 
because of difficulties in reconciling the patient details on 
prescriptions with the PCRS patient records. 
At the outset, I should point out that pharmacists are 
willing to co-operate with the HSE in resolving ongoing 
issues and it was precisely for this reason that we put 
forward our proposals on the 28th May last. We also 
expressed our strong concerns at that meeting and indeed 
at my meeting with you about the practice of withholding 
or rejecting claims or changing procedures without giving 
any advance notice to pharmacists or explaining why 
claims are being rejected. This practice is not acceptable 
and, as members of the public dealing with a public 
service organisation, surely pharmacists have a right to be 
informed in advance of any such decisions being taken. 
As late as last night, I had a call from a member whose 
advance payment was deducted from his payments this 
month again without any notice. These practices and 
concerns must be addressed if we are to build trust and 
confidence between contractors and the HSE. Equally, it 
is important that there is openness and transparency on 
the volume of claims that are being withheld or rejected 
and the reasons for so doing. In relation to the obligations 
mentioned in your correspondence, the first and most 
important obligation of all parties must be to the patients 
to ensure that they get their medication in a timely manner. 
The first clause of the pharmacy contract requires the 
pharmacist to “supply, with reasonable promptness….such 
medicines as may be ordered.”
The fundamental issue here relates to the HSE databases 
which are clearly not up to date and are grossly inaccurate. 
The databases held locally in HSE offices are not compatible 
with the PCRS list. We have a multitude of examples, 
including cases where the patient, according to the HSE 
records, is deceased but is alive and well and cases where, 
according to the local HSE office, the patient has a valid 
card but the PCRS system is showing the card to be invalid. 
Another case came to light recently where an 83 year old 
man has a valid card but the PCRS database is showing the 
card to have expired. No system will resolve these problems 
unless the base material is accurate and this is the first 
issue that must be tackled. 
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Section 14 (2) of the contract states that “the pharmacy 
contractor shall co-operate with the chief executive officer 
and the general Medical Services (Payments) Board in the 
discharge of any statutory obligations imposed upon them 
including the obligation to establish the accuracy of claims.” 
This does not place an obligation on pharmacists to verify 
the accuracy of prescription details but to co-operate 
insofar as they can in assisting the PCRS in the discharge of 
their obligations and we are anxious to do this in a practical 
manner. 
Indeed, the Union has worked with the PCRS in previous 
years in relation to the Drugs Payment Scheme where it 
was evident that the datasets held in Local Health Offices 
and the PCRS did not match. The PCRS was legitimately 
concerned that some of these claims were invalid, however, 
it transpired that most of the claims related to patients that 
were eligible under the DPS Scheme but were “unmatched” 
by the PCRS to its database. 
From the evidence given to the Union by its members, the 
Union is confident that the same situation is now arising 
in relation to the GMS Scheme and the majority of the 
claims in question are claims for eligible patients that are 
“unmatched” by the PCRS to its own database. This can arise 
for several reasons such as delays in the HSE in processing 
of medical card applications, as recently evidenced by the 
Oireachtas Committee on Health, and invalid data in the 
PCRS and Local Health Office datasets, for example where a 
death has been reported in error. 
The Union is concerned that any change to current practice 
would have the effect of denying patients their entitlements 
under the Community Drug Schemes and this could, in some 
instances, lead to drastic consequences to the patient’s health 
status. You will agree that this is a situation that should not 
and cannot be allowed to happen. Pharmacists must at all 
times consider their responsibility to their patients under 
the Code of Conduct of the Pharmaceutical Society while 
at the same time co-operating with the HSE in resolving 
administrative issues. 
It was for all of these reasons that the Union offered to 
provide assistance to the HSE in resolving their current 
difficulties at the last meeting of the Joint Consultative 
Group on 28 May. Essentially, our proposal was that the HSE 
should apply a similar approach to medical card patients as 
they do to patients on the Long-Term Illness Scheme (LTI). I 
think it is important that I clarify our proposal which would 
involve:
1. The PCRS informing pharmacists in advance that the 
HSE will be left with little option but to withhold 
payments in specified cases unless the eligibility of the 
patients has been resolved to their satisfaction (see 
draft letter attached). This letter, specific to each case, 
would be sent at the same time as the pharmacy gets 
the detailed payment listing from the PCRS. Therefore, 
if a patient was dispensed a medicine on 6 January the 
pharmacy will receive notification from the PCRS in 
early March and, as I stated at our meeting, a further 
dispensing will probably have been made by the time 
the notification is received. 
2. The PCRS would provide an additional copy of this letter 
to the pharmacist, who would hand it to the patient 
when they next visit the pharmacy and advise the 
patient of the position and suggest to them that they 
contact the local HSE office to clarify their eligibility.
3. If the matter is not resolved within a reasonable period 
(to be discussed and agreed) from the first intervention 
by the pharmacist, then the pharmacist will act on 
the advice of the HSE and advise the patient that 
they must pay for their medicine. In other words, the 
pharmacy would be paid for that particular patient up 
to the end of the agreed period after which time the 
patient must pay for their medicines if their eligibility 
has not been clarified. One would hope, however, that 
once the letter has been handed to the patient by the 
pharmacist that the matter can be quickly resolved by 
the HSE directly with the patient. You can be assured 
that the Union will encourage our members to fully 
co-operate with this initiative.
The HSE databases must be reconciled, otherwise these 
problems will continue to arise and any new system 
developments will not resolve current problems. This is 
further evidenced by the fact that a patient will have 
already visited the GP and obtained a prescription before 
visiting a pharmacy and it is at that juncture that issues 
of this nature should come to light. I welcome your 
confirmation that the GPs are checking and confirming 
eligibility. The mere fact that these problems are not being 
resolved at this juncture again confirms that the source of 
the problems rests with the HSE’s own records and delays 
in processing renewals and new applications. I understand 
that the HSE is obliged to keep the GPs informed of changes 
in client eligibility. You will also be aware that evidence was 
given to an Oireachtas Committee earlier this year that a 
survey of 60 GP practices showed that 645 patients either 
had cards or were entitled to a card, but they did not appear 
on the PCRS database. 
In conclusion, the Union is open to discussing longer term 
solutions but it is important that we first address the root 
of the problem. You will also be aware that we put forward 
a proposal over a year ago on a process through which we 
could advance our respective IT agendas and we are happy 
to discuss this matter with you at any time. The Union’s 
offer of assistance in resolving these issues is an attempt to 
assist the HSE in a practical and workable way to address 
the obvious problems you have with current systems and 
databases. Pharmacists will not lightly refuse medication 
to their patients and the HSE should accept that the first 
obligation of all parties is to ensure that patients get timely 
access to their medicines. The patient should be given 
adequate time to deal with any administrative issues before 
any entitlement is withdrawn. 
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In these circumstances, I would again ask that you reinstate 
the payments that are being withheld contrary to the 
terms of the pharmacy contract, consider the Union’s offer 
of practical assistance and co-operation in resolving these 
issues, which we first made almost one month ago, that 
you give a commitment to advise pharmacists in advance 
of any claims being rejected or withheld and the reasons for 
so doing and provide figures on the total number of claims 
not being paid, for whatever reason, on an ongoing basis. 
As we have a Contractors’ Committee scheduled for early 
July, I would welcome an early response from you as we are 
anxious to move forward as quickly as possible. The Union 
is also available for a meeting if you think that would be 
helpful. 
draft Letter from PCRS to the Pharmacist
Dear pharmacist,
Re: Name and Address of Patient 
I wish to refer to the claim received in respect of the above 
patient and to advise you that according to our records this 
patient …………………………………………………………………
I would appreciate if you would bring the matter to 
the attention of the patient when they next visit your 
pharmacy and advise them that this matter must be 
resolved or they will no longer be able to avail of medicines 
under the community drugs scheme. Please advise the 
patient to contact the local HSE office for assistance. 
You may wish to note this on your own records so that 
you will be aware that payments will not be paid after 
……………….2010.
In this context, I enclose an additional copy of this letter for 
your records.
Fees for Pharmacists and Pharmacies – Letter 3
From Secretary General to Assistant Secretary dohC 
[22 September 2010]
The Minister for Health and Children has indicated that it 
was her intention to obtain savings from the Agreement 
with the Association of Pharmaceutical Manufacturers 
(APMI) in September 2010 similar to the level of savings 
made under IPHA. 
I have been asked by the Pharmacy Contractors’ Committee 
(PCC) that the implementation of any price reductions 
should allow sufficient time to update our IT system and to 
allow pharmacists to try to dispense stock reimbursed at 
the higher price. 
It is essential that there is continuity of supply for 
medicines for patients and that pharmacies are reimbursed 
at the old price for a two month transition period. 
The Union would also request that members have access to 
the list of products well in advance of the implementation 
date to make sure that they are in a position to manage 
their stock while continuing to ensure that they retain an 
adequate supply for their patients. The HSE has informed us 
that there is no list at this time.
Fees for Pharmacists and Pharmacies – Letter 4
From Secretary General to Assistant Secretary dohC 
[9 december 2010]
I wish to refer to the recent announcement, as part of 
Budget 2011, of price reductions and other measures which 
are expected to contribute up to €200m in savings. 
I have been asked by the Pharmacy Contractors’ Committee 
(PCC) that the implementation of date of any further 
price reductions should allow sufficient time to update 
our IT system and to allow pharmacists sufficient time to 
dispense stock reimbursed at the higher price. 
As you are aware, January is the worst month of the 
year for such a change to be implemented because of 
the potential effects on both stock availability and, more 
critically, patient access to medicines. During the Christmas 
and New Year period there is increased hospital discharge 
rates, reduced access for patients to GP services, a reduced 
wholesaler delivery to pharmacies, an increased level of 
urgent prescriptions and unpredictable patterns of patient 
demand, which all routinely put pressure on the supply 
system.
It is essential that there is continuity of supply for 
medicines for patients during this critical time and any 
reductions arising from the agreement with IPHA should 
apply to medicines dispensed from 1 February 2011. 
Fees for Pharmacists and Pharmacies – Letter 5
From PCRS Contract Manager to Assistant Secretary 
General dohC 
[8 March 2011]
Re: Reductions in the Cost of Medicines
I wish to refer to the price reductions announced by the 
Department of Health and Children over the past 12 
months, specifically the reductions which took place in:
n	  February 2010;
n	  September 2010; 
n	  January 2011.
I have been asked by the Pharmacy Contractors’ Committee 
(PCC) to highlight the significant loss experienced by 
pharmacy contractors due to the lack of notice provided 
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by the Department. The Union estimated in the recent 
Submission to the FEMPI Review in January 2011, that 
the average pharmacy lost in the order of €10,000 due 
to the overnight devaluation of their stock. While the 
Union welcomes the reduction of the cost of medicines 
to the patient, the manner in which the reductions were 
implemented is disgraceful. 
The Committee have asked that, in future, when the 
Department intends to reduce the costs of medicines they 
should alert the Union and pharmacists well in advance 
of the implementation date. A minimum of 4 to 6 weeks’ 
notice is necessary to allow sufficient time for the Union to 
update our IT system and to allow pharmacists adequate 
time to dispense stock reimbursed at the higher price. 
The PCC is seeking a commitment from the Department to 
put arrangements in place with appropriate safeguards to 
give adequate notice of future reductions so as to prevent 
a loss of the scale experienced in January of this year from 
happening in the future.
Fees for Pharmacists and Pharmacies – Letter 6
From Assistant Secretary General dohC to PCRS Contract 
Manager 
 [10 March 2011]
I refer to your letter of 8 March concerning reductions in 
price of medicines in recent times, with particular reference 
to the reductions that took effect in January 2011. 
As you will recall, this matter was raised by the IPU during 
its oral submission to the Department under the FEMPI 
process on 7 January last. On that occasion, I acknowledged 
the difficulties that the short notice of the price reductions 
had posed for pharmacists and other stakeholders. I 
explained that discussions between the Minister and 
the Irish Pharmaceutical Healthcare Association had 
concluded on 2 December. It was then a matter for the 
member companies of IPHA to notify the HSE of their new 
prices. These were received by the HSE during the month 
of December and were notified to the IPU without delay. 
Ideally, longer notice would have been given but, due to the 
serious financial challenges facing the HSE, the price cuts 
had to take effect from the earliest possible date in order to 
maximise savings in 2011. 
I also pointed out that it was well known within the 
trade that further price reductions were under discussion 
between the Department, HSE and IPHA and that our 
understanding was that pharmacists ran down stock levels 
in December in anticipation of same. In addition, we were 
aware that IPHA companies had taken action to mitigate 
the level of stock loss when previous price cuts took effect 
and it seemed reasonable to conclude that the same would 
apply on this occasion. 
The Department is not in a position to accept the validity 
of the claimed average stock loss of €10,000 per pharmacy 
due to the most recent price cuts as neither ourselves or the 
HSE have any means of assessing the levels of stock held 
by the pharmacy sector, the value of that stock, the actual 
price paid to suppliers or the mitigation measures that 
might have been negotiated by pharmacists. 
Looking to the future, you can be assured that the Department 
will strive to give as much notice as possible in the event of 
further price reductions. However given the State’s ongoing 
financial difficulties, it is not possible to give any commitment 
with regard to the length of any notice period. 
PReSCRIPtIOn ChARGeS
Prescription Charges – Letter 1
From Secretary General to Minister for  
health and Children  
[26 March 2010]
I wish to refer to a discussion in the Dáil on 25 March 2010 
about the introduction of prescription levy for medical card 
patients.
When questioned by Deputy Ó Caoláin about the 
implementation of the prescription levy, an Tánaiste stated 
that: ‘the legislation is in draft form and will be brought as 
quickly as possible to the house.’
In your letter, dated 5 January, you assured the Union 
that officials from the Department would consult 
with the Union when preparing the legislation for the 
implementation of the levy.
The Union would like to seek a meeting with officials from 
your Department to address our members many concerns 
about the introduction of the levy which we have previously 
brought to your attention.
Prescription Charges – Letter 2
From Secretary General to Minister for  
health and Children 
[10 May 2010]
I wish to refer to our meeting on Thursday 29 April. 
Prescription Levy
The Union believes that the issues of misuse and wastage 
can be addressed in other ways that may have less impact 
on patient welfare. However, if the levy is to be introduced 
the Union looks forward to discussing this matter with your 
officials as already agreed.
As discussed at the meeting, it would be helpful if the 
Department could provide a response to our letter of 17 
December 2009 in advance of the meeting to discuss the 
draft legislation.
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review of FeMPi act & extent of the Cuts 
We mentioned at the meeting that the Union has written 
and/or emailed your Department and the HSE on at 
least six occasions for information relating to the FEMPI 
Regulations.
The information requested was:
n	  Information showing the estimated amount 
being saved for each month by the HSE since the 
introduction of the cuts, including the calculations as is, 
methodology and underpinning computations; and
n	  Information on dispensing trends and payments over 
the past six months.
As highlighted during the meeting on Thursday, any 
further delay in getting these figures may interfere with 
the Union’s ability to make an informed submission to the 
FEMPI Review.
The Union also wrote to the Department on 11 February 
2010 highlighting concerns about information in the Farrell 
Grant Sparks report in relation to the projected calculation 
of the savings arising from last year’s cuts. We would 
welcome a response to this letter as soon as possible. 
reference Pricing  
Further to the discussion at the meeting, the Union looks 
forward to receiving a copy of the report by Mark Moran 
and his group. The introduction of a reference pricing 
system will have a significant effect on patient welfare 
and pharmacy income as we outlined at the meeting. 
It is our firm belief that this issue and other changes 
together with the long-term implications of increased 
medicine consumption on public expenditure can be best 
addressed in the context of a review of existing contractual 
arrangements for pharmacists. The Union looks forward to 
further engagement on these issues. 
Competition Law 
Any amendment to Competition law to facilitate any 
negotiations with other Representative Bodies should also 
be extended to the Union. The Union would welcome a 
formal response to our previous correspondence and legal 
advice submitted to the Department on this matter.
iPu agM Motions 
A further copy of the motions passed at the IPU AGM on  
24 April is attached for your information and response in 
due course.
Prescription Charges – Letter 3
From Secretary General to Minister for health  
and Children 
[16 June 2010]
I have been asked by the Pharmacy Contractors’ Committee 
to refer to my letters dated 17 December, 29 March and 6 
May and recent discussions with Department officials on 
the introduction of prescription charges for Medical Card 
patients.
The Union understands that the reason for introducing 
the charges is to deal with issues of underuse, overuse and 
misuse of medicines. The Union has advocated that the 
most appropriate way to deal with issues of this nature is 
through the introduction of medicine use reviews, which have 
been introduced in other jurisdictions. This approach would 
not compromise patient welfare and would not have the 
administrative difficulties associated with prescription charges.
The Union is extremely disappointed that the intention 
appears to be that pharmacists will be lumbered with 
the task of collecting these charges. This approach will 
fundamentally change both the nature of the relationship 
between a pharmacist and a patient and the contractual 
relationship between the pharmacist and the HSE. The 
burden and cost associated with the collection of these 
charges should not fall on pharmacists and the Union sees 
no reason why the HSE cannot collect these charges directly.
The introduction of such a charge for medical card 
patients will affect the most vulnerable patients in society. 
Community pharmacists will face many ethical dilemmas 
if these charges are forced upon them. Our understanding 
is that no process has been put in place to deal with 
situations where patients refuse, or cannot afford, to pay 
for their medication. This needs to be addressed before any 
charges are introduced.
The Union also has major concerns about patients on 
methadone and those who avail of the Psychiatric Scheme 
in the Eastern Region. As we understand it, the position is 
that these patients will have to pay the charge for all their 
medication, other than methadone. This is unworkable and 
will put a further strain on pharmacists and HSE clinics. 
These vulnerable patients should be exempted from these 
charges; otherwise they may not take their medication and 
end up in hospital care. 
It is also important that homeless patients and patients in 
community and institutional care are exempt from these charges.
Certain patient cohorts can have their medicines changed 
on a weekly/daily basis (palliative care patients) and a 
mechanism will be required to address this situation. Issues 
will also arise in relation to imposing a charge for multi-
preparation and combination packs and differing pack sizes, 
e.g. 1 x Zocor 60 mg (50 cent) versus 3 x Zocor 20mg (€1.50).
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The definition of a “family” also needs to be addressed in the 
context of the intention to introduce a maximum charge.
In conclusion, the Union would ask that you reconsider your 
position on these charges and not proceed with them. The 
Union believes that these charges will have consequences 
for the health and wellbeing of vulnerable patients and 
will be an administrative and costly nightmare for those 
administering them and charged with their collection. If 
the proposal proceeds, it is vital that all the issues set out in 
this letter and in previous correspondence, as well as those 
discussed at various meetings, are adequately addressed in 
the legislation.
Prescription Charges – Letter 4
From Secretary General to Assistant Secretary dohC 
[22 July 2010]
I have been asked by the Pharmacy Contractors’ Committee 
(PCC) to refer to the recent prescription levy legislation 
passed by the Oireachtas.
As you are aware, the PCC believes that there are more 
appropriate ways in which to deal with the issue of 
medicine wastage, however, now that the legislation has 
been passed, the PCC would request a further meeting to 
discuss the implementation and administration of the levy. 
This introduction of the levy for medical card patients 
will fundamentally change the nature of the relationship 
between the pharmacist and their patient. The prescription 
levy will also place a significant administrative burden and 
cost on pharmacies and this needs to be addressed by the 
Department. The Committee is seeking the payment of an 
administrative fee which would be added to the dispensing 
fee to cover the cost to the pharmacy. 
The PCC also has concerns and questions around the 
administrative difficulties associated with the prescription 
levy which need to be discussed well in advance of the 
introduction of the levy. Concerns raised previously with the 
Department include:
n	  Patients receiving treatment under the Methadone 
Treatment Scheme who are on other medicines;
n	  Patients receiving medicines under the Psychiatric 
Scheme in the Eastern Region;
n	  Homeless patients and patients in community who are 
not exempt from these charges;
n	  Certain patient cohorts who have their medicines 
changed on a weekly/daily basis including palliative 
care patients;
n	  The definition of a “family”;
n	  Situations where patients refuse, or cannot afford, to 
pay for their medication.
There are also a number of practical implementation issues 
that need to be considered and addressed before the levy is 
introduced.
I look forward to hearing from you on when the 
Department and HSE will be in a position to engage with 
the Union on these issues.
Prescription Charges – Letter 5
From Secretary General to Minister for  
health and Children 
[2 december 2010]
The introduction of the prescription charges has given 
rise to considerable difficulties for some patients and 
also imposed a significant cost burden on community 
pharmacists who were handed the responsibility of 
collecting the charges. In particular, difficulties have 
arisen with certain patients and the Union believes that a 
relatively small number of patients should be exempted 
from these charges altogether. In particular, we would 
ask you to exempt the following patient cohorts from 
prescription charges:
n	  Patients in nursing homes; 
n	  Patients receiving treatment under the Methadone 
Treatment Scheme in respect of other medication that 
they may be taken;
n	  Patients receiving psychiatric medicines;
n	  Homeless patients including those in homeless 
shelters;
n	  Patients who have their medicines changed on a 
weekly/daily basis including palliative care patients;
n	  There also needs to be some restrictive provision that 
would allow pharmacists to exercise their discretion to 
dispense medicines in situations where patients refuse, 
or cannot afford, to pay for their medication.
The Union appreciates the current budgetary constraints 
that the Government is facing but the cost associated with 
these exemptions would be very small in the overall context 
of the yield from the charges. Indeed the cost to health 
expenditure would be far greater if these patients did not 
take their medication as a consequence of the charges. 
I would ask you therefore to consider amending the current 
regulations to exempt these patients.
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Prescription Charges – Letter 6
From Assistant Secretary doh to PCRS Contract Manager 
[4 March 2011]
I refer to your letter of 4 March concerning the provision 
in the Memorandum of Understanding between the 
Government and the EU-IMF relating to ensuring that the 
elimination of the 50% mark-up paid for medicines under 
the Drugs Payments Scheme is enforced. 
As you are aware, in July 2009 the then Minister made 
regulations under the FEMPI legislation to reduce the 
retail mark-up paid to pharmacists by the Health Service 
Executive under the DPS from 50% to 20%. As you say, the 
lower mark-up is being applied where expenditure on drug 
purchases is met by the HSE. However. the reference in the 
MOU does not relate to the above but rather to the fact 
that many pharmacists are not passing on the mark-up 
reduction to patients whose expenditure is not met by the 
HSE e.g. where monthly expenditure by a person or family is 
below the €120 per month threshold under the DPS. 
The relevant agencies are examining the actions that are 
required to ensure that the commitment in the MOU is 
implemented.
ReJeCted CLAIMS
Rejected Claims – Letter 1
From Secretary General to national director Integrated 
Services - Performance and Financial Management, hSe 
[10 May 2010]
We have been inundated with calls from members who 
have had a substantial number of their last month’s claims 
rejected by the PCRS. When they contact the PCRS they are 
advised to write to Mr Paddy Burke and no one else there 
can offer any assistance to callers.
This situation is totally unacceptable and needs to be 
addressed urgently. Examples of cases where claims have 
been rejected are as follows:
n	  Claims have been rejected for patients who are 
recovering heroin addicts when the prescription is for a 
medication other than methadone. Certain medicines 
would be commonly prescribed for a recovering heroin 
addict to treat withdrawal symptoms. The pharmacist 
was informed yesterday that the HSE is refusing to 
pay for these additional medications. Many of these 
patients cannot afford to pay for the medicines 
themselves and the HSE gave no warning that they 
would no longer be paying for them. The pharmacist 
will no longer be able to provide these patients with 
their medicines unless this matter is resolved.
n	  Claims have been refused for medicines that a 
pharmacy dispensed to patients who are living in 
sheltered accommodation in Dublin’s city centre. The 
medical card that some of these patients have been 
using expired last May. Without warning the HSE are 
now refusing to pay for these medicines and these 
patients are not in a position to renew their cards.
n	  The HSE are refusing to pay for medicines dispensed 
to a patient as they claim the patient is dead. However 
the patient is alive and well and still requires her 
medication. 
n	  The HSE are refusing to pay for medicines dispensed 
to a psychiatric patient. The patient is entitled to a 
medical card but his current card has expired. The 
patient does not understand what the HSE are writing 
to him about in terms of renewing his card, he does 
not understand that the card has expired and he would 
be unable to fill out the renewal forms. Neither is he in 
a position to pay for the medications.
There are thousands of other claims being rejected on the 
basis that the GMS numbers are incorrect. Other claims 
have been rejected in respect of patients who have valid 
cards in their possession. The responsibility for accuracy of 
medical card numbers does not rest with pharmacists – 
their responsibility is to ensure that patients get access to 
their medications when they need them. 
This matter is now extremely urgent as the welfare and 
health of these patients is now at risk. In the circumstances 
please advise how you propose to deal with these issues 
and ensure that these patients, many of whom lack the 
capacity and resources to look after their own needs, are 
not put at risk. 
I would welcome an immediate response to this letter 
as the Union has now no option but to highlight this 
intolerable approach in the interests of patients and their 
health and wellbeing. 
I have tried unsuccessfully to talk to Mr Burke about  
these issues.
Rejected Claims – Letter 2
From Assistant national director Finance Shared Services-
PCRS to Secretary General 
[18 June 2010]
At our meeting (Joint Consultative Group) on Friday 28th 
May 2010, we agreed to draft a protocol, which could 
provide a solution in relation to the issue of incomplete 
claims. 
To move this process forward in a way which ensures:
n	  that eligible persons have access to their drugs and 
medicines without disruption, 
n	  pharmacists have certainty about payment for services 
they provide to eligible persons and 
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n	  the accountability responsibilities of the HSE are  
fully addressed,
I would suggest that the following protocol, which 
encompasses the proposal suggested by the IPU at the JCG, 
be considered at an early meeting of the Group:
1)  Where a claim does not have the correct number of an 
eligible patient, it will be reported on the Pharmacists 
Detailed Payment Listing so that the pharmacists is 
alerted to the fact that the patient number is not 
correct. The pharmacist can then alert the client to 
regularise their medical card registration to continue 
to access the item(s) free of charge. The client will be 
assisted to do this by the HSE Local Health Office. The 
PCRS will process and pay this claim on a once off basis 
(for the first month), without prejudice, to allow the 
client to regularise their eligibility and registration on 
the national list. 
2)  I believe that it is important that pharmacists have 
access to the available software tools to support 
completion of claims and minimise error. Therefore, 
I will arrange to advise pharmacy system vendors to 
provide the patient identification tools to pharmacies 
and I will communicate with all pharmacists and advise 
them that these tools are now available to them. It is 
important that the IPU does not restrict pharmacist 
use of these tools.
3)  As a matter of good practice both the IPU and the HSE 
will jointly advise pharmacists that incorrect claiming 
is not acceptable. The HSE will continue to closely 
monitor claims to identify if any additional measures 
are required. 
The context allowing the HSE to propose this approach is 
very important. The HSE must ensure that all public monies 
are used to reimburse valid claims only. It cannot be agreed 
by the HSE to reimburse claims which cannot be verified 
on an ongoing basis. This protocol is proposed to operate 
through 31st December 2011 during which time the conjoint 
working of client, HSE and pharmacy will arrive at the point 
where eligibility confirmation at point of service is routine 
for all parties.
Further to our meeting on 28 May 2010, I have drafted an 
additional piece of correspondence which will issue to each 
individual pharmacist where reimbursement has been held, 
which I attach for your information and observations. 
Subject to agreement and implementation of this new 
protocol, I would propose to issue this type of letter to 
pharmacists where there is a breach of faith in relation 
to operation of the protocol and in advance of ceasing 
reimbursement, in addition to the normal notification on 
the detailed payment listing. 
I would like to take this opportunity to provide an overview 
regarding the processing of pharmacy claims in 2010 in 
response to concerns raised by the Irish Pharmaceutical 
Union (IPU) and the background against which this solution 
is proposed.
I can confirm that the policy regarding the processing 
and treatment of pharmacy claims has not changed in 
any way. As an integral part of our function to process 
claims and make payments the PCRS is also charged with 
verification of the accuracy and reasonableness of all claims. 
A basic aspect of this verification is to ensure that where a 
pharmacy claims to have provided a service to a patient, the 
patient can be identified as eligible for the service. Where 
claims are identified, which raise concerns, reimbursement 
of these claims is held pending verification and the 
pharmacy is informed on their Detailed Payment Listing 
in the normal way. As soon as the pharmacist provides the 
required claim detail for any such claims these are paid in 
the next payment run. Nothing has changed in this regard. 
While the policy has not changed, PCRS has identified a 
relatively small number of pharmacies that stand out from 
the norm. Under normal circumstances the pharmacist 
ensures that the patient is eligible under the Medical 
Card (GMS) Scheme as per his/her contract with the 
HSE. Once the dispensing is completed the pharmacist 
submits a claim for reimbursement providing the medical 
card number of the patient. A relatively small number of 
pharmacies (132, or 8.1%, in April 2010) do not appear to 
adhere to this process. These pharmacies submit large 
numbers of claims without providing the number of 
the eligible person to whom medicine was dispensed. 
Reimbursement of these claims has been withheld until 
the pharmacist furnishes the medical card number of the 
eligible person. The pharmacist is notified in each and 
every case on their monthly Detailed Payment Listing, and 
immediately the missing data is provided the held claim 
will be paid. 
PCRS commenced holding claims from those pharmacies 
with unusually high levels of these claims, in the first instance, 
with the payment in February 2010 (January 2010 claims). Prior 
to holding any claims PCRS go through a rigorous procedure 
to ensure that only incomplete claims which require a 
pharmacist to provide additional information are held. Aside 
from the single case regarding Methadone Clinics/Sheltered 
Accommodation, about which we have already communicated 
and have resolved, no other systematic issues have been 
identified with this process. Therefore PCRS await hearing 
from the pharmacies concerned for details which can support 
the individual claims they have submitted in order to release 
payment for same. 
In 2009 PCRS reimbursed Pharmacists more than €1.23bn 
(€244m fees) under the Medical Card Scheme, in respect of 
51 million claim items. 
The table below provides a summary of the claims which 
have been held over the months February 2010 through 
May 2010.
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Month
Number of 
Pharmacies
Number 
of 
Claims 
Held
Value of 
Claims 
Held
Total Value 
of Pharmacy 
Claims
Number of 
Pharmacies 
Paid
Number 
of Claims
Feb 2010
(Jan 
Claims)
80 813 €59,711 €98,371,621.64 1,615 1,388,682
Mar 2010 
(Feb 
Claims)
77 654 €46,057 €86,912,340.43 1,625 1,313,440
Apr 2010 
(Mar 
Claims)
132 3,698 €232,866 €101,250,622.17 1,627 1,540,575
May 
2010 (Apr 
Claims)
171 3,047 €206,778 €89,839,434.56 1,500 1,415,408
notes
(1)  The figures for May 2010 refer to early payment only 
since normal pay will issue in June 2010.
(2)  The value of claims held is a gross figure whereas the 
total value of pharmacy claims is a net figure.
An anomaly which has emerged in relation to the 
requirement for primary care professionals that have 
with contracts with the HSE to confirm client eligibility 
at the point of service, is the different approach taken 
by pharmacists as compared to the GP community. The 
following facts highlight this starkly.
n	  At least three vendors supplying software to GPs 
have integrated PCRS supplied tools to enable GPs to 
confirm client eligibility at the point of service. This 
suggests a level of demand for this function from GPs. 
Other GPs use the PCRS supplied internet browser 
and SMS based tools. Pharmacy software vendors 
consistently report that they can make this function 
available to their customers, however it has been 
reported to PCRS that the IPU has instructed that 
pharmacies should not have access to these tools to 
assist them.
n	  The number of times GPs confirm client eligibility 
at point of service currently ranges from 25,000 to 
35,000 per day or over 6 million per year. GPs have 
incorporated these tools so that the checking of 
client eligibility is automated with action required on 
behalf of the GP only in exceptional circumstances. 
Because the process is effortless, GPs confirm client 
eligibility upon the setting of each appointment. In the 
case of pharmacies it would be sufficient to confirm 
client eligibility once per month per client. This check 
could be automated in pharmacy software with the 
pharmacy being alerted on an exceptional basis. The 
number of times pharmacists currently confirm client 
eligibility at point of service using the same tools that 
GPs use is practically zero.
n	  Some pharmacists also operate anomalous and 
inconsistent processes in relation to their acceptance 
of cards for payment purposes. PCRS understand that 
when bank cards (VISA, Laser, MasterCard etc) are 
accepted for payment that patient eligibility towards 
reimbursement of the dispensing cost covered by 
that bank card is confirmed by the pharmacist in 
each and every case. However, it seems those same 
pharmacists will not confirm patient eligibility to have 
the dispensing cost covered by the medical card in any 
case.
I believe that the approach suggested by the IPU at the JCG 
which forms the basis for the proposal outlined above has a 
real potential for dealing with all of the issues and to deliver 
a solution in this area. I would welcome your comments.
Rejected Claims – Letter 3
From the Secretary General to national director 
Integrated Services - Performance and Financial 
Management, hSe 
[22 July 2010]
At their recent meeting the Pharmacy Contractors’ 
Committee (PCC) considered the payments that are 
currently being withheld by the PCRS because of difficulties 
in reconciling the patient details on prescriptions with the 
PCRS patient records. The Committee wishes to express 
their strong concern and annoyance about the delay in 
having these claims paid. The practice of withholding or 
rejecting claims or changing procedures without giving 
any advance notice to pharmacists setting out clearly in 
writing the legal or contractual reason why claims are being 
rejected is not acceptable. 
The PCC noted that it has been five months since we first 
raised this matter with the PCRS yet there has been no 
progress made on the matter and claims continue to be 
arbitrarily rejected. 
We have repeatedly stated that pharmacists are willing 
to co-operate with the PCRS in resolving ongoing issues 
and indeed in my letter dated 25 June we put forward an 
approach, based on a LTI circular from the PCRS that would 
help the HSE in dealing with this issue. 
In a further effort to assist, the PCC wishes to put forward 
the following proposal to assist in resolving the matter. If the 
PCRS immediately stops rejecting GMS claims and pays all 
the outstanding rejected GMS claims for the 31 pharmacies 
involved. The PCC would be prepared to sit down with the 
HSE and agree the terms of reference for a six month pilot of 
the validation process with the pharmacies concerned whose 
claims have been rejected. The Union would expect that the 
HSE cease this arbitrary approach to the rejection of claims 
and pay all outstanding claims. 
At the same time, the PCC would again request that the 
HSE review the accuracy of their database. The PCC has 
serious concerns about the reliability of the HSE databases 
which are clearly not up to date and are grossly inaccurate. 
The data bases held locally in local HSE offices are not 
compatible with the PCRS list. We have a multitude of 
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examples including cases where the patient according to 
the HSE records is deceased but is alive and well and cases 
where according to the local HSE office the patient has a 
valid card but the PCRS system is showing the card to be 
invalid. These cases have been raised with the PCRS on 
numerous occasions.
Recent developments around the LTI Scheme have also 
highlighted the lack of communication between the PCRS 
and the Local HSE offices. Pharmacists are being told they 
have approval to dispense medicines to patients with long 
term illnesses by the local HSE offices; however, these 
claims are subsequently rejected by the HSE. The PCRS 
refuses to accept the letter of authorisation from the 
pharmacist and insists that this is provided directly to them 
by the local office. Pharmacists are not responsible for the 
breakdown of communication within the HSE and should 
not be penalised by the arbitrary withholding of claims. This 
matter has been raised with the PCRS; however, they have 
failed to respond on the matter.
It is not acceptable for the PCRS to withhold or reject claims 
without prior explanation. It is unfair and unreasonable 
for the PCRS to change claiming procedures without 
giving any advance notice to pharmacists. Due to the lack 
of engagement by the PCRS, we are currently preparing a 
dossier on the 37 cases. If there is no progress on paying 
these currently withheld claims, the PCC believes it will 
be left with little option but to bring these cases to the 
attention of the Ombudsman for investigation. The Union 
has also been informed that the matter may also be 
pursued by individual pharmacists through the courts. The 
PCC would prefer to have these issues resolved through 
discussion and agreement however, due to a lack of 
engagement on the matter, the PCC cannot sit back and 
allow these practices to continue. 
needLe exChAnGe PROGRAMMe
needle exchange Programme – Letter 1
From Secretary General to Assistant national director 
Finance Shared Services-PCRS 
[11 June 2010]
I wish to refer to your letter email of 27 April 2010 in 
response to the Union’s submission from October 2009.
The Pharmacy Contractors’ Committee noted your proposal 
at its meeting on 25 May and asked me to convey their 
comments on the proposal.
As discussed at the Joint Consultative Group meeting on 
28 May, there is a considerable workload for community 
pharmacists involved in the operation of the Needle 
Exchange Programme. Factors to be taken into account 
when considering a pricing structure should include, but are 
not limited to:
n	  The impact on and risks to pharmacy staff;
n	  The impact on and risks to other pharmacy customers;
n	  Added administrative burden on community 
pharmacies providing the service;
n	  The training needed for pharmacy staff working in 
participating pharmacies;
n	  The extra time and counselling needed for this patient 
cohort;
n	  The labour-intensive nature of provision of Needle 
Exchange Programme.
The Committee feels that the HSE’s proposal does not 
adequately address the issues raised in the Union’s 
proposal. 
A more reasonable approach, taking cognisance of the 
issues mentioned above would be either:
n	  Current dispensing fee of €3.50 for a pharmacy 
accepting dirty needles and €3.50 for the issuing of 
clean needles; Or
n	  Current dispensing fee of €7 for a patient transaction 
(accept dirty needles and issue clean needles).
The retainer of €1250 seems appropriate but should 
continue for three years. The associated costs, including 
increased security; time spent with this cohort of patient 
is continuous. These costs to the pharmacy will not 
decrease after year two. Where a new pharmacy joins the 
programme, this retainer should be offered to them. 
The Union highlighted the need for a review of the 
operation of the Needle Exchange Programme after the 
initial roll out of the programme. Arrangements should 
be reviewed by the PCC and HSE following two years of 
operations. The Review should be completed and agreed 
between the parties before the end of the third year. 
The IPU would see this review taking cognisance of the 
following: 
n	  Adequacy of the training course material (both face to 
face and distance learning);
n	  The work load for pharmacies providing Needle 
Exchange;
n	  The number of pharmacies providing Needle Exchange;
n	  The locations of the pharmacies providing Needle 
Exchange;
n	  The level of remuneration (the annual retainer and the 
transaction fee) for the provision of Needle Exchange 
Programme, if it is to continue after the three year 
period; and
n	  Input from the patients participating in the 
programme.
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In its submission from October 2009 the Union agreed to 
support and advocate for the roll out of a Needle Exchange 
Programme based on the HSE’s agreement to support 
pharmacists in a number of manners. As this aspect of our 
submission was not addressed in your response, we wish 
the HSE to confirm that it agrees to cover these services.
A commitment was given to appoint a National Pharmacy 
Liaison Officer. The Union believes that, in the interests of 
patients and providers of the service, a National Pharmacy 
Liaison Officer should be appointed, without further delay, 
to oversee the implementation of the Needle Exchange 
Programme and to provide training and back up to 
pharmacies participating in the provision of all addiction 
services, including the Methadone Scheme. 
Once this appointment is made this will send a strong 
signal to pharmacy that unlike the Methadone Scheme, 
the HSE will be supporting pharmacies participating in the 
Needle Exchange Programme from day one. This support 
will ensure the participation of community pharmacists in 
the Programme and will help to attract new community 
pharmacists to join the Programme. This will be of benefit 
to every community in Ireland, and most importantly, to the 
patients themselves. 
needle exchange Programme – Letter 2
From the Secretary General to head of Addiction  
Service, hSe 
[4 november 2010]
I wish to refer to our discussions regarding the possible roll 
out of a needle exchange programme through pharmacy.
The matter was considered by the Pharmacy Contractors 
Committee (PCC) today and from our soundings, the roll out 
of this initiative is not feasible or viable for the fees currently 
on offer. We have explained previously in some detail the 
effort, risk and costs involved in delivering this service. The 
Committee had originally suggested a significantly higher 
fee than is currently on offer to cover the costs involved. The 
PCC believes that €5 is the minimum fee that should be 
offered for a service of this nature. Such a fee can be easily 
accommodated within the existing claiming arrangements by 
assigning a specific code to this service. 
The Committee has also asked me to point out that the 
Regulations made by the Minister in 2009 did not set any 
precedent for determining payments for any new services 
nor did it create a “normal patient encounter fee”. In 
addition, the training currently being provided by the ICCPE 
envisages a level of service and interaction with patients 
that will simply not be possible to deliver for a fee of €5.
In conclusion, this is an initiative that pharmacists are 
happy to explore with the HSE to see if it could be delivered 
through pharmacy. Discussions have dragged on for a very 
long time and I would ask you to review the HSE position 
on the matter again. 
The Executive Committee is meeting on 10 November and I 
would welcome a response before then.
needle exchange Programme – Letter 3
From Assistant national director Finance Shared Services-
PCRS to Secretary General 
[9 november 2010]
It is disappointing that you consider that it is not feasible 
or viable to rollout this initiative for the fees on offer. 
The HSE conducted a comparison of Needle Exchange 
Programmes earlier in the year and consider that the 
arrangements proposed by the HSE compare favourably 
with other jurisdictions. The HSE considers that a review of 
all aspects of the service in one year allows an assessment 
with indigenous data of the particular demands of the Irish 
environment. Community Pharmacists would be availing of 
the generous retention fee during this timeframe and it is 
possible that some locations would have little demand for 
services in the initial stages.
You will be aware that the HSE has an agreement in place 
with the Elton John AIDS Foundation to financially support 
the roll out over 3 years – it will not be possible to continue 
with this initiative unless agreement is reached this month. 
The HSE is also ready to advertise the new post of Pharmacy 
Coordinator for Harm Reduction (outside of Dublin). As the 
primary focus of this post is the development of Needle 
Exchange services, it would not be possible to proceed in 
the absence of agreement on the service. This would be 
disappointing for all concerned. The interest of attendees 
at the ICCPE course was very encouraging and the HSE was 
arranging local integration with Addiction services as a 
support for participating pharmacies.
The development of a Needle Exchange Service opened up 
other possibilities in this environment. In proceeding within 
the current schedule of fees, the administrative burden for 
all involved would have been kept to a minimum. I would 
ask that the Executive Committee consider the matter 
carefully before making a final decision.
needle exchange Programme – Letter 4
From the Secretary General to Assistant Secretary, dohC 
[23 december 2010]
We have been working with the HSE for some time to get 
a needle exchange scheme off the ground. The scheme will 
be funded for an initial three year period by the Elton John 
Foundation. 
We have made very good progress on the matter however 
a problem has arisen over the level of fees being paid for 
the service which is now holding up its launch. The sides 
were considerably far apart on the matter but the Union’s 
views on an appropriate level of fee for this service have 
been modified considerably. Essentially, the Union’s bottom 
line on the matter now is that the fee for each transaction 
should be €5 while the HSE holds the view that the fee 
should fall within the current scaled fee structure for 
dispensing medicines. 
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As a profession and Union, we would like to be able to 
get behind this worthwhile project notwithstanding 
the obvious difficulties that will be involved in its 
implementation from our member’s perspective. I would 
appreciate if you could review the matter and see if there is 
anything you can do to move this matter forward.
needle exchange Programme – Letter 5
From PCRS Contract Manager to Assistant national 
director Finance Shared Services-PCRS 
[8 March 2011]
I wish to refer to the HSE’s letter of 14 February on the 
Needle Exchange Programme.
The Pharmacy Contractors’ Committee noted your recent 
proposal at its meeting on 2 March and asked me to convey 
their comments on the proposal.
As previously discussed, there is a considerable workload for 
community pharmacists involved in the operation of the 
Needle Exchange Programme. The Committee feels that 
the HSE’s proposal does not adequately address the issues 
raised in the Union’s previous proposal and that the fee on 
offer is inadequate. However, given the importance of this 
service to the people involved and to the wider community, 
the Committee is prepared to support and advocate for 
the roll out of a Needle Exchange Programme through 
community pharmacies on the basis that:
Service Outline
n	  The Needle Exchange Programme will be based on 
a simple transaction of exchanging dirty needles for 
clean needles;
n	  The Needle Exchange Group, with officials from the 
HSE and the IPU, will continue to meet to assess 
the progress of the programme and the locations of 
pharmacies participating in the programme;
n	  The position of National Pharmacy Coordinator will be 
filled by an appropriate candidate before the roll out of 
the programme;
n	  The HSE will provide support to all community 
pharmacy contractors providing Needle Exchange;
n	  The HSE will, through ICCPE, provide face-to-face 
training on Needle Exchange to all pharmacists 
participating in the programme;
n	  A distance learning pack will be provided by ICCPE to 
assist in the training of other pharmacy staff;
n	  The HSE will provide information for people 
participating in the programme;
n	  All staff working on the premises should be aware that a 
Needle Exchange Programme is being operated and should 
be covered for Hepatitis B immunisation by the HSE;
n	  The HSE will provide a protocol on the management of 
needle stick injuries;
n	  The HSE will provide stickers to be displayed in 
participating pharmacies; 
n	  The HSE will provide clean injecting equipment locally 
and a safe disposal system for the return of used 
injecting equipment;
n	  The HSE will provide sharps bins and set up collection 
services for pharmacies providing the Needle Exchange 
Programme;
n	  The HSE will, in conjunction with the IPU in the Needle 
Exchange Group, address any areas of concern that 
arise for pharmacies participating in the programme in 
a timely manner.
Pricing Structure
n	  A needle exchange transaction will always attract a fee 
of not less than €5;
n	  The retainer of €1250 per pharmacy involved is 
guaranteed for three years. The associated costs, 
including increased security and time spent with this 
cohort of patient, are continuous. These costs to the 
pharmacy will not decrease after year one. Where a 
new pharmacy joins the programme, this retainer 
should be offered to them. 
review of the needle exchange Programme
n	  Arrangements should be reviewed by the PCC and HSE 
following one year of operation. The review should be 
completed and agreed between the parties before the 
end of the second year. The IPU would see this review 
taking cognisance of the following: 
• Adequacy of the training course material (both 
face to face and distance learning);
• The work load for pharmacies providing Needle 
Exchange;
• The number of pharmacies providing Needle 
Exchange;
• The locations of the pharmacies providing Needle 
Exchange;
68
AnnUAL RePORt 2011
• The level of remuneration (the annual retainer and 
the transaction fee) for the provision of Needle 
Exchange Programme, if it is to continue after the 
three year period; and
• Input from the patients participating in the 
programme.
The Union is available immediately to discuss the roll out of 
the Needle Exchange Programme based on the above and 
looks forward to working with the HSE in the provision of 
this significant service.
I look forward to hearing from you or your colleagues on a 
date for the next meeting of the Needle Exchange Group.
needle exchange Programme – Letter 6
From Assistant national director Finance Shared Services-
PCRS to PCRS Contract Manager 
[8 March 2011]
I am writing to you in relation to your correspondence 
to the HSE of the 8th of March in relation to the Needle 
Exchange Project. 
The HSE has reviewed the conditions outlined in your 
letter and is in agreement to meet with the documented 
conditions. It is now important that we should jointly 
proceed at haste on the basis set out and also on the 
condition that the terms of this once-off arrangement will 
not prejudice any other future arrangements or payments 
systems for other services and that we are in joint 
agreement that the pilot programme including the service 
and payment arrangements will be reviewed after one year. 
The details of the review will be arranged in due course 
between the respective parties. 
A meeting of the Needle Exchange Group should now 
take place as soon as possible to progress the roll out of 
the Needle Exchange Project. As you are aware, the HSE 
membership of this group includes: Rory Keane, Joe Doyle, 
Denis O’Driscoll, Gretta Crowley, Kate Mulvenna and 
Rebecca Loughry. In this regard, I would appreciate if you 
would advise me of the nominated IPU representatives on 
the Needle Exchange Group. My colleague, Rebecca Loughry, 
Specialist Social Inclusion, will be in touch with you to 
follow up on this. 
I wish to acknowledge the support of the IPU for the Needle 
Exchange Project and we look forward to now expediting 
the project with you. 
hARdShIP And PSyChIAtRIC
hardship and Psychiatric - Letter 1
From the Secretary General to the Minister for health 
and Children 
[19 January 2010]
At our meeting in December, the Union raised the ongoing 
delay facing pharmacists participating in the Hardship 
and Psychiatric Schemes. Unfortunately the matter is still 
unresolved. 
Many pharmacists have been supplying medicines to 
patients under both these schemes for over 6 months 
without payment. In some areas pharmacists have been 
paid the cost of the medicines but no fee or mark-up 
has been paid. Where there have been payments made 
pharmacists have not been given any paperwork and are 
unaware of what claims have or have not been paid. In 
other areas no payments at all have been made leaving 
pharmacists with unpaid claims of thousands of Euro. 
Despite numerous requests, the HSE have failed to clarify 
the payment structures for these schemes. The Union has 
been requesting a meeting with the HSE to discuss the 
situation however to date a meeting has not taken place.
The situation is unacceptable and needs to be resolved 
without delay and we would ask you to intervene and raise 
the matter urgently with the HSE.
hardship and Psychiatric - Letter 2
From the Secretary General to Assistant national director 
Finance Shared Services-PCRS 
[25 January 2010]
I wish to refer to your letter of 21 January 2010.
I wish to express the Union’s disappointment that, despite 
commitments given by the HSE to revert to us on the 
Hardship and Psychiatric Schemes within a week of our 
meeting on 5 November 2009, it has taken the HSE over 
two months to respond. It is also disappointing that the 
fundamental issues raised at that meeting in relation to:
n	  changing scheme arrangements retrospectively; 
n	  significant delays in making payments; 
n	  inadequate payment levels; 
n	  the lack of communications; and 
n	  the lack of engagement;
have still not been addressed.
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hardship arrangements 
I welcome the HSE’s intention to publish a list of medicines 
reimbursable under this arrangement; however, it is not 
clear whether this list will include codes and prices for these 
medicines. 
The administration required for the Hardship arrangement 
is excessive and the proposed payments are completely 
inadequate. These issues need to be addressed immediately. 
It is unacceptable that pharmacists are still waiting to get 
full payment and, in some cases, any payments, months 
after they have dispensed medicines to patients. The PCRS 
list of Claims Paid is inadequate and it is not possible for 
pharmacists to reconcile payments being received with the 
claims they have submitted.
DPS refund Claims 
You will appreciate that it is a matter for each individual 
pharmacist to determine prices for their private patients 
and clients. It is not clear from your letter what precisely 
is being proposed or how it can be implemented on a 
practical basis. This issue needs to be discussed further.
hSe (unified Claims Form) receipts 
It is not clear what is proposed in your letter in relation to 
the Unified Claim Form and how it differs from current 
arrangements. Again this issue requires further discussion 
and clarification.
reimbursement for Psychiatric Drugs 
The FEMPI Regulations did not cover this scheme or the 
Hardship Arrangements. It may be the desire of the HSE to 
bring payments under this scheme into line with the recent 
payment changes but this is not mandated by regulation. 
Furthermore, there was no communication from the HSE 
of their intention to change this scheme until November 
2009, four months after the introduction of the regulations, 
and this communication was confusing and was not sent to 
every pharmacist. 
As was raised at the JCG meeting in November, the 
HSE cannot implement price changes or administrative 
arrangements retrospectively. This issue is not addressed 
in your letter. Many pharmacists have not been 
submitting their claims, pending clarification from the 
Local HSE Offices, and many members have been told 
by HSE personnel that they do not know what payment 
arrangements will apply, or when payments will be made. 
This scheme applies to a very vulnerable cohort of patients 
and these issues should be resolved without any further 
delay.
The issues outlined above need to be resolved immediately 
and a meeting between the Union and the HSE is required 
urgently. The Union will make itself available on either 
Wednesday or Thursday of this week for such a meeting. 
It would be helpful if the issues set out in this letter are 
considered in advance of the meeting so that progress can 
be made on these matters. 
hardship and Psychiatric - Letter 3
From the Secretary General to national director 
Integrated Services - Performance and Financial 
Management, hSe 
[4 March 2010]
I am writing to you on behalf of our members who 
participate in the Hardship and Psychiatric Schemes (“the 
Schemes”). 
The reimbursement arrangements on these schemes were 
changed without notice to pharmacists and this has given 
rise to long delays in making payments. Following several 
meetings with HSE officials, some of these administrative 
issues are now being resolved. 
The HSE has reported to reduce payments to pharmacists 
under the Schemes in line with the Health Professionals 
(Reduction of Payments to Community Pharmacy 
Contractors) Regulations 2009. However, these Regulations 
do not apply to the Schemes. In addition, the HSE is seeking 
to apply the reduction retroactively to claims as far back as 
July 2009 and all pharmacists were only officially notified of 
these changes in January of this year. 
Firstly, as the Schemes are not affected by the Regulations, 
the HSE is not entitled to unilaterally reduce payments 
under the Schemes. Furthermore, payments to pharmacists 
under these Schemes are approved in advance by the local 
HSE office. In some instances this agreement is verbal, 
while in other cases a written form is issued by the HSE. 
In all instances however there is an agreement in place 
between the pharmacy and the HSE prior to the dispensing 
of the relevant products by the pharmacy. The pharmacy 
has reasonably relied upon the terms of this pre-approval 
in performing its part of the agreement and dispensing 
the respective product. The retroactive application of the 
reduction in payments is not only inappropriate, but the 
failure by the HSE to pay the agreed amount is a breach of 
the terms of the agreement between the pharmacy and 
HSE. This breach entitles the pharmacy to seek legal redress.
I would ask you to intervene to resolve this matter and I 
would welcome an early opportunity to meet to discuss 
these matters with you.
hardship and Psychiatric - Letter 4
From the Secretary General to Assistant national director 
Finance Shared Services-PCRS 
[22 March 2010]
I wish to refer to my letter of 4 March to Ms Laverne 
McGuinness about the ongoing problems pharmacists 
are encountering with payments relating to the Hardship 
Arrangements and the Psychiatric Scheme. To date, we have 
not had any response.
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In May of last year An Tánaiste Mary Coughlan, T.D Minister 
for Enterprise, Trade and Employment, announced that 
the Government would reduce the payment period for 
Government Departments from 30 to 15 days. This new 
arrangement, established to ease the cash flow difficulties 
of small business, came into effect from 15 June 2009. 
Many pharmacists are currently waiting on payments 
from the HSE dating back months. Many pharmacies 
have hundreds of thousands of Euro outstanding under 
the Psychiatric Scheme and Hardship Arrangements and, 
despite commitments given in January by the HSE, there are 
still significant payments outstanding to pharmacies. 
The HSE’s failure to pay in a timely manner is further adding 
to the worry and concern that pharmacists are experiencing 
with their business due to the economic downturn and 
the cuts imposed last year under the Financial Emergency 
Measures in the Public Interest regulations.
In the press release announcing the payment initiative 
in 2009, it also stated that Government Departments 
automatically include late payment interest where late 
payments are made after 30 days. 
I would like you to clarify that the HSE are paying interest to 
pharmacy payments which are not made within 30 days. 
I would also like you to clarify the amount of interest that has 
been paid out to pharmacists in each of the past three years.
dPS ReIMBURSeMent 
dPS Reimbursement Letter 1
From Secretary General to national  
director Integrated Services  
Performance and Financial Management, hSe 
[4 March 2010]
I wish to refer to previous correspondence on 11 December 
2009, regarding DPS Reimbursement letters sent to 
patients [please see enclosed letter].
I have yet to receive a response to the matters raised in 
this letter. The Union has also been informed that patients 
continue to receive inaccurate letters from the HSE. 
In order to avoid further action being taken by any 
pharmacies referred to, directly or indirectly, in the letter 
that HSE has sent, we require you to confirm immediately 
that the steps referred to in my previous letter have been 
carried out.
dPS Reimbursement Letter 2
From Secretary General to national  
director Integrated Services 
Performance and Financial Management, hSe 
[8 October 2010]
Following up on our letter of 11 December 2009, we 
understand that the HSE is still contacting some patients 
who are due a refund under the DPS, with a letter which 
informs the patient that the pharmacy has not charged 
them the correct price. As stated in our previous letter 
to you, there is no “correct” price for products sold to 
private patients below the threshold (currently at €120). 
The statement that the pharmacist is charging incorrect 
amounts is not only inaccurate but is also damaging to the 
business and reputation of the pharmacist involved. 
It has also come to our attention that the HSE continues 
to make reference to this so-called overcharging by 
pharmacists, which is inappropriately inflammatory and 
damaging to the business and reputation of the IPU and 
the pharmacists individually.
In order to avoid further damage to the business and 
reputation of any of our members we insist that you direct 
your employees to refrain from making or repeating such 
false accusations to the media.
Furthermore, in order to avoid further damage to the 
business and reputation of any of our members so 
referenced, directly or indirectly, in your letter, the IPU insists 
that you direct your local offices to:
1. Ensure that they have sent a copy of the first enclosed 
draft letter to all patients who have received a 
letter which included the language above or similar 
language;
2. Forward to this office a list of all patients to whom the 
local office has sent the original version of the letter so 
that the IPU can confirm among its members that their 
patients have received the corrected version; and
3. In the future, send the second enclosed draft letter to 
patients receiving a refund under the DPS.
In order to avoid legal action being taken by any of the 
pharmacies, including those referred to directly or indirectly 
in the letter the HSE has previously sent, we require your 
confirmation within fourteen (14) days of the date of this 
letter that the steps set out above have been or are in the 
process of being carried out.
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MeMORAndUM OF UndeRStAndInG
Memorandum of Understanding Letter 1
From the PCRS Contract Manager to Assistant Secretary 
to the department of health  
[4 March 2011]
I am writing to you in relation to the Memorandum of 
Understanding between the IMF and the Irish Government. 
There is only one action point that relates to pharmacy:
‘ensure the recent elimination of 50 per cent mark-up paid 
for medicines under the State’s Drugs Payment Scheme is 
enforced’.
For the record, the Union wishes to confirm that the HSE 
PCRS has been paying pharmacy contractors in line with the 
FEMPI Regulations since 1 July 2009.
Memorandum of Understanding Letter 2
From Secretary General to Minister for Finance  
[12 April 2011]
I wish to refer to the proposal in the Memorandum of 
Understanding between the IMF and the Irish Government 
which states:
‘ensure the recent elimination of 50 per cent mark-up paid 
for medicines under the State’s Drugs Payment Scheme is 
enforced’.
The IPU has been in correspondence with the Department 
of Health on this matter and is extremely concerned about 
the implications of this proposal.
The IPU would welcome an early opportunity to discuss this 
matter with you or your officials.
Memorandum of Understanding Letter 3
From Secretary General to Minister for health  
[12 April 2011]
I wish to refer to ongoing correspondence between 
the Union and your Department in relation to the 
Memorandum of Understanding between the IMF and the 
Irish Government.
The Union is surprised that the Department has taken 
this view of this recommendation. The Union’s position, 
supported by legal advice, is that a pharmacist’s private 
business is entirely a matter between the pharmacist and 
the patient and the Union has no role to play in this matter. 
The normal rules of competition apply and the patients will 
go to the pharmacy where they achieve the best value in 
terms of price and service.
The Financial Emergency Measures in the Public Interest Act 
2009 states that:
‘the Minister for Health and Children may, with the consent 
of the Minister for Finance, by regulation, reduce, whether 
by formula or otherwise, amount or the rate of payment 
to be made to health professionals, or classes of health 
professionals, in respect of any services that they render to 
or on behalf of a health body’ [emphasis added]
The Health Professionals (Reduction of Payments to 
Community Pharmacy Contractors) Regulations 2009 
also refers to payments that are made to a community 
pharmacy contractor in respect of services rendered by 
the pharmacist on behalf of the State. This legislation only 
applies to services provided on behalf of the State under 
the various State schemes. 
As confirmed in our previous letter, the PCRS now 
reimburses pharmacists a 20% mark up under certain 
State schemes however the relevant regulations are not 
applicable to private patients. Your letter suggests that an 
attempt may be made to force all pharmacists to apply 
the same mark-up as set out in the regulations to private 
patients. This is akin to forcing all GPs and Solicitors to 
charge the same for a consultation with a private customer 
as they are receiving for the delivery of services on behalf 
of the State. This makes no sense whatsoever. It flies in the 
face of Competition Law, would erode the capacity of small 
businesses to determine their own business strategies, and 
indeed their viability, and is not in the interests of patients, 
consumers or pharmacy employees.
There have been very significant reductions in the price of 
medicines over recent years and as far as the IPU is aware, 
all of these reductions have been passed on to patients 
and indeed acknowledged by many of them. However, 
pharmacists are private businesses that operate in one of 
the most competitive pharmacy markets in the EU and it 
is for each individual pharmacist to decide for themselves 
what price they charge to private patients, including sub 
threshold patients. 
As this appears to be a consumer/ competition matter, 
the Union also intends pursuing this matter further with 
the Minister for Enterprise, Jobs and Innovation and the 
Minister of State for Small Business.
The IPU would welcome an opportunity to meet with you 
to discuss this matter further.
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Memorandum of Understanding Letter 4
From Secretary General to Minister for enterprise,  
Jobs and Innovation  
[12 April 2011]
I wish to refer to the proposal in the Memorandum of 
Understanding between the IMF and the Irish Government 
which states:
‘Ensure the recent elimination of 50 per cent mark-up paid 
for medicines under the State’s Drugs Payment Scheme is 
enforced’.
The IPU has been in correspondence with the Department 
of Health on this matter and is extremely concerned 
about the implications of this proposal and a copy of this 
correspondence is attached for your information.
As this is largely a consumer/ competition /employment 
issue, the IPU would welcome an early opportunity to 
discuss this matter with you.
It ISSUeS
From the Secretary General to Assistant national 
director, Finance Shared Services-PCRS 
[15 november 2010]
We had some communication at the beginning of October 
on a number of IT issues. I gave you feedback from our IT 
Steering Group on each of your proposals but have not had 
any response from you to date. Hereunder are the issues we 
discussed.
1.  Prescription Levy 
The IT Steering Group reviewed and discussed your 
proposal on Prescription Charge per Item in which 
the itemised claims listing design was detailed to 
show how the prescription levy will be displayed on 
pharmacy itemised listings. The ITSG agreed that the 
proposed design was satisfactory but that it would 
be beneficial to members to receive the report in 
.xml format. This information was emailed to PCRS 
on 8 October but, to date, no response has been 
received. The IPU sent the proposal to system vendors 
on 8 October 2010. It would be useful if you could 
acknowledge if you can facilitate sending the report to 
pharmacies in .xml format. 
It has also been reported to us that PCRS contacted a 
pharmacist who had indicated on their claims form 
that a medicine was not dispensed because the patient 
did not have the prescription levy. It is alleged that the 
PCRS suggested that medicines should be dispensed, 
regardless of whether the patient paid the levy or not. 
The Pharmaceutical Society of Ireland has recently 
reminded pharmacists that:
“From 01 October 2010, it is a legal requirement for a 
community pharmacy contractor to collect the levy 
of €0.50 per item dispensed under the Medical Card 
Scheme. a failure to collect the prescription levy is a 
breach of this legislation and it should be noted that 
all pharmacists are obliged to comply with all relevant 
laws, regulations, rules, professional standards (Principle 
3 of the Code of Conduct for Pharmacists) and also to 
practise within relevant legislative and professional 
regulatory guidance (Principle 4 of the Code of Conduct 
for Pharmacists). any pharmacist who fails to collect this 
levy in accordance with this legislation may be subject to 
disciplinary process under Part 6 of the Pharmacy  
act 2007.”
Perhaps you could clarify the position of PCRS 
in this matter. 
2.  1st Generation Claiming Wind down 
At the IT Steering Group meeting of 5 October, the 
Group reviewed a letter sent from PCRS on 1 October, 
proposing that the 1st Generation Electronic Claiming 
Interface be wound down for claims submitted for 
December 2010. We replied to you on 9 October 
pointing out that we felt that a significant cost would 
be incurred by pharmacies moving from 1st to 2nd 
Generation software and that PCRS would benefit 
financially from this move year-on-year. Therefore, 
PCRS should incentivise pharmacies to make this 
move; otherwise the pharmacies may consider that a 
manual option would be better for them. In addition, 
we felt that asking any Retail Pharmacy Business to 
make a significant change to their operation over the 
busy Christmas period was impractical and proposed 
that the move be deferred. We would appreciate if you 
could confirm that you are agreeable to what we have 
proposed and we can discuss the matter further at the 
next meeting of the Joint Consultative Group.
3.  Pharmacy Security Certificates 
PCRS wrote to the Union on 8 October 2010, proposing 
that Pharmacy Security Certificates would be sent 
directly to pharmacists rather than system vendors. 
The Union replied on 9 October that, whilst in principle 
this would appear to be appropriate, it could create 
a significant workload for pharmacists and system 
vendors, especially if the timescales involved were tight. 
You replied on 11 October that you plan to commence 
renewing certificates directly before the end of the year 
and going forward as they fall due. Can you please let 
me have the up to date position on this matter and 
confirm if or when this has been communicated to all 
pharmacists and system vendors?
There was one other issue which you asked us to consider. 
On 30 September, you sent us a proposal on Approaches to 
Electronic Prescribing/Invoicing. The proposal was reviewed 
by the IT Steering Group and we proposed that a small 
working group should be set up to work with PCRS to 
further develop this proposal. I suggest that we discuss this 
further at the next Joint Consultative Group meeting. 
I also emailed you about a couple of individual cases on 
12 October, 1 November and 11 November to which I have 
received no response to date and would welcome a reply at 
this stage.
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GeneRIC SUBStItUtIOn And ReFeRenCe PRICInG
From the Secretary General to Assistant Secretary dohC 
[22 July 2010]
The Pharmacy Contractors’ Committee (PCC) reviewed 
the recent report by the Reference Pricing Group on 
Reference Pricing and Generic Substitution and reaffirmed 
its commitment to work with the Department on the 
implementation of the initiative.
As acknowledged in the report, the introduction of a 
reference pricing system and generic substitution will have 
a significant impact on pharmacy. It would be imperative 
that further discussion on the recommendations of the 
report and on the implementation of the system take 
place between the Union and the Department. These 
discussions should commence in advance of drafting of the 
necessary legislation to ensure that there is a broad shared 
understanding of the issues involved and how they might 
be addressed. Perhaps you could let us know when the 
Department will be in a position to engage with the Union 
on the matter.
The PCC welcomed the establishment of the Committee 
on Interchangeable Medicines. It is important that 
stakeholders participate in the work of the Group and in 
this context the PCC requests the appointment of two 
nominees from the Union to the Group. 
neW SeRVICeS
From Secretary General to national director, quality and 
Clinical Care 
[4 May 2010]
I wish to refer to our discussion at the meeting between the 
Minister and the IPU last week. As agreed at that meeting 
the IPU would welcome the opportunity to meet with you 
to discuss pharmacist involvement in new services. 
I would like to suggest the week beginning May 24 for such 
a meeting but if this week is not suitable perhaps could you 
indicate some alternative dates. 
You might arrange to contact Roisin Molloy to arrange a 
mutually acceptable date. 
MethAdOne tReAtMent
From PCRS Contract Manager to Methadone treatment 
Review Group, department of Public health and  
Primary Care 
[30 december 2010]
Pharmacies are not obliged to participate in the methadone 
treatment scheme under their contract with the HSE; 
they do so on a voluntary basis. The scheme has been 
very successful to date enabling those addicted to heroin 
to regain control of their lives, allowing them to re-enter 
employment or education, provide for their families and be 
positive contributors to society in general. Needless to say, 
methadone is only part of the solution; an ideal situation 
would be where patients would be free of addiction 
completely. 
Delivering methadone treatment through community 
pharmacies is not only beneficial for the patient but it is 
also less conspicuous and more convenient for them to 
receive treatment from the local pharmacist than to travel 
to one of the methadone clinics. It has also been proven to 
be more cost effective for the State. 
The IPU welcomed the opportunity to be involved in the 
recent review of the Methadone Treatment Protocol and 
broadly welcomes the recommendations in the recent 
published Opioid Treatment Protocol.
The Union believes that where issues of concern for 
community pharmacists are addressed then there is 
considerable scope to expand the numbers of pharmacies 
participating in methadone treatment scheme with a 
network of over 1,500 pharmacies across the country. 
Pharmacists participating in the Methadone Treatment 
Scheme countrywide on a daily basis deal with the 
implementation of the Scheme, therefore it is imperative 
that a representative from community pharmacy be 
nominated to this group. 
The Union wishes to nominate Mr Edward MacManus to 
the Group as the community pharmacy representative on 
this group.
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Appendix X
A SeLeCtIOn OF PReSS ReLeASeS ISSUed tO the nAtIOnAL MedIA dURInG the yeAR On VARIOUS MAtteRS
1.  PReSCRIPtIOn LeVy
  23 April 2010
  Pharmacists oppose new 50 cent prescription levy
On the eve of its Annual General Meeting, the Irish 
Pharmacy Union (IPU) has said that it is strongly 
opposed to the Government’s plan to introduce a 50 
cent prescription levy for medicines. The issue will be 
one of the matters debated at the AGM where it is 
anticipated that it will be strongly criticised.
Speaking today, Liz Hoctor, a pharmacist from 
Westmeath and outgoing President of the IPU, said 
the levy was little more than a “tax on sickness” which 
would cause additional hardship for the poorest in 
the community and would be extremely difficult to 
implement. She said; “the amount being proposed 
may not appear much, but any disincentive for people 
particularly those on low incomes or seriously ill to 
take medicines should be avoided.” She warned also 
that the proposal may end up costing the Exchequer 
more as people would risk longer term medical 
complications if they did not comply strictly with 
their medicine regimes.
Ms Hoctor said “this prescription levy will mean 
that some of the poorest patients, who have serious 
illnesses, will have to go without their medicines.” 
Galway Pharmacist and Vice President of the IPU, 
Darragh O’Loughlin said “While there is a need 
to tackle the problem of medicines being wasted, 
introducing a levy on prescriptions is not the answer 
and will damage patients’ health and put increased 
pressure on hospitals.”
He argued that the international trend is to phase 
out prescription charges and said that the charges 
had been recently been abolished in Northern Ireland 
and Wales. 
The IPU has approached the Minister for Health and 
Children on a number of occasions with alternative 
measures to reduce the overuse, inappropriate use 
and wastage of medicines. These proposals, which 
are already in place in other jurisdictions, include 
the introduction of Medicines Use Reviews to make 
sure patients are getting the full benefit from their 
medicines and to ensure patients are taking only 
those medicines which are clearly necessary for  
their treatment. 
The Minister has committed to further discussions 
with the Union around the implementation of 
prescription charges. Mr O’Loughlin said there were 
still serious issues to be resolved: “What about 
the patients who cannot afford to pay this levy on 
medicines? What about patients living in institutions, 
including nursing homes and prisons? What about 
patients with alcohol or drug addiction problems? 
Who is going to collect these charges and what is  
the cost of collecting them and more importantly 
what will be the costs, if some patients stop taking 
their medicines?” 
Pharmacists call for caution in introducing reference 
pricing for medicines as it could limit patients’ access 
to medicines and further undermine the viability  
of pharmacies. 
  24 April 2010
 Pharmacists call for equal treatment under new 
Competition Law
The Irish Pharmacy Union (IPU), the representatative 
body for 1,800 pharmacists, has today called on 
the Government to ensure equal treatment for all 
healthcare professionals under competition law. 
The Government has committed to amending 
competition law to facilitate its negotiations with 
the Irish Medical Organisation (IMO), the body 
representing doctors. The IPU believes that any 
exemption in the legislation that is applied to doctors 
should also be applied to the representative bodies 
for other healthcare professionals. The call was made 
at the IPU’s Annual General Meeting, which took 
place today [Saturday] in Mullingar. 
Rory O’Donnell, Donegal Pharmacist and Vice-
Chairperson of the Union’s Community Pharmacy 
Committee put forward the motion: “that this agM 
calls on both the Minister for enterprise, trade and 
innovation and the Minister for health and Children to 
ensure that any exemption that may be granted in the 
new Competition act to the irish Medical Organisation 
should also apply to all representative bodies for 
healthcare professionals.”
The IPU has strong legal advice that there are no obstacles 
in competition law to Government neogitating fees with 
the IPU. However, any concerns that the Government may 
have in relation to this matter should be addressed in 
the new legislation and any changes introduced should 
be applied to all representative bodies, including the Irish 
Pharmacy Union.
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The European Commission gave its opinion on this issue 
in July 2008. Mr. O’Donnell pointed out that this opinion 
vindicates the rights of pharmacists to be represented 
by their Union on all issues. The Union always believed 
that negotiating fees with the HSE was not a breach of 
competition law as the Minister for Health and Children 
always made the final decision in terms of setting 
pharmacists’ fees. The Commission stated “…the fixation 
of fees for pharmacy services would only be problematic 
from the point of view of eC competition law if it was not 
the irish State which had the final word in fixing the price...”
 24 April 2010
 AGM hears concerns about medicine shortages
The AGM of the Irish Pharmacy Union (IPU) has heard 
concerns that medicine shortages could follow the 
introduction of reference pricing for medicines in 
Ireland. The IPU said that the experience in the UK, 
had shown exactly this problem arising. The Minister 
for Health and Children has indicated her intention  
to introduce a system of reference pricing for 
medicines in 2011.
The IPU also warned that reference pricing could 
further undermine the viability of community 
pharmacies. The IPU called on the Minister to adopt a 
cautious approach in relation to reference pricing. 
Speaking today, Noel Stenson, a pharmacist 
from Mayo and a member of the IPU’s Pharmacy 
Contractors’ Committee said “in some countries 
reference pricing has led to a situation where patients 
cannot obtain certain medicines. For instance, in the 
uK, medicines such as Femara, a cancer treatment, 
and Cipralex, an antidepressant medicine, have been 
unavailable to patients in recent months. it has reached 
such critical proportions that the Department of 
health in the uK called a major summit meeting of all 
stakeholders to try and resolve the supply crisis for certain 
fundamental drugs. this is not a situation we want in 
ireland – this would be a bad situation for patients.”
Mr Stenson also pointed out that the impact of 
introducing the various models of reference pricing 
on community pharmacies would have to be 
assessed. He said: “Pharmacists have already suffered 
a major blow due to cuts imposed by the Minister for 
health and Children last year. 1,600 jobs have already 
been lost and patient services have been curtailed. 
this must be taken into account as part of any plan to 
introduce reference pricing.”
The Minister has indicated that in addition 
to reference pricing, she intends to introduce 
pharmacist-led generic substitution. Mr Stenson 
welcomed the Minister’s decision to introduce 
pharmacist led-generic substitution, which he said  
“is essential to reduce the cost of medicines.”
 24 April 2010
Pharmacists’ AGM hears of medical card chaos
At its AGM in Mullingar today, the IPU has warned 
that thousands of patients are being prevented from 
getting medical cards because of administrative 
problems at the HSE.
The AGM has called on the Minister for Health 
and Children and the HSE to urgently address the 
issues that are delaying the processing medical 
card applications to ensure that those who are 
entitled to medical cards get them as quickly and 
efficiently as possible. It is vitally important that the 
HSE streamlines its management structure so that 
patients and healthcare professionals know who in 
the HSE is responsible for these important decisions. 
Speaking today, Joe Carroll a pharmacist from Galway, 
said elderly patients are amongst those experiencing 
major problems in having their medical cards renewed. 
“One of my patients is in his early eighties and is hard of 
hearing. his medical card was cancelled by the hSe last 
year, even though he is entitled to a medical card. he 
reapplied, but he was waiting for months for the hSe to 
send him a new card.”
“What makes matters worse was that when he or 
his family called the central hSe office to find out 
what had happened to his application, they were 
left waiting on hold for ages. Since the hSe began 
centralising medical card applications, it has become 
extremely difficult to speak to a hSe official, if you 
have a query or problem,” he said.
The Joint Committee on Health and Children recently 
recommended that the HSE should ensure that 
all medical card applications are dealt with in no 
more than 15 days. The IPU strongly supports this 
recommendation. 
Pharmacists also criticised the HSE for not paying 
pharmacists for medicines, which they dispensed to 
patients in good faith. John Barry a pharmacist from 
Templeogue in Dublin said: “the hSe is now suddenly 
refusing to pay for medicines which i have dispensed, 
on foot of medical card prescriptions written and 
signed by a gP, claiming they are somehow invalid. 
Most of the patients involved are over 70 and some 
have special needs. For the last 20 years, i have 
dispensed prescriptions in good faith to patients who 
need their medicines. it is unacceptable for the hSe to 
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suddenly refuse to pay for these. this has gone on for 
three months and i’m facing the prospect of having to 
turn medical card patients away if they can’t pay for 
their medicines. i’m fully convinced that the patients 
involved are eligible for free medicines having dealt 
with most of them over many years. it’s incredulous 
that the organisation charged with caring for such 
patients could leave them in such a position. the 
hSe must begin to put the health and well being of 
patients first.”
24 April 2010
Pharmacists AGM hears calls on Government to 
move quickly against head Shops
The AGM of the IPU has called for the Government to 
immediately force the closure of the growing number 
of so-called “head Shops” opening across the country, 
as they are a serious risk to public health.
Michelle Concannon, a pharmacist from Athlone, 
said: “it is disturbing to see kids coming out of head 
shops with products, which could be lethal. there is no 
information on what the effects of these substances 
could be. in the uK, teenagers have died after taking 
mephadrone, a product which was bought in head 
shops. this product is now banned in the uK. however, 
there is no regulation on the sale of these products 
in ireland and they are being handed out a casual, 
indiscriminate manner to young, naïve people.” 
“as a pharmacist, i know the side-effects of the 
medicines i dispense and advice my patients on them. 
these medicines have been carefully tested and have 
been licensed by the irish Medicines Board for the irish 
market. People must understand that they are taking 
huge risks by using products from head shops.”
Ms Concannon welcomed the growing realisation 
amongst Government and policy makers that was 
is a real problem, but criticised the slowness to act 
“there’s talk of ban lists and increased garda powers 
by the Summer but we need to act now. there’s no 
time to waste.”
29 April 2010
Statement from the IPU on the Supreme Court 
Ruling in favour of the department of health and 
Children on the Advance Payments case
The IPU, the representative body for 1,800 
pharmacists, said that it was disappointed with the 
outcome of today’s Supreme Court ruling on the 
Advance Payments case, which ruled that Advance 
Payments do not form part of the pharmacy contract. 
However, the Union welcomes confirmation from 
the Supreme Court that changes to the pharmacy 
contract should be brought about through 
agreement and, if this is not possible, through 
mediation. 
The Union said that it will review the ruling and its 
impact, if any, on the terms of the contract between 
pharmacists and the Health Service Executive in 
consultation with its legal advisors. The IPU will be 
seeking a meeting with the Department of Health 
and Children to discuss the implications of the ruling. 
Today’s Ruling states: 
“there is no question of any State party having 
a general inherent or residual power to alter or 
terminate binding contractual terms unless some 
unilateral power is agreed between the parties to such 
an arrangement...”
“the Minister is…in a position…to vary the terms of the 
pharmacy contracts, this does not place the Minister in 
a position in any way superior to the iPu in terms of 
such a change”
“i do not find therefore that this clause – which clearly 
vests power in the Minister to negotiate… with the 
iPu in respect of any term which may be agreed, and 
which may, after agreement, become pursuant to 
Clause 19(3) of the Pharmacy Contract, a future term of 
that amended pharmacy contract - adds anything to 
the respondent’s case, or that by virtue of clause 19(5) 
“the Minister retained full control over any agreement 
to vary the terms of the individual contract,” since 
equally, the IPU retained the same full control, on 
behalf of its members, over any agreement to vary 
the terms of the same. 
Background
In July 2006, the IPU, along with four co-plaintiffs, 
lodged a claim in the High Court against the 
Department of Health and Children over its unilateral 
decision in 2002 to discontinue the payment of 
Advance Payments to new pharmacy contractors 
and to freeze payments to existing contractors. In 
an affidavit submitted by the IPU, it was estimated 
that pharmacists had suffered losses of €32 million 
in Advance Payments as a result of the unilateral 
decision to discontinue these payments. 
The High Court ruled in July 2007 that the Advance 
Payments Scheme formed part of the contractual 
relations between individual pharmacists and 
the HSE and the decision to discontinue Advance 
Payments amounted to a unilateral variation in the 
contractual terms, which was not permissible. 
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This ruling was appealed to the Supreme Court by 
the Department of Health and Children.
The Advance Payment was introduced in 1971 as part of an 
agreement of the participation of community pharmacists 
in the reorganised General Medical Services (GMS) 
Scheme. The Advance Payment enables pharmacists to 
stock medicines to meet the requirements of medical 
card patients. It also compensates pharmacists for the 
delay in payment by the State for medicines and services 
provided by pharmacists to medical card patients. Advance 
Payments were paid to community pharmacy contractors 
from 1971 until December 2002, when the Minister 
unilaterally decided to alter their payment arrangements.
2. PReSCRIPtIOn LeVy
1 October 2010
n	  50c Prescription Levy introduced today
n	  Pharmacists criticise HSE on lack of information 
on Levy
n	  Certain Patient Groups should be exempt
n	  Patients should continue to take their Medicines
Darragh O’Loughlin, President of the IPU has 
criticised the HSE for its failure to communicate to 
the public about the introduction of the new 50 cent 
levy on prescription medicines which comes into 
force from today. The IPU is the representative body 
for pharmacists in Ireland. 
Under new legislation, a medical card patient must pay 
a 50 cent levy for each item on a prescription dispensed 
under the medical card scheme. This is subject to a cap 
of €10 per month per individual or family. 
“this levy has faded from the public consciousness 
since it was first announced in last year’s Budget. 
the hSe has not run an adequate public information 
campaign to ensure that medical card patients would 
be alerted to the imposition of this charge, something 
which we believe should have happened long before 
now.”
“We agree with the Minister for health and Children 
that the wastage of medicines is a problem; however, 
we don’t believe that imposing a levy on prescription 
medicines for medical card holders is the best way to 
tackle it. Prescription charges have been abolished in 
many other jurisdictions, including northern ireland 
and Wales.”
“this levy will cause hardship to many patients, 
particularly the homeless and those living in sheltered 
accommodation, and may even prevent certain 
patients from taking their medicines entirely. We 
would call on the Minister for health and Children to 
exempt certain patient groups from paying the levy, 
including homeless patients, patients in sheltered 
accommodation and patients in nursing homes.”
In terms of the implementation of the levy he said: 
“Pharmacists are opposed to the levy; however, we are 
legally obliged to collect it on behalf of the hSe. We 
would encourage patients to continue taking their 
medicines as prescribed. if people have any questions 
on their medication, they should drop in to their local 
pharmacist for advice.”
16 March 2011
Pharmacists welcome commitment to abolish 
Prescription Levy 
The Irish Pharmacy Union (IPU), the representative 
body for pharmacists, welcomes today’s 
announcement by the Minister for Health, Dr James 
Reilly TD that he intends abolishing the prescription 
levy later this year. Pharmacists opposed the 
introduction of this levy as it hit the most vulnerable 
patients in the community. Pharmacy is increasingly a 
lifeline in hard times for accessing health advice and 
treatment. 
Patients’ reliance on community pharmacy comes 
just as the financial basis of pharmacies is under 
increasing stress. The IPU’s submission of January 
2011 to the Department of Health “time for a new 
approach” highlights how pharmacists suffered 
large and disproportionate cuts in payments since 
July 2009, when the former Minister for Health 
and Children introduced cuts under the Financial 
Emergency Measures in the Public Interest Act 2009. 
The same document outlined how pharmacies are 
well placed to do much more in the cost effective 
delivery of primary health care. The IPU urged the 
Minister to engage with pharmacists in reviewing all 
contractual arrangements with a view to identifying 
how savings could be made without undermining 
pharmacy services in the community, especially for 
the most vulnerable patients whom the Minister 
rightly referred to today.
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3. eMeRGenCy COntRACePtIOn
30 August 2010
Pharmacists call for Morning After Pill to be made 
available without Prescription
In response to a call this morning from Choice 
Ireland, the Irish Pharmacy Union has reiterated 
its call for pharmacists to be enabled to provide 
Emergency Hormonal Contraception, also known as 
the Morning After Pill, to patients without a doctor’s 
prescription. The Union said that pharmacists have 
the skills and competencies to dispense hormonal 
contraceptives and provide appropriate advice and 
counselling to such patients. 
 Meath pharmacist Kathy Maher said: “it is important 
that patients get timely access to emergency 
hormonal Contraception and many often find it 
difficult to get a prescription at the weekend and 
come into pharmacies urgently looking for emergency 
hormonal Contraception. Pharmacists should be able 
to provide such a service and this could be done with 
appropriate advice, counselling and within agreed 
protocols. emergency hormonal Contraception should 
never be the only form of contraception used and 
pharmacists could also refer patients back to their 
gP, where appropriate, for a consultation on their 
contraceptive choices once the morning after pill has 
been dispensed.” 
Pharmacists already provide advice to patients on 
sexual health and on sexually transmitted diseases. 
Campaigns have been organised throughout Irish 
pharmacies to raise awareness about contraception 
options and the dangers of sexually transmitted 
infections.
 A study published in the British Medical Journal after 
patients in the UK were enabled to access Emergency 
Hormonal Contraception directly from pharmacists 
found that it did not appear to have led to an 
increase in its use or to a decrease in the use of other 
forms of contraception. 
The Irish Pharmacy Union is the representative body 
for 1,800 community pharmacists across the country.
16 February 2011
Pharmacists welcome IMB decision to make 
emergency hormonal Contraception available from 
the Pharmacist without Prescription
The Irish Pharmacy Union (IPU) today strongly 
welcomed the decision by the Irish Medicines Board 
(IMB) to allow Norlevo, one brand of Emergency 
Hormonal Contraception (EHC) to be made available 
from the pharmacist without a prescription. The IPU, on 
behalf of community pharmacists, has repeatedly called 
for this step. This is a landmark decision for women and 
an important one for Irish pharmacy as a profession. 
Kathy Maher, Meath-based pharmacist and member 
of the IPU’s Executive Committee said: “Women in 
ireland will now have prompt access to emergency 
hormonal Contraception. Community pharmacists 
are healthcare professionals with the skills and 
competence to dispense this medicine to patients, 
where appropriate and to provide relevant advice. 
Patient safety and personal sensitivity are paramount. 
as a profession we are committed and capable of 
delivering appropriate care for our patients.”
Welcoming the announcement, IPU President, 
Darragh O’Loughlin, said: “there are many medicines 
available from the pharmacist in other eu countries 
for which patients in ireland currently require a 
prescription. these medicines have a good safety record 
and should be made available from pharmacists who 
are qualified health professionals.”
The medicines which pharmacists would like to see 
deregulated are: 
n	 chloramphenicol for bacterial conjunctivitis 
n	 oral fluconazole for thrush
n	 sumatriptan for migraine
n	 terbinafine and griseofulvin for fungal infections 
of the skin 
n	 aspirin 75mg for prevention of heart disease and 
stroke
n	 statins for prevention of heart disease
n	 trimethoprim for urinary tract infections
The IPU is a key stakeholder on the Switch On to Self 
Care Working Group, along with representatives from 
the Irish College of General practitioners (ICGP), the 
pharmaceutical industry and Schools of Pharmacy, 
who published a paper last year on “Self Care First”, 
advocating that the range of medicines made 
available to patients should be expanded through 
switching or deregulation. Mr O’Loughlin said:  
“i hope that this decision by the iMB on norlevo will 
be a precedent that will allow irish citizens the same 
access to medicines as their european counterparts.”
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4. OtheR MAtteRS
1 November 2010
Patients encouraged to ask about speaking to the 
pharmacist in private
Pharmacists are encouraging patients to seek a 
private consultation if they wish to discuss an issue 
with the pharmacist in private. From today, all 
pharmacies are obliged to have a private consultation 
area available to patients. 
Rory O’Donnell, Donegal Pharmacist and Vice 
President of the IPU said “this is a great facility and 
i would encourage patients to use it, especially if they 
feel uncomfortable about asking for advice across 
the counter of a pharmacy. Some patients may feel 
embarrassed to ask at the counter about certain 
health issues – such as thrush, contraception, sexually 
transmitted infections or headlice in children etc. 
Pharmacists are healthcare professionals and advise 
on these issues every day.”
He continued “Pharmacists are now getting involved 
in providing new services such as blood pressure and 
cholesterol testing and testing for risk of diabetes. 
the private consultation area is the ideal location to 
provide such services.”
However, O’Donnell pointed out that the costs involved 
in installing a consultation area had presented a 
challenge for many pharmacists. “there is an ever 
increasing burden of regulation on pharmacists. however, 
the private consultation area will enhance the experience 
of many patients in the pharmacy.”
2 December 2010
Community Pharmacists warn on Mixing Alcohol 
and Medicines in run up to Christmas
Community Pharmacists have today warned about 
the dangers of consuming alcohol while taking 
medicines or herbal remedies. Even moderate 
amounts of alcohol when mixed with certain 
medicines can lead to significant drowsiness and can 
impair judgment and the ability to drive. The warning 
comes at a time when many people are suffering 
from coughs, colds and flu and the Christmas party 
season will be shortly underway. Unfortunately, many 
people are unaware of the risks of mixing medicines 
and alcohol. Some medicines, including many cough, 
cold, flu and allergy treatments, commonly used 
pain relievers and even certain herbal remedies can 
interact with alcohol. People should always ask their 
pharmacist about the effects of taking alcohol with 
their medicine. 
According to Darragh O’Loughlin, Galway Pharmacist and 
President of the Irish Pharmacy Union, “everyone has seen 
the warning about not consuming alcohol when taking 
certain medicines; it’s important to take that warning 
seriously. Mixing alcohol with certain medications can be 
harmful and occasionally even dangerous. 
“Some medicines can increase the effects of alcohol 
on the body while, at the same time, alcohol can 
actually worsen the side-effects of certain medicines 
– leading to increased drowsiness, impaired judgment 
or loss of co-ordination and a risk of nausea, vomiting, 
headaches or fainting. People can put their personal 
safety and the safety of others at risk, often without 
even realising it.”
“in addition to these dangers, alcohol can occasionally 
make medicines less effective or even useless, or it may 
potentially make some medicines harmful or toxic 
to the body. the message we want to give today is: 
before taking alcohol with any medicine, always ask 
your pharmacist whether it is safe to do so. Be safe 
and be certain when you are taking medication”, Mr 
O’Loughlin said.
The warning from pharmacists applies to both 
prescription and non-prescription medicines and also 
to herbal remedies. 
14 December 2010
Pharmacists welcome plans to enable them 
dispense cheaper generic medicines
The Joint Committee on Health and Children is today 
considering plans to introduce generic substitution 
and reference pricing. 
Darragh O’Loughlin, President of the Irish Pharmacy 
Union (IPU), said: “generic substitution by pharmacists 
is standard practice in many other countries and will 
mean lower medicine prices for patients and considerable 
savings for the State. generic substitution should be 
introduced without delay.” 
However, in relation to the introduction of reference 
pricing, the IPU is recommending a cautious 
approach. O’Loughlin said: “reference pricing is a 
highly complicated mechanism and is not a quick 
fix. Careful consideration and engagement with key 
stakeholders is required to ensure that there is no 
disruption to supply. the impact that reference pricing 
will have on patients and pharmacists very much 
depends on the model of reference pricing that is 
introduced. in some countries, reference pricing has led 
to a shortage of certain medicines.”
The IPU is the representative body of pharmacists  
in Ireland. 
Pharmacists also warned that some groups are at 
greater risk, particularly women and older people, 
and should exercise caution to avoid putting their 
health or safety at risk.
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20 December 2010
Pharmacists welcome recommendation to expand 
methadone treatment services outside of dublin
The IPU, the representative body for pharmacists in 
Ireland, has welcomed the “introduction of the Opioid 
treatment Protocol”, a report published today by the 
HSE. President of the IPU, Darragh O’Loughlin, said 
“no part of the country has been spared the scourge 
of heroin addiction. the scale of the challenge is 
underlined by the fact that it is estimated there are 
over 20,000 opiate users in ireland, only 8,551 of whom 
are receiving treatment. We welcome in particular the 
recommendation to expand methadone treatment 
services into areas outside Dublin. there is an urgent 
need to reach out and support people who wish to 
overcome addiction in more rural areas. to ensure 
this can happen, a national pharmacy co-ordinator 
should be appointed to support pharmacists who 
provide methadone treatment services in their local 
communities.
 “Pharmacists have an important role to play but 
we need to be more integrated with other parts of 
addiction treatment services. Outside of Dublin and 
other cities we are too often left to deal with the issues 
of methadone treatment on our own, without other 
appropriate supports in place. Pharmacists are at the 
coalface in treating those who have an addiction to 
heroin, helping them to regain control of their lives. 
the Methadone treatment Protocol has been very 
successful to date in enabling the patients involved 
to re-enter employment or education and to provide 
for their families. needless to say, methadone is only 
part of the solution; an ideal situation would be where 
patients would be free of addiction completely. For this 
to happen, patients need other support services, such 
as addiction counselling.”
10 January 2011
the IPU strongly supports significant expansion of 
the role of pharmacists
The Irish Pharmacy Union (IPU) today re-stated its 
strong support for an expanded role for pharmacists 
in delivering primary healthcare to Irish patients. In 
response to the announcement by Boots that from 
12 January its pharmacists will provide Emergency 
Hormonal Contraception to women, where 
appropriate, under a patient group direction (PGD) 
following a consultation, the IPU, as a representative 
organisation, stated that it has been to the fore in 
advocating an enhanced role for pharmacists. The IPU 
is working hard to ensure that pharmacists generally 
are in a position to provide a wider range of services 
to patients including those announced today.
Kathy Maher, Meath pharmacist and member of 
the IPU’s Executive Committee, said “Pharmacists 
already provide advice to patients on sexual health 
and on sexually transmitted infections. Campaigns 
have been organised throughout irish pharmacies to 
raise awareness about contraception options and the 
dangers of sexually transmitted infections.”
The Irish Pharmacy Union is the representative body for 
over 1,600 community pharmacists across the country.
6 April 2011
Pharmacists respond to Centre for Ageing Research 
& develop Ireland Research on long-term patients 
taking inappropriate medicines
The findings of this report are concerning. If patients 
are taking inappropriate medication their health 
may be at risk. The Irish Pharmacy Union calls on 
the Minister for Health to implement proposals to 
introduce pharmacist led Medicine Use Reviews 
for patients who are using multiple medications. 
The introduction of this initiative which has been 
advocated by the IPU in recent years will highlight 
problems in a patient’s medication regime and, lead 
to safer and more cost effective medicine use, better 
outcomes for patients and fewer hospital admissions.
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Appendix XI
A SeLeCtIOn OF LetteRS PUBLIShed In neWSPAPeRS
IRISh MedICAL tIMeS 3 deCeMBeR 2010
A margin of error
The recent editorial in IMT, entitled ‘tough medicine 
for tougher times’ (November 19, see www.imt.ie/
opinion/2010/11/toughmedicine-for-tougher-times.html), 
refers to a study, which claims that pharmacy margins 
in Ireland are around 43%. This figure bears no reality to 
pharmacy margins in Ireland. 
Data in the 2008 report from the HSE’s Primary Care 
Reimbursement Service is very clear. In 2008, of the total 
expenditure on medicines by the HSE, 24% comprised fees 
and mark-ups paid to pharmacies, which in effect represents 
the gross margin for pharmacies for supplying medicines 
and ensuring that patients’ needs are looked after. 
Secondly, a 2007 review of the sector by 
PricewaterhouseCoopers (PWC) found that the net profit 
margin of an average pharmacy in Ireland was 6.6%. 
However, the margin today is substantially lower as 
payments to pharmacists have since been cut by 30% by 
the Minster for Health from July of last year. 
The editorial also refers to proposed measures to bring 
about the greater use of generic medicines. Offering 
patients the choice of cheaper generic medicines is a 
change that pharmacists have advocated for many years. 
We welcome the commitment of the Minister for Health 
to legislate for generic substitution next year. 
A number of figures have been reported in the media 
recently as to the level of potential savings that could be 
made from generic medicines, including one of EUR300 
million. However, no analysis has been published on how 
this figure has been calculated. The Irish Pharmacy Union 
believes that considerable savings can be generated from 
generics, but not necessarily the amount that is being 
reported. 
The National Centre for Pharmacoeconomics carried out 
research in July 2009, which found that there was the 
potential at that time to generate savings of EUR77.7 
million for the State from dispensing generic medicines, 
where a generic medicine is available, on the medical card 
scheme and the drugs payment scheme. 
However, this does not take account of the fact that 
since then the price of 300 commonly used off-patent 
proprietary medicines was reduced by 40% and their 
generic equivalents were reduced by a similar amount. 
Therefore, the level of potential savings is likely to be 
lower than this figure. 
Generic substitution has an important role to play 
in delivering cost savings for our healthcare system. 
However, the value of the proposal must be accurately 
costed in advance and effectively delivered thereafter. 
Significant overestimation of what can be delivered is in 
nobody’s interest, least of all the services and the patients 
dependent on the savings to be achieved. 
Darragh O’Loughlin, MPSI, President, IPU. 
[Editor notes: The report referred to above - comparing 
the price of medicines and margins in Norway with 
nine European countries - was compiled in 2008 by 
the Norwegian Institute for Research in Economics 
and Business Administration on behalf of the country’s 
Minister for Health. To download English version 
visit www.regjeringen.no/en/dep/hod/ Whats-new/
News/2008/report-on-pharmaceutical-prices.]
IRISh tIMeS 5 JAnUARy 2011
Pharmacies offering vaccines 
For the last number of weeks, your newspaper has carried 
reports on the increase in cases of swine flu, along with 
advice from the HSE that the best protection from this 
virus is the flu vaccine, which this year includes the swine 
flu strain. However, every article implies that the vaccine 
is available only from GPs. 
My pharmacy has in fact been vaccinating patients since 
October of last year and for a lot of people, dropping into 
their local pharmacist is an alternative and sometimes 
more accessible and convenient way of getting their flu 
shot. Indeed in the US, in those states where pharmacist 
vaccination occurs, uptake of vaccines has been up to 50% 
greater than in those states where it is given by GPs alone. 
At present, over 50 Boots pharmacies nationwide are 
authorised to provide the service with other pharmacies 
expected to follow in the coming year. Given the often 
negative press my profession has received in recent times, 
I think it’s important initiatives such as this get due 
attention so that the public are aware of the broad range 
of sources from which clinical services can be obtained. 
I hope future articles will correct this undoubtedly 
unintended omission 
David Carroll, MPSi, Boots, grafton Street, Dublin 2.
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IRISh tIMeS 31 JAnUARy 2011
Cherry-picking clinics and pharmacies 
There is a sweet irony running through your recent 
correspondence from Dr Mel Bates (January 19). The 
biblical admonition about motes and planks cannot be 
far away. At the best of times, medical politics cannot be 
separated from doctors’ income. 
While the recent VHI increases are partially a testament 
to a rampant medical test industry, it would be fair to say 
that many patients would be seriously uncomfortable 
with the tenor of the debate that Dr Bates is stimulating. 
While it is obviously not his intention to denigrate his 
colleagues, he does make a valid point about the greed of 
many professionals. 
In my own professional arena, community pharmacy 
faces many commercial threats, most of which have 
been well reported. What has not been made clear is 
the rapacious attitude of some of Dr Bates’ colleagues 
towards my profession. The development of some primary 
care centres has been characterised by an extraordinary 
attempt to capitalise on the commercial prescribing 
power of groups of clinicians. 
Indeed, the long-running saga of the Killarney primary 
care centre has been marked by an apparent unhealthy 
dependence of the whole project on the income to be 
generated from a pharmacy. 
The parallels with Dr Bates’ nightmare scenario are 
uncanny. Cherry-picking clinics or pharmacies are all faces 
of a common problem. In both situations the public end 
up on the losing end. 
I welcome the call for a debate on the future of 
healthcare policy, although I fear that it is already much 
too late. The shelves are groaning under the weight of 
all the reports that have been prepared. What is missing 
is a vision where patient needs are central. Perhaps the 
minister-in-waiting will put the needs of the patient 
before the professional. In an era of unique events, 
another milestone could be achieved. 
Jack Shanahan, MPSi, Church Street, Castleisland, Co Kerry.
IRISh tIMeS 19 MARCh 2011
Dr James Reilly, our new Minister for Health, proposes 
that the prescription government levy which is 50c per 
item be discontinued. I would recommend hastening 
slowly on this point. 
As a practising pharmacist, I have been surprised at the 
very low to non-existent level of opposition by medical 
card holders to this levy. 
I had expected that many people would opt not to have 
their prescriptions dispensed because of the charge, and 
that there would be a noticeable reduction in the number 
of prescriptions dispensed, but this has not been the case, 
in my limited experience. 
That some would comment on the, “very good value” for 
the prescription levy, was something I had not expected. 
However, my experience may not be that of other 
pharmacists. 
I hope the Minister can quantify the number of 
prescriptions written but not dispensed, both before 
and after the introduction of the prescription levy, so as 
to quantify the effect of the levy in reducing patients’ 
compliance with their prescribed treatments. 
richard J O’rourke, MPSi, Drogheda Street, Monasterevin, 
Co Kildare.
IRISh tIMeS 22 MARCh 2011
Scrapping prescription charges
The imposition of a tax on medical card patients receiving 
prescribed medication is fundamentally unfair. The whole 
idea of the medical card system is that it grants free medical 
care to those who require it. I find it interesting that Dr 
Niall Cawley GP (March 19) should seek to penalise the 
patient. Perhaps a proper medication review incorporating 
the patient’s usage requirements would have been more 
appropriate in the circumstances. I wonder if Dr Cawley 
would be quite as enthusiastic about the tax were he 
obliged to collect it himself. An interesting anomaly in 
the system is that patients receiving medication from 
dispensing doctors are not required to pay the tax, while 
patients receiving medication from dispensing pharmacists 
must pay it. Go figure! 
In relation to the comments by Richard J O’Rourke, 
pharmacist (March 19th), there is one point on which we 
agree - his views may not be shared by other pharmacists. 
The fact that there is little resistance to the tax does not 
mean that it is right. Irish people have shown themselves 
to be remarkably stoic in the face of inequities and 
unfairness in recent times. 
One should not tax the vulnerable just because it is easy 
to do so. Mr O’Rourke obviously does not mind the role 
of unpaid tax collector eating into his contact time with 
patients - as a practising pharmacist, I do. Mr O’Rourke 
must not have the horrible administrative experience 
of trying to collect this prescription tax from vulnerable 
patients in nursing homes, residential care units and 
other institutions for whom no exception has been made. 
It is right and proper that we should seek to minimise 
waste in prescribing and medication usage. But don’t 
penalise the patient! 
Conan Burke MPSi, Calry, Co Sligo.
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IRISh tIMeS 31 MARCh 2011
In your Editorial (March 29th) you rightly concluded 
that the Minister for Health, Dr James Reilly is correct 
to abolish the prescription charge, but that he must 
prioritise other means of tackling waste of unused 
medications.
Pharmacists have an important role ensuring patient 
safety and in tackling waste through medicines 
use reviews. There is a Medicines Use Reviews pilot 
programme currently being evaluated which we hope 
will eventually be fully rolled out. This will ensure better 
compliance, better quality of life for patients, reduced 
wastage and less admission to hospitals.
gerard howlin,
head of Policy and Public affairs, iPu.
I
IRISh tIMeS 25 APRIL 2011
Competition among pharmacies 
There has been much ill-informed comment recently 
about a supposed need to increase competition among 
Irish pharmacies. In fact, Ireland already has the most 
liberal and competitive pharmacy market in the EU. 
There are a higher proportion of pharmacies per head of 
population in Ireland than almost any other country in 
the EU with an average of 1:2,800 people compared to 
a European average of 1: 5,100. The previous restriction 
preventing foreign-trained pharmacists from establishing 
new pharmacies (which was not unique to Ireland and 
which remains a feature of regulation in several other 
EU member states, including Britain, France, Germany, 
Netherlands and Portugal) was abolished in 2007 with 
the passing of the new Pharmacy Act. 
We are one of the few countries where there are no 
restrictions on who can establish or operate a pharmacy; 
in the majority of EU states only pharmacists can own 
a pharmacy and there are population or geographical 
criteria restricting the opening of new pharmacies. 
In 2005, the European Free Trade Association (EFTA) 
completed a Europe-wide study of the regulation of 
professions, including pharmacists, and found that Ireland 
had the most de-regulated pharmacy market of all 25 
EU member states. Similarly, a separate study, entitled 
Competition in Professional Services, published that same 
year by the European Commission, concluded that Ireland 
has the least regulated pharmacy market in Europe. 
Of late, there have been substantial falls in the prices of 
hundreds of medicines, all of which have been passed on 
to patients by pharmacists who have themselves suffered 
dramatic cuts in their payments for providing medicines 
on behalf of the State. 
The two main drivers of the national drugs bill at this 
stage are the increase in the number of medical cards (a 
by-product of soaring unemployment) and greater use 
of very expensive high-tech medicines, both of which 
schemes attract zero per cent mark-up for pharmacists. 
Darragh J O’Loughlin, MPSi, President, iPu.
